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The functional role of FOXQ1 in human cancers has recently and rapidly emerged a 
year ago, which was almost a decade after it was first identified. In this study, I have 
shown that FOXQ1 is closely associated with basal-like breast cancer subtype and 
colorectal cancers. Its clinical relevance as provided by Oncomine database suggest 
that FOXQ1 has potential therapeutic significance against breast cancer progression 
and invasion. 
 
In this study, the functional role of FOXQ1 was investigated in both breast and 
colorectal cancers. During breast cancer progression, FOXQ1 was demonstrated to 
participate in the aggressive behaviour of metastatic breast cancer cell line MDA-MB-
231. When ectopic FOXQ1 expression was introduced into immortalized human 
mammary epithelial cell line (HMLER), this triggered a transformation from 
epithelial morphology towards mesenchymal stage and the process is called 
‘Epithelial to Mesenchymal Transition’ (EMT). FOXQ1 also generated breast cancer 
stem cell-like population as defined by cells with surface antigen CD44+/CD24- 
staining, and this enhanced the growth ability of mammospheres in vitro. 
 
The induced EMT phenomenon by FOXQ1 was also observed in colorectal 
carcinoma cell line HCT116 which has a typical epithelial morphology. Hence, the 
resulting EMT by ectopic expression of FOXQ1 in HCT116 cells provided more 
evidence that FOXQ1 may have a broader role to play in regulating epithelial 
plasticity in human cancers. In HCT116 cells, FOXQ1 induced EMT also conferred 
resistance to a series of chemotherapeutic drug-induced apoptosis. In view of the anti-
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apoptotic ability of FOXQ1 in colorectal cancer cells, I believe that FOXQ1 can be a 
potential therapeutic target. In addition, depletion of FOXQ1 expression by RNAi in 
aggressive breast cancer MDA-MB-231 cell line increased their sensitivity towards 
several DNA-damaging drug-induced apoptosis by more than fifty percent in terms of 
active Caspase 3 activity. 
 
As a transcription factor, FOXQ1 regulates different targets in breast and colorectal 
cancers. In breast cancer, no significance changes to known EMT regulators that 
correlated with FOXQ1 were noticed in microarray gene expression analysis of 
FOXQ1 ectopic expression or knockdown systems. As reporter assay demonstrated 
that FOXQ1 was able to repress CDH1 promoter region of 450bp upstream and 193bp 
downstream in vitro, I therefore propose that FOXQ1 directly regulated CDH1 
transcriptional activity. In colorectal cancer, FOXQ1 has significantly increased two 
well-known factors CTGF and Slug which were previously reported to regulate EMT. 
What’s more, my reporter assay results showed that both CTGF and Slug promoters 
were activated by FOXQ1, and CTGF promoter responded much more intensively to 
FOXQ1 than Slug. Hence, CTGF promoter activity was used as an indicator in my 
study of the functional domains of FOXQ1 protein. By constructing various FOXQ1 
deletion mutants, I have further identified the transactivation domain, nuclear 
localization signal (NLS) and inhibitory domain of FOXQ1 protein. 
 
This thesis studied intensively the function of FOXQ1 in human cancer cells and 
further identified its downstream transcriptional targets. The evidence presented in 
this thesis showed that FOXQ1 is an important forkhead factor in cancer progression 
and demonstrated that it is worth further exploring.  
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1.1 Overview of tumor 
A tumor is a lesion resulting from autonomous or relatively autonomous abnormal 
growth of cells which persisted even after the initiating stimulus had been removed. 
Tumors can result from neoplastic transformation of any nucleated cell in the body, 
although some cell types are more prone to tumor formation than others. The term 
‘cancer’ means malignant tumor and it develops in approximately 25% of human 
population with higher tendency in older people. The mortality rate associated with 
cancer is high and is therefore of great clinical significance (Underwood 2004). 
 
1.1.1 Structure of tumor 
Solid tumors consist of neoplastic cells and stroma. The neoplastic cell population 
reproduces to a variable extent depending on the growth pattern and synthesis activity 
of the parent cell of origin. There is a functional resemblance to the parent tissue. The 
neoplastic cell population is embedded in and supported by a connective tissue 
framework called the stroma. It provides mechanical support and nutrition to the 
neoplastic cells. Tumor stroma contains blood vessels which perfuse the tumor and 
provide nutrition. The growth of a tumor is dependent upon its ability to induce blood 
vessels to perfuse it, and this process is named angiogenesis. Histologically, a tumor 
has the appearance of lost differentiation, weakened cellular cohesion, enlarged 




1.1.2 Tumor classification 
Tumors are classified according to their behavior and cell of origin. Depending on 
behavior, they are classified into two groups, namely benign and malignant. Benign 
tumors are relatively mild and remain localized within basement membrane. They are 
slow growing lesions that do not invade the surrounding tissues or spread to distant 
sites in the body. Malignant tumors on the other hand are rapidly growing and poorly 
circumscribed. They bear less resemblance to parent cell or tissue compared to benign 
tumor. Malignant tumor erodes into and destroys adjacent tissues, enabling neoplastic 
cells to penetrate the walls of blood vessels and lymphatic channels, thereby 
disseminating to distant sites. This important process is called metastasis and can 
result in development of secondary tumors which are called metastases. However, not 
all malignant tumors exhibit metastatic behavior. For example, basal cell carcinoma 
of the skin rarely forms metastases, yet is regarded as malignant because it is highly 
invasive and destructive (Zollinger 1968). 
 
Tumors can arise from any part of the body. Depending on the cell of origin, 
malignant tumors can be divided into several groups. Malignant tumors arising from 
the epithelium are called carcinoma; from the mesenchyme or connective tissue are 
called sarcoma; teratoma has a mix of origin. Carcinoma is the most popular 
malignant tumor. Here, I will only focus on carcinomas, which arise in epithelial 
tissues. Normally, cells that form the epithelial sheets in tissues are tightly bound to 
neighboring cells as well as to the underlying basement membrane by adherens 
junctions which are tight junctions that effectively immobilize them in these sheets. 
These tight physical constraints are not only limited to normal epithelial cells, but also 
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those within many benign carcinomas. However, when a tumor progresses, the 
carcinoma cells liberate themselves from these associations and begin to migrate out 
on their own, first by dissolving underlying basement membranes and then invading 
adjacent stromal compartments. This invasiveness seems to empower carcinoma cells 
to both intravasate and subsequently extravasate (Thiery and Sleeman 2006). 
 
1.1.3 Metastasis of cancer 
Metastasis is responsible for as much as 90% of the great cancer-associated mortality. 
Yet, it remains the most poorly understood component of cancer pathogenesis. During 
metastatic dissemination, a cancer cell from a primary tumor executes a sequence of 
steps. First of all, it locally invades the surrounding tissue. Secondly, it enters the 
microvasculature of the lymph and blood systems (intravasation). Thirdly, it survives 
and translocates largely through the bloodstream to microvessels of distant tissues, 
then exits from the bloodstream (extravasation), survives in the microenvironment of 
distant tissues, and finally adapts to the foreign microenvironment of these tissues in 
ways that facilitate cell proliferation and the formation of a macroscopic secondary 
tumor (colonization) (Fidler 2003). This complex metastatic cascade can be 
conceptually broken down into two major phases: (i) physical translocation of a 
cancer cell from the primary tumor to the microenvironment of a distant tissue and 
then (ii) colonization (Figure 1.1). Presently, our knowledge of physical dissemination 
is becoming clearer, whereas the second phase, colonization, involves complicated 
interactions that may still require many years of research before we fully understand 
the mechanism. From the standpoint of treatment, knowing the mechanisms of 
physical translocation is likely to be important for preventing metastasis in patients 
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who are diagnosed with early tumor, whereas understanding the mechanisms leading 
to successful colonization may lead to effective therapies for patients with existing 
metastases (Chaffer and Weinberg 2011). 
 
 
Figure 1.1 The metastatic cascade 
Metastasis can be envisioned as a process that occurs in two major phases: (i) physical 
translocation of cancer cells from the primary tumor to a distant organ and (ii) 
colonization of the translocated cells within that organ. (A) To begin the metastatic 
cascade, cancer cells within the primary tumor acquire an invasive phenotype. (B) 
Cancer cells can then invade into the surrounding matrix and toward blood vessels, 
where they intravasate to enter the circulation, which serves as their primary means of 
passage to distant organs. (C) Cancer cells traveling through the circulation are 
circulating tumor cells (CTCs). They display properties of anchorage-independent 
survival. (D) At the distant organ, CTCs exit the circulation and invade into the 
microenvironment of the foreign tissue. (E) At that foreign site, cancer cells must be 
able to evade the innate immune response and also survive as a single cell (or as a 
small cluster of cells). (F) To develop into an active macrometastatic deposit, the 
cancer cell must be able to adapt to the microenvironment and initiate proliferation 




1.2 Breast cancer 
1.2.1 Epidemiology of breast cancer 
Breast cancer is currently the most leading cancer among women with an estimated 
1.38 million new cancer cases diagnosed in 2008 (23% of all cancers), and ranks 
second overall (10.9% of all cancers). It is now the most common cancer in both 
developed and developing regions with an estimated 690,000 new cases in each 
region. Incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.7 
per 100,000 women in Western Europe, and are high (greater than 80 per 100,000) in 
developed regions of the world (except Japan) but low (less than 40 per 100,000) in 
most of the developing regions. The range of mortality rates is however lower 
(approximately 6-19 per 100,000) because of the more favorable survival of breast 
cancer in (high-incidence) developed regions. As a result, breast cancer ranks as the 
fifth cause of death from cancer overall (458,000 deaths), but it is still the most 
frequent cause of cancer death in women in both developing (269,000 deaths, 12.7% 
of total) and developed regions, where the estimated 189,000 deaths is nearly equal to 
the estimated number of deaths from lung cancer (188,000 deaths) (Ferlay J, Shin HR 
et al. 2010). 
 
1.2.2 Internal structure of mammary gland 
Each mammary gland has 15-20 lobes arranged in a circular fashion, each of which 
has many smaller lobules. At the end of the lobules are tiny bulb-like glands, or sacs, 
where milk is produced. The lobes, lobules and glands are connected by thin ducts. 
These ducts channel milk to openings in the nipple. The lobules are secretory units of 
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breast, each lobule consists of a certain number of acini, or glands, embedded within 
loose connective tissue and connecting to the intralobule duct. Each acinus is 
composed of two types of cells, namely epithelial and myoepithelial cells. The 
epithelial cells form glandular lumens surrounded by myoepithelial cells which rest 
on the basement membrane (Figure 1.2). The most frequent type of breast cancer 
starts in the duct (ductal cancer), while other types begin in the lobes or lobules 
(lobular carcinoma). Less common is the inflammatory breast cancer where the breast 










Figure 1.2 Internal structure of mammary gland  
The acinus is lined by epithelial cells surrounded by myoepithelial cells and the 













1.2.3 Subtypes of breast cancer 
Breast cancer is a heterogeneous disease characterized by different gene expression 
patterns. Gene expression array analysis led to the identification of four major breast 
cancer subtypes. They are intrinsic subtypes including hormone receptor (HR)-
positive Luminal A and B, human epidermal growth factor receptor 2 (HER2)-
positive and basal-like breast cancer (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 
2001). These different subcategories of breast cancer have different prognoses. 
However, gene expression array is not practical for routine identification of breast 
cancer subtypes. A more common subtype classification clinically is to obtain by 
immunohistochemistry (IHC) analysis the degree of tumor expression of estrogen 
receptor (ER), progesterone receptor (PR) or HER2. By utilizing this simple analysis, 
it is possible to identify three major breast cancer subtypes: the ER/PR-positive, or 
hormone receptor-positive (HR) subtype, which basically includes the Luminal A and 
B intrinsic subtypes; the HER2-positive subtype; the triple-negative subtype, which 
lacks of the expression of all the three receptors (ER, PR and HER2) (Nielsen, Hsu et 
al. 2004; Arslan, Dizdar et al. 2009). 
 
According to the classification of breast cancer, triple-negative subtype shares certain 
similarities with basal-like breast cancer in terms of genetic makeup and tumor 
behavior. Overall, triple-negative and basal-like breast cancer accounts for 12-17% of 
all types of breast cancer (Cleator, Heller et al. 2007). Histologically, they are poorly 
differentiated, show necrosis and are often accompanied by an aggressive clinical 
history. Both triple-negative and basal-like breast cancer occur more frequently in 
young women of black and hispanic ethnicity than in other ethnic groups. In addition, 
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BRCA1 mutation is common in both triple-negative and basal-like breast cancer. 
They have a mutual relationship with BRCA1 dysfunction. BRCA1 is an important 
breast cancer susceptibility gene; more than 75% of female tumors carry a mutation in 
this gene presents with a triple-negative phenotype, a basal-like phenotype, or both. 
BRCA1 plays a central role in repair of double-stranded DNA breaks and a lack of 
BRCA1 therefore results in genomic instability thereby increasing the chance of 
developing malignant diseases. Hereditary BRCA1-mutated breast cancer very 
frequently exhibits basal-like gene expression patterns and sporadic triple-negative 
breast cancers often have BRCA1 dysfunctions (Sorlie, Perou et al. 2001; Turner, Tutt 
et al. 2004). 
 
Triple-negative breast cancer is highly though not exactly concordant with basal-like 
breast cancer as defined by gene expression analyses. Basal-like breast cancer is 
assumed to arise from the outer basal layer of breast ducts because its gene 
expressions can be found in the basal or myoepithelial cells of the human breast. 
Preparations of these tumors stain positively for basal cell cytokeratins (CK5, 6 and 
17) and have the absence or low expression of ER, PR, and very low HER2 
expression. For clinical purposes, after the term ‘triple-negative breast cancer’ was 
first mentioned in October 2005, large numbers of literature recognize the importance 
of this subtype of breast cancer. Triple-negative breast cancer has certain degree of 
overlay with basal-like breast cancer depending on the different criteria used for 





Compared with HR-positive and HER2-positive patients, patients with triple-negative 
breast cancer have much higher likelihood of distant recurrence. The peak risk of 
recurrence occurs within the first three years after initial treatment of the disease with 
the majority of deaths occurring in the first 5 years. On the contrary, the risk for late 
recurrences declines by 50% over the next 5 years, compared with HR-positive 
disease (Dent, Trudeau et al. 2007). Triple-negative breast cancer tends to metastasize 
hematogenously instead of via the lymphatics and they are associated with more 
axillary lymph node metastasis than non-triple-negative breast cancers (Van Calster, 
Vanden Bempt et al. 2009). Both triple-negative and basal-like breast cancers are 
more likely than other subtypes of breast cancers to metastasize, particularly to the 
lungs and brain, but are less likely to metastasize to bone (Nam, Kim et al. 2008). 
 
Breast cancer cell lines in-vitro displayed the same heterogeneity as the primary 
tumors. In hierarchical clustering of transcriptional profiles of 51 breast cell lines with 
published primary, Neve and team identified that luminal cluster was generally 
uniform across all samples, but basal-like cluster contained at least two major subsets 
including Basal A and B. Basal A cluster matched closely to the Perou’s basal-like 
signature, but basal B showed a stem-cell like expression profile and may reflect the 
clinical ‘triple-negative’ tumor types (Neve, Chin et al. 2006). 
 
1.2.4 Treatment of breast cancer 
Luminal A and B breast cancers are potentially sensitive to hormonal treatment; the 
HER2-positive subtype is potentially sensitive to trastuzumab, lapatinib and other 
HER2-directed targeted drugs. However, the triple-negative breast cancer is 
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insensitive to the standard drugs used against breast cancer due to the lack of all three 
receptors (Rouzier, Perou et al. 2005). Therefore, the only systemic treatment option 
available for these patients is chemotherapy with standard cytotoxic agents. 
Neoadjuvant chemotherapy trials have shown that triple-negative breast cancers were 
more responsive to anthracyclines and taxanes than hormone-receptor-positive 
subtypes, as demonstrated with higher pathological complete response rates (Liedtke, 
Mazouni et al. 2008). 
 
Nevertheless, triple-negative breast cancer still has ominous prognosis, especially in 
patients with poor response to chemotherapy. Novel therapeutic targets are urgently 
needed to improve the management of this subtype of breast cancer. It is not a single 
disease but instead encompasses a variety of diseases grouped together solely on the 
basis of absence of ER, PR, and HER2 expression, plus lacking a single common 
pathway of pathogenesis. Thus, multiple targeted therapies might be necessary in the 
management of these tumors (Carey, Dees et al. 2007). Besides chemotherapy, there 
are other inhibitors also designed to target triple-negative breast cancer. Poly (ADP-
ribose) polymerases (PARPs) inhibitors specifically inhibit PARP-1 and, 
consequently of the DNA single strand break repair system. This PARP inhibitor 
could be used alone or combined with other DNA damaging agents to maximize DNA 
damage and destroy the repair system in cancer cells. Several PARP inhibitors are 
currently in clinical trials (Rottenberg, Jaspers et al. 2008). Epidermal growth factor 
receptor (EGFR) has been found to be 80% overexpressed in triple-negative breast 
cancer and this has been linked to poor outcome. Also, patients with triple-negative 
breast cancers have shown elevated levels of vascular endothelial growth factor 
(VEGF) (Linderholm, Hellborg et al. 2009). Angiogenesis is therefore regarded as a 
13 
 
key target for the development of new therapeutic strategies. Bevacizumab, a drug 
targeting angiogenesis, is now in phase II study and results in the neoadjuvant 
treatment of colorectal cancer and breast cancer are promising (Van Meter and Kim 
2010). 
 
1.3 Colorectal cancer  
1.3.1 Epidemiology of colorectal cancer  
Colorectal cancer is the third most common cancer in men (663,000 cases, 10.0% of 
the total) and second in women (571,000 cases, 9.4% of the total) worldwide. Almost 
60% of the cases occur in developed regions. Incidence rates vary 10-fold in both 
sexes worldwide, the highest rates being estimated in Australia/New Zealand and 
Western Europe, the lowest in Africa (except Southern Africa) and South-Central 
Asia, and are intermediate in Latin America. Incidence rates are considerably higher 
in men than in women. About 608,000 deaths from colorectal cancer are estimated 
worldwide, accounting for 8% of all cancer deaths, thus making it the fourth most 
common cause of death from cancer. As observed for incidence, mortality rates are 
lower in women than in men, except in the Caribbean. There is less variability in 
mortality rates worldwide (6-fold in men, 5-fold in women), with the highest 
mortality rates in both sexes estimated in Central and Eastern Europe (20.1 per 
100,000 for male, 12.2 per 100,000 for female), and the lowest in Middle Africa (3.5 




Every year in the United States, 160,000 cases of colorectal cancer are diagnosed, and 
57,000 patients die of the disease, making it the second leading cause of death from 
cancer among adults (Jemal, Siegel et al. 2008). Worldwide, 655,000 death cases 
occur every year, and it ranks the third leading cause of cancer-related death in 
western countries. Colorectal cancer arises from adenomatous polyps in colon. Benign 
colorectal tumors are not deadly unless ignored for years after which it may develop 
into cancer and become invasive. About 73% of invasive colorectal cancers are 
curable when completely removed by surgery followed by chemotherapy. However, 
cancer that metastasized to distant sites are usually not curable, and chemotherapy can 
only help to delay death. Metastatic colorectal cancer often invade blood vessels and 
lymphatic channels first. It may then spread to lung, bone and/or brain. Chemotherapy 
for metastatic colorectal cancer can be administrated before/after surgery, or as 
primary therapy. 
 
1.3.2 Molecular mechanism of colorectal cancer 
The molecular etiology of colorectal cancers can be explained by genetic instability 
and epigenetic alteration which can occur either in inherited germ-line mutation or 
acquired somatic mutation. This can happen as a result of either inactivation of tumor 
suppressor or activation of oncogene. 
 
1.3.2.1 Inactivation of tumor suppressor in colorectal cancer 
In colorectal cancer, the initiating event is activation of Wnt signaling pathway. Wnt 
signaling occurs when the oncoprotein β-catenin bind to nuclear partners (member of 
the T-cell factor-lymphocyte enhancer factor family) to create a transcription factor 
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that regulates genes involved in cellular activation. The β-catenin degradation 
complex controls levels of β-catenin protein by proteolysis. A component of this 
complex APC, not only degrade β-catenin but also inhibits its nuclear localization. In 
colorectal cancer, the most common mutation is inactivation of gene encoding the 
APC protein. In the absence of functional APC, which serves as a brake to stop β-
catenin, Wnt signaling is inappropriately and constitutively activated. Germ-line 
mutations of APC is responsible for close to 100% risk of familial adenomatous 
polyposis by the age of 40. Somatic mutations and deletions of APC are observed in 
most of sporadic colorectal adenoma and cancers (Goss and Groden 2000; Lynch, 
Lynch et al. 2008). 
 
The second genetic step in colorectal cancer is the inactivation of p53 pathway by 
mutation of TP53, a well known tumor suppressor in a wide range of tumor. p53 
pathway mediates cell-cycle arrest and as a cell-death checkpoint, it can be activated 
by multiple cellular stresses. In most tumors, the mutation of TP53 gene can 
inactivate the transcription activity of p53 and the inactivation of p53 coincides with 
transition of adenomas to invasive carcinomas. In addition, mutation of apoptotic 
effectors of wide type p53 pathway also contributes to colorectal cancer progression 
(Baker, Preisinger et al. 1990; Vazquez, Bond et al. 2008). 
 
The third step during colorectal cancer progression is mutation of TGF-β pathway. 
During early tumor formation, this pathway is functional as a tumor suppressor that 
regulates cell growth arrest and apoptosis. In colorectal cancer, about one third of 
them carries somatic mutation of TGFBR2 (TGF-β receptor 2) which result in 
inactivation of TGF-β signaling. In addition, inactivation of downstream effectors of 
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TGF-β such as Smad2, Smad3 and Smad4 can also abolish TGF-β signaling 
(Markowitz, Wang et al. 1995; Parsons, Myeroff et al. 1995; Grady, Myeroff et al. 
1999; Grady and Markowitz 2008). 
 
1.3.2.2 Activation of oncogene pathway in colorectal cancer 
During inactivation of tumor suppressor pathway, several oncogenes may in 
concomitant play key roles in promoting colorectal cancer. Oncogenic mutations of 
RAS and BRAF, which activate the mitogen-activated protein kinase (MAPK) 
signaling pathway occur in 37% and 13% of colorectal cancers respectively (Davies, 
Bignell et al. 2002; Rajagopalan, Bardelli et al. 2002). These mutations consistently 
result in activation of pro-survival and apoptosis suppression pathway in PI3K-PDK1-
PKB and RAF-MEK-ERK1/2 (Bos, Fearon et al. 1987). The activation of somatic 
mutations in PI3KCA, which encodes the catalytic subunit of phosphatidylinositol 3-
kinase (PI3K), also accounts for one third of colorectal cancer. This mutation results 
in loss of the inhibitor of PI3K (PTEN) and activation of an upstream activator (IRS2). 
Both signalings result in amplification of downstream effectors of PI3K signaling and 
colorectal cancer progression (Parsons, Wang et al. 2005; Parsons, Jones et al. 2008). 
 
1.4 Cancer stem cell 
Cancer stem cell (CSC) is also known as tumor-initiating cell (T-IC), which is 
responsible for initiating cancer. This idea was first introduced in hematopoietic 
system by Dr. John Dick and team. This identification has been accomplished in acute 
myeloid leukemia (AML), where it was demonstrated that a specific subpopulation of 
leukemic cells (that expressed CD34+/CD38- markers similar to normal 
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hematopoietic stem cells) was consistently enriched for clonogenic activity in non-
obese diabetic/severe combined immunodeficient (NOD/SCID) immunocompromised 
mice, whereas other cancer cells were depleted of clonogenic activity (Lapidot, Sirard 
et al. 1994; Larochelle, Vormoor et al. 1996; Bonnet and Dick 1997). This concept 
emphasized the heterogeneity of a tumor and was soon followed by several tumor 
heterogeneity models with further identification of cancer stem cells in solid tumor. 
As more cancer stem cells were identified in different types of tumor, the biological 
and therapeutic values of cancer stem cell will be discussed in detail below. 
 
1.4.1 Models of tumor heterogeneity 
Cancer is a heterogeneous disease histologically and functionally. Currently, two 
mutually exclusive models are used to explain tumor heterogeneity, namely the 
stochastic and the hierarchy model. 
 
The stochastic model predicts that the tumor is relatively homogeneous and the 
tumorigenic mechanisms (pathways, genetic programs) that underlie the malignancy 
are functional in all cells. Thus, key features of the tumor can be identified by 
studying the bulk of the cells that make up the tumor mass. The behavior of the cancer 
cells is affected by intrinsic (e.g., levels of transcription factors, signaling pathways) 
or extrinsic (e.g., host factors, microenvironment, immune response) factors. These 
influences are unpredictable as well as random and can result in heterogeneity in the 
expression of cell surface markers or other markers of maturation, in entry to cell 
cycle, or in tumor initiation capacity. A key tenet of this model is that all cells of the 
tumor are equally sensitive to such stochastic influences and also that tumor cells can 
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revert from one state to another because these influences do not induce permanent 
changes (Wang and Dick 2005). 
 
In contrast, the hierarchy model predicts functional heterogeneity among the cells that 
make up the tumor and that the rare cancer stem cells are different from the vast 
majority of cells that constitute the tumor. Therefore, tumorigenic pathways may 
function differentially in distinct tumor subpopulations. This model also predicts that 
although eradication of the non-cancer stem cell may result in a remission, the disease 
will relapse if the tumor initiating cells are not destroyed. Resolution of the tumor 
initiating cell problem requires both purification of tumor cells into subfractions as 
well as a functional assay to detect cells with the capacity to initiate tumor growth in 
vivo (Figure 1.3) (Reya, Morrison et al. 2001; Dick 2008). 
 
Thus, both the stochastic and hierarchy models accommodate the existence of cancer 
stem cell. The essential difference is that, in the stochastic model, cancer stem cells 
arise randomly and every tumor cell has the potential to behave like a cancer stem cell 
given the right conditions; whereas in the hierarchy model, there is only a distinct 
subset of cells that has the potential to behave like cancer stem cell. The stochastic 
model suggests that it will be impossible to predict which kind of cells become tumor 
initiating cell and that stochastic events will cause tumor initiating cells to be 
identified in any two sorted cell fractions with equal probabilities. By contrast, the 
hierarchy model predicts that it should be possible to separate tumor initiating cell 
from non-tumor initiating cell. Thus, theoretically it should be able to sort tumors into 
fractions with or without cancer stem cell activity if the hierarchy model is correct. In 
contrast, the stochastic model predicts that cancer stem cell activity may be observed 
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in any fraction and cannot be prospectively isolated because it assumes that all tumor 






Figure 1.3 Models of tumor heterogeneity 
Tumors are composed of phenotypically and functionally heterogeneous cells. There 
are 2 theories to explain how this heterogeneity arises. According to the stochastic 
model, tumor cells are biologically similar and their behavior is determined by 
internal and external factors. Thus, tumor-initiating activity cannot be enriched by 
sorting cells based on intrinsic characteristics. In contrast, the hierarchy model 
postulates the existence of biologically distinct classes of cells with differing 
functional abilities and behavior. Only a subset of cells can initiate tumor growth; 
these cancer stem cells possess self-renewal and give rise to nontumorigenic progeny 
that make up the bulk of the tumor. This model predicts that tumor-initiating cells can 
be identified and purified from the bulk nontumorigenic population based on intrinsic 






1.4.2 Stem cell and cancer stem cell 
Many human tissues undergo rapid and continuous cell turnover. In the colonic 
mucosa or in the peripheral blood, for example, the average life span of a mature, 
differentiated cell (e.g., a goblet cell in a crypt of the large intestine or a circulating 
granulocyte) can be measured in days or even hours. Despite the ephemeral nature of 
most of their individual cell components, human tissues maintain their mass and 
architecture over time through a tightly regulated process of reconstruction. Under 
physiological conditions, this process is sustained by a small minority of long-lived 
cells with extraordinary renewal potential, known as stem cells. Stem cells are defined 
by three main properties: 1. differentiation-the ability to give rise to a heterogeneous 
progeny of cells, which progressively diversify and specialize  according to a 
hierarchical process, constantly replenishing the tissue of short-lived, mature elements; 
2. self-renewal-the ability to form new stem cells with identical, intact potential for 
proliferation, expansion, and differentiation, thus maintaining the stem cell pool; 3. 
homeostatic control-the ability to modulate and balance differentiation and self-
renewal according to environmental stimuli and genetic constraints (Reya, Morrison 
et al. 2001). 
 
Like their normal tissue counterparts, tumors are composed of heterogeneous 
populations of cells that differ in their apparent state of differentiation. Indeed, the 
morphological and architectural differentiation features of a tumor are the key 
parameter used routinely by hospital pathologists to define a tumor’s primary 
anatomical origin. This simple observation suggests that tumors are not mere 
monoclonal expansions of cells but might actually be akin to ‘abnormal organs’, 
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sustained by a population of diseased cancer stem cell which are  endowed with the 
ability to self-renew and undergo aberrant differentiation (Reya, Morrison et al. 2001; 
Clarke and Fuller 2006). This hypothesis is further justified by the fact that cancer is 
known to result from accumulation of multiple genetic mutations in a single target 
cell, sometimes over a period of many years (Fearon and Vogelstein 1990). Because 
stem cells are the only long-lived cells in many tissues, they are the natural candidates 
in which early transforming mutations may accumulate. Currently limited knowledge 
of normal stem cells, partly due to the overall paucity of research on their functions 
has added a layer of smoke screen to the cancer stem cell theory. A new wave of 
studies, however, has recently began to probe this concept using an innovative, purely 
empirical approach, based on in vivo self-renewal assay (Clarke 2005). Starting from 
whole tumor tissues, cancer cells are purified into single-cell suspensions and 
subsequently fractioned in different subsets according to the expression of a specific 
repertoire of surface markers. Once isolated, individual cancer cell subsets are 
injected into suitable hosts (in most cases orthotopic tissues of immunodeficient 
mouse strains), and the tumorigenic capacity of different subsets compared. 
According to the cancer stem cell model, only a specific subset of the cancer cell 
population (i.e., the long-lived cancer stem cell subset) and not all other subsets 
should be able to sustain in vivo tumor growth. Indeed, this assumption has now been 
repeatedly confirmed in several tumor systems. Three key observations classically 
define the existence of a cancer stem cell population: 1. Only a small percentage of 
cancer cells within each tumor are usually endowed with tumorigenic potential when 
transplanted into immunodeficient mice. 2. Tumorigenic cancer cells are 
characterized by a distinctive profile of surface markers and can be differentially and 
reproducibly isolated from non-tumorigenic ones by using flow cytometry or other 
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immunoselection techniques. 3. Tumors grown from tumorigenic cells contain a 
mixture of tumorigenic and nontumorigenic cancer cells, thus recreating the full 
phenotypic heterogeneity found in the parent tumor (Reya, Morrison et al. 2001). 
 
It is important to understand that, based on this approach, the term cancer stem cell 
represents a working definition with a purely operational significance. The term is 
used to indicate a subset of tumor-initiating cell population that can generate a 
heterogeneous progeny, similar in composition to its original parent tissue from which 
it was isolated. In most cases, it is currently not possible to define with certainty the 
‘genealogical’ relationship between cancer stem cell and normal stem cells of the 
corresponding tissues (i.e., whether cancer stem cell originate directly from normal 
stem cells or the early stages of their progeny). Irregardless of the actual origins of 
cancer stem cell, the identification of a cancer stem cell population establishes a 
functional hierarchy within a tumor tissue and encompasses both the self-renewal and 
differentiation hallmarks of stem cells. First developed in human myeloid leukemias, 
the cancer stem cell working model is currently being progressively expanded to 
include several solid tumors, along with several biological and therapeutic 
implications (Dalerba, Cho et al. 2007). 
 
1.4.3 CSCs in solid tumor 
The cancer stem cell model was described for hematologic malignancies in 1997. 
John Dick’s team provided evidence that leukemia growth and propagation were 
driven by a small population of leukemia cells that have the ability to perpetually self 
renew. They called this cell population cancer stem cells (CSCs) (Bonnet and Dick 
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1997). Since then, more evidence has emerged to support this hypothesis for many 
solid tumors as well. Importantly, these studies led to increasing depth of 
understanding of normal hematopoietic development over the past four decades. 
Functional assays in vitro and in vivo are available for all stem and progenitor cell 
types ranging from the primitive pluripotential stem cells to multipotential and 
unipotential progenitor (Weissman 2000). In addition, a rich collection of cell surface 
differentiation markers enabled detailed characterization of normal hematopoietic 
development, as well as providing insight into how normal differentiation becomes 
disrupted in human leukemia. It is clear that leukemic tissues, although abnormal, still 
retain remnants of normal differentiation and developmental programs (Appelbaum, 
Rowe et al. 2001). Following the knowledge and mature techniques on identification 
and isolation of hematopoietic stem cell, CSCs have been recognized in several solid 
tumors (Ailles and Weissman 2007). 
 
1.4.3.1 CSCs in breast tumor 
On the basis of these observations, Hajj and team undertook a new study to test 
whether a CSC model could be applied to the description of solid tumors, focusing on 
human breast cancer as a model system (Al-Hajj, Wicha et al. 2003). Their results 
showed that, in most human breast cancers, only a minority subpopulation of the 
tumor clone, defined as CD44+/CD24(-/low) and representing 11% to 35% of total 
cancer cells, is endowed with the capacity to sustain tumor growth when xenografted 
in NOD/SCID mice. Most importantly, tumors grown from CD44+/CD24(-/low) cells 
were shown to contain a mixed population of epithelial tumor cells, recreating the 
heterogeneous phenotype seen in parent tumors. This study demonstrated for the first 
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time the existence of a functional hierarchy reminiscent of stem cell systems in a solid 
human epithelial tumor. After that, putative CSCs have been isolated from many other 
tumors including brain, colon, pancreas, prostate, lung and head and neck tumors 
(Anton Aparicio, Garcia Campelo et al. 2007; Glinsky 2007; Li, Heidt et al. 2007; 
Prince, Sivanandan et al. 2007; Seo, Sung et al. 2007; Ceder, Jansson et al. 2008; 
Eramo, Lotti et al. 2008; Ferrandina, Bonanno et al. 2008). 
 
Proponents of the ‘breast cancer stem cell hypothesis’ argue that cancer stem cells are 
ultimately responsible for the maintenance of a population of malignant cells with 
metastatic potential. Cancer cells from triple-negative and basal-like breast cancers 
display a profile of cell surface markers that is similar to that of breast cancer stem 
cells, characterized by the phenotype CD44+/CD24- (in which CD44 is expressed at 
high levels but levels of CD24 are low or undetectable) and also the expression of 
aldehyde dehydrogenase 1 (ALDH1). Although the population of cells expressing 
these markers is enriched with tumorigenic potential, not every cancer cell with this 
profile has the properties of cancer stem cells. Cancer stem cells do not necessarily 
originate from tissue stem cells. They may originate from a differentiated cancer cell 
that has acquired the ability to self-renew; the phenotypic plasticity of cancer cells is a 
well-documented phenomenon. Notably, breast-cancer cells that undergo epithelial to 
mesenchymal transition display characteristics that can be all but indistinguishable 
from those of breast-cancer stem cells. Basal-like breast cancers often display gene-
expression patterns that are consistent with those of cells undergoing epithelial to 
mesenchymal transition. Basal-like breast cancer frequently express an ‘embryonic 
stem-cell signature’, exhibit well-established characteristics of epithelial to 
mesenchymal transition, and commonly express a CD44+/CD24- phenotype which 
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has been linked to ‘stem-cell’ phenotype (Ben-Porath, Thomson et al. 2008; Honeth, 
Bendahl et al. 2008; Sarrio, Rodriguez-Pinilla et al. 2008). 
 
1.4.3.2 CSCs in brain tumor 
The CSC working model has also been successfully applied to brain tumors. Studies 
performed on glioblastoma multiforme and medulloblastoma have shown that 
tumorigenic cells are confined to the CD133+ subpopulation, which usually 
represents about 5% to 30% of total tumor cells. As expected from the CSC model, 
tumors resulting from orthotopic, intracerebral injection of CD133+ cells reproduced 
the phenotypic diversity and differentiation pattern of the parent tumors. In the study 
of brain tumors, the availability of a well-characterized cell culture system for normal 
neural stem cells (the ‘neurosphere’ assay) provided a robust tool for the in vitro study 
of their candidate pathological counterparts. Based on this method, Galli et al. 
succeeded in the isolation and serial propagation from human glioblastoma 
multiforme of ‘cancer neurospheres’, which are highly enriched in long-term self-
renewing, multilineage-differentiating, and tumor initiating cells. Notwithstanding the 
unclear relationship between CD133+ cells and cancer neurospheres which required 
further exploration, it is safe to assume that ex vivo purification of brain tumor CSCs 
based on CD133 coupled with in vitro functional studies using neurosphere assays 
will provide one of the most effective probes for the study of solid tumor CSCs in the 




1.4.3.3 CSCs in colorectal tumor 
Amongst all the malignant tumor, colorectal cancer has the highest heterogeneity with 
varying degrees of differentiation. This heterogeneity suggest that the tumor mass 
within colorectal cancer may have diverse functions. In colorectal cancer, the 
tumorigenic cells within included a high-density of CD133+ subpopulation and these 
subpopulations of cells comprised 2.5% of total tumor cells. When CD133+ cell 
subpopulation is injected into immunodeficient mice subcutaneously, it can reproduce 
the original tumor, whereas CD133- population failed to generate any tumor. In 
addition, CD133+ subpopulation of colorectal cancer can maintain its tumorigeneity 
after a series of transplantation into animals. CD133+ cells can grow exponentially in 
vitro for a very long time in the undifferentiated form, yet reproduce the original 
tumor under favourable conditions. Hence, CD133+ subpopulation play an active role 
and is a useful marker in colorectal cancer propagation and maintenance (Ricci-
Vitiani, Lombardi et al. 2007). 
 
This model proposes that certain cells within the tumor mass are pluripotent, capable 
of self-renewal, and possessed enhanced ability to initiate distant metastasis. The 
cancer stem cell model has important implications for cancer treatment, since most 
current therapies target actively proliferating cells and may not be effective against 
cancer stem cells which are the culprits responsible for recurrence. In recent years, 
great progress has been made in identifying markers of both normal and malignant 
colon stem cells. Proposed markers of colon cancer stem cell include CD133, CD44, 
CD166, ALDH1, Lgr5, and several others (Kemper, Grandela et al. 2010; Sanders 




In vitro expansion of colon CSCs isolated from clinical specimens can be maintained 
in culture enabling the identification of CSC cell surface-associated proteins. From 
primary colon tumor, isolation of enriched CD133+ population gave rise to long-term 
tumor sphere cultures carrying CD133 expression. These tumor sphere cells were able 
to self-renew and differentiate into adherent epithelial lineages and recapitulate the 
phenotype of the original tumor. Relative to their differentiated progeny, tumor sphere 
cells were more resistant to the chemotherapeutic agent irinotecan. Other surface 
markers such as CD44, CD166, CD29, CEACAM5, cadherin 17, and biglycan were 
also identified by mass spectrometry and found to be enriched in CD133+ tumor 
spheroid cells in vitro (Fang, Kim et al. 2010). 
 
1.4.4 CSCs and biology of cancer metastases 
CSC is believed to participate in tumor generation and propagation. The critical step 
for tumor propagation is cancer metastasis and during this process, the role of CSC is 
obvious. Tumor initiation by implanted cells under experimental condition is 
theoretically analogous to dissemination of cancer cells in a patient. Both processes 
depend on the ability of cancer cells to function as parent cells that spawn essentially 
unlimited numbers of descendants. Hence, the very traits that are used to define 
CSCs-self-renewal and tumor-initiating ability-would seem to be inextricable 
elements of successful metastasis formation. Hence, the concept of CSC model sheds 
new light on the biology of metastases and explains why is it that comparison of 
paired samples of primary tumors and autologous lymph node and/or distant-site 
metastases usually reveals striking similarities over a wide range of parameters 
despite extensive intra-tumor heterogeneity. These parameters included tissue 
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morphology, repertoire of somatic genetic mutations, expression of tumor-suppressor 
and immunomodulatory proteins, expression of epigenetically controlled genes, and 
overall transcriptional profile as defined by gene expression arrays. 
 
These observations are in contrast to predictions from traditional cancer models, 
where metastases are considered to originate from monoclonal expansions of very 
specific, individual tumor subclones endowed with specific genotypic and phenotypic 
features, and therefore are postulated to be substantially different from primary 
tumors. However, if we take into account the CSC model and we assume that, in each 
individual tumor, the differentiation pattern is controlled by its specific repertoire of 
genetic mutations, then we can predict that, if two lesions share identical genetic 
backgrounds and similar genetic abnormalities, they will also undergo similar 
differentiation programs and display similar patterns of intratumor heterogeneity in 
the expression of differentiation antigens (Dalerba, Cho et al. 2007). 
 
1.4.5 Implication of CSCs for cancer therapy  
The CSC model has important implication for cancer therapy. Currently, most of 
chemotherapeutic drugs target rapidly dividing cells, which represent the majority of 
the tumor mass. However, conventional cancer therapy frequently fail to eliminate the 
CSC population and can result in relapses,  and more importantly, inadvertently led to 
generation of therapy-resistant and more aggressive cancer cells. Several features of 
CSCs possibly make them hard to eliminate. CSCs are relatively quiescent and this 
allows them to escape from chemotherapeutic regimens that typically target actively 
dividing cells. Moreover, as shown in their normal counterparts, CSCs have been 
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proposed to exhibit high expression level of multidrug transporter family genes 
leading to more efficient efflux of chemotherapeutic drugs as well as innate multidrug 
resistance. In order to develop an efficient therapeutic approach, we must first identify 
distinctive molecular pathways active in CSCs. Next is the identification of agents 
that can either block CSC proliferation or induce CSC differentiation so as to enhance 
sensitivity to chemotherapeutic drugs (Ricci-Vitiani, Fabrizi et al. 2009; Fabrizi, di 
Martino et al. 2010). CSCs can be generated through EMT process. Hence, targeting 
molecules which are involved in generation of EMT should be a logical strategy in 
drug development. Gupta and colleague found that salinomycin treatment can 
selectively kill CSCs using EMT model (Gupta, Onder et al. 2009). 
 
1.5 Epithelial to mesenchymal transition 
Epithelial to mesenchymal transition (EMT) is a biological process whereby epithelial 
cells detach from surrounding to acquire mesenchymal phenotype. This process is 
governed by multiple biochemical processes and eventually results in the acquisition 
of enhanced migratory ability, invasiveness, elevated resistance to apoptosis, and 
greatly increased production of ECM components (Kalluri and Neilson 2003). 
Depending on the different functional consequences and the various origins of this 
transition process, EMT is parsed into three distinct biological settings. In a 2007 
meeting in Poland and a 2008 meeting in Cold Spring Harbor Laboratory, the 
suggestion of EMT subtypes were well discussed and divided into three types based 
on context. Type 1 EMT is associated with implantation, embryo formation, and 
organ development processes. In these processes they share a common mesenchymal 
phenotype despite belonging to different cell types. Type 1 EMT generates 
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messenchymal cells (primary mesenchyme) from primitive epithelial cells as part of 
gastrulation and primitive neuroepithelial cells generating migrating neural crest cells. 
In such situations, some of the cells generated by EMT have the potential to 
subsequently undergo a mesenchymal to epithelial transition (MET) to create 
secondary epithelia. Type 2 EMT is associated with would healing, tissue 
regeneration, and organ fibrosis. In this type of EMT, secondary epithelial or 
endothelial cells transit into resident tissue fibroblasts in response to a repair-initiated 
trigger. During this event, fibroblasts are generated to reconstruct tissue after trauma, 
inflammation or other injuries. Type 2 EMT stops when the triggering event is 
attenuated after wound healing and/or tissue regeneration. In organ fibrosis, type 2 
EMT is continuous in response to ongoing inflammation and eventually results in 
organ destruction. Type 3 EMT occurs in neoplastic cells that harbor genetic and 
epigenetic changes which give rise to tumors, and these are the changes that 
distinguishes type 3 EMT from the other two types. Epithelial carcinoma cells can 
metastasize by undergoing type 3 EMT transit to mesenchymal cancer cells. During 
metastatic cascade, type 3 EMT enabled cancer cells to migrate into blood stream and 
travel to distant sites in which some revert back to epithelial identity while others 
become fully mesenchymal. In this study, I will focus on the investigation of type 3 
EMT (Kalluri 2009; Kalluri and Weinberg 2009; Zeisberg and Neilson 2009). 
 
EMT not only occurs in gastrulation during early embryo development and generation 
of new fibrosis during wound healing and tissue inflammation, but also plays a role in 
cancer progression and metastases under definition of type 3 EMT. Type 3 EMT is 
exclusive to cancer and is linked to morbid consequences. Excessive epithelial cell 
proliferation and angiogenesis are hallmarks of initiation and early growth of primary 
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epithelial cancer also known as carcinoma. The subsequent invasiveness and 
metastatic dissemination is initiated by breaking through the basement membrane. 
The molecular mechanism governing the acquisition of invasive ability is frequently 
linked to type 3 EMT lately. Accumulating evidence suggest that type 3 EMT is 
triggered by certain signals to activate the malignant behavior of epithelial cancer 
cells. The full spectrum of signals that contribute to EMT of carcinoma cells remains 
unclear. One possibility is tumor-associated stroma of primary tumor that undergoes 
genetic and epigenetic alterations to provide specific EMT-inducing signal (Kalluri 
2009). 
 
Type 3 EMT is illustrated in Figure 1.4 (Thiery 2002). Under normal conditions, 
epithelial cells line the walls of cavities. Excessive epithelial cell proliferation and 
angiogenesis led to formation of carcinoma in situ which can remain benign if the 
epithelial boundary remained intact. This benign tumor can be successfully removed 
surgically. However, benign tumors can develop into malignant tumors before full 
diagnosis. During the development of malignancy, the immature epithelial cells 
within benign carcinoma shade their epithelial morphology, digest the basement 
membrane to enter the surrounding stroma, and in turn gain access to vascular 
channels to travel through the blood vassels to distant sites to become secondary 
tumors at these sites. The start of this malignant process is triggered by EMT signals. 
Epithelial cells induced by EMT signals gain mesenchymal morphology, and erode 
the basement membrane to enter blood vassels because of increased motility. When 
they arrive at the new site, the invading mesenchymal cells would shed their 
mesenchymal morphology, revert to epithelial and settle down to grow into a new 
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secondary tumor. This process is known as MET. Several inducers are known to 











1.6 E-cadherin as a downstream effector in epithelial to 
mesenchymal transition 
It is unavoidable to notice the protein E-cadherin if one mentions EMT. E-cadherin is 
a central adhesion molecule located at cell-cell junctions and is essential for formation 
and maintenance of epithelium phenotype. Loss of E-cadherin expression is 
considered a crucial step in the progression from benign to invasive carcinoma (Perl, 
Wilgenbus et al. 1998). This is a fundamental event in EMT. The reduction of cell 
adhesion between carcinoma cells facilitates their ability to migrate individually and 
invade their surroundings. Much effort has been devoted to understanding how E-
cadherin is regulated during cancer progression. The E-cadherin promoter is 
frequently regulated by two ways: direct or indirect repression by transcription factors.  
Transcription factors such as Snail, Zeb, E47, and KLF8 physically bind to and 
repress E-cadherin promoter activity, whereas Twist, Goosecoid and FOXC2 inhibit 
E-cadherin transcription activity indirectly (Kang and Massague 2004; Hartwell, Muir 
et al. 2006; Mani, Yang et al. 2007; Peinado, Olmeda et al. 2007; Ray, Wang et al. 
2010). I will proceed to discuss how E-cadherin is regulated by these individual 
factors. 
 
1.6.1 TGF-β signaling 
TGF-β is a regulatory cytokine whose members regulate organism development. 
TGF-β evolved to regulate the expanding systems of epithelial and neural tissues, the 
immune system, and wound repair. The consequence of malfunction of TGF-β 




TGF-β signaling regulates tumorigenesis and in human cancer its signaling pathways 
are often altered during tumor progression. Prior to initiation and in the early stages of 
cancer progression, TGF-β acts upon the epithelium as a tumor suppressor. However, 
at later stages, it is often a tumor promoter. In normal and premalignant cells, TGF-β 
enforces homeostasis and suppresses tumor progression directly through cell-
autonomous tumor-suppressive effects (cytostasis, differentiation, apoptosis) or 
indirectly through effects on the stroma (suppression of inflammation and stroma-
derived mitogens). However, when cancer cells lose TGF-β tumor-suppressive 
responses, they can use TGF-β to their advantage to initiate immune evasion, growth 
factor production, differentiation into an invasive phenotype, and metastatic 
dissemination or to establish and expand metastatic colonies. There are two major 
ways that TGF-β can lose its suppressive function: one is mutation of TGF-β 
receptors such as TGFBRII mutation in colorectal, ovarian, and head and neck 
cancers; two is downstream alteration of suppressive arms such as defective cytostatic 
responses in breast cancer and glioma (Pasche, Knobloch et al. 2005; Antony, Nair et 
al. 2010; Bellam and Pasche 2010; Moore-Smith and Pasche 2011). 
 
The TGF-β ligands (TGF-β1, TGF-β2 and TGF-β3), receptors and downstream 
signaling components have been the subject of a large number of studies involving 
cancer over the past two decades. In cancer, TGF-β1 is upregulated to a greater extent 
than either TGF-β2 or TGF-β3, and as a result TGF-β1 has been the focus for most of 
the cancer related studies to date. TGF-β1 is a pleiotropic factor that plays a 
physiological role in regulating proliferation, differentiation, development, wound 
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healing, and angiogenesis. In early neoplasia, TGF-β1 can be a potent suppressor of 
proliferation (Roberts and Wakefield 2003). Conversely, TGF-β1 can promote the 
migration and proliferation of tumor cells in late-stage metastatic cancer (Gold 1999; 
Lu, Reh et al. 2004). TGF-β1 signals by first binding to TGF-β1 type II receptor 
(TGFBR2), which then recruits the TGF-β1 type I receptor (TGFBR1) to form a 
heterodimer serine/threonine kinase complex. This activated heterodimeric complex 
transphosphorylates TGFBR1 and enables TGFBR1 to directly phosphorylate 2 
carboxyterminal serines on Smad2 and Smad3, leading to activation of these 
transcription factors (Derynck and Zhang 2003). Smad2 or Smad3 dimerizes with 
Smad4 and translocate to the nucleus, where the activated complexes associate with 
Smad-binding elements in promoters of numerous genes (Lagna, Hata et al. 1996; 
Heldin, Miyazono et al. 1997; Liu, Pouponnot et al. 1997). In human cancer, 
TGFBR2 is often mutated and these conserved mutations in a large percentage of 
cases led to pathway inactivation (Grady, Myeroff et al. 1999). TGFBR2 mutations 
occur frequently in colon cancer, gastric, glioma, non-small cell lung cancer and 
pancreatic cancer (Akhurst and Derynck 2001). 
 
Colon cancer develops as a result of uncontrolled cellular proliferation and 
dysregulation of cell death mechanisms. Inactivation of TGF superfamily signaling 
appears to play a key role too. Inactivation of TGF signaling occurs in about 80% of 
colon cancer (Grady, Rajput et al. 1998). HCT116 cells are deficient in DNA 
mismatch repair and TGFBR2 (Veigl, Kasturi et al. 1998). In response to TGF-β1, the 
biochemistry of cancer cells can change and transit towards a metastatic phenotype 
(Muraoka, Dumont et al. 2002). Some epithelial cells may adopt a mesenchymal 
phenotype, which is termed EMT (Zavadil and Bottinger 2005). 
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1.6.2 The Snail family of gene repressors 
Snail family members encode zinc-finger transcription factors that are essential for 
mesoderm formation in several organisms, from flies to mammals (Nieto 2002). The 
Snail family has emerged in recent years as an important regulator of EMT, a process 
that occurs at defined stages of embryonic development and during cancer 
progression. In vertebrate, the Snail family contains two important members namely 
Snail and Slug. They have now been firmly established as repressors of E-cadherin, 
one of the key molecules in the EMT process, both in early development and in 
different murine and human carcinoma and melanoma cell lines and tumors (Batlle, 
Sancho et al. 2000; Cano, Perez-Moreno et al. 2000; Hajra, Chen et al. 2002; Thiery 
2002; Bolos, Peinado et al. 2003). The transcriptional repression of Snail and Slug 
occurs through binding to the consensus gene sequence of six bases CAGGTG to E-
box to exert the transcriptional repressor function. The importance of Snail in 
triggering EMT in mammals is its ability to convert normal epithelial cells into 
mesenchymal cells through direct repression of E-cadherin expression by binding to 
the E-box of the E-cadherin gene promoter region (Cano, Perez-Moreno et al. 2000). 
During cancer development, however, additional target genes are most likely required 
to assist the role of Snail in cell migration and cancer development, such as the 
recently identified mucin-1, collagen IIa1 or MMP-2 (matrix metalloproteinase-2) 
genes (Guaita, Puig et al. 2002; Seki, Fujimori et al. 2003; Yokoyama, Kamata et al. 
2003). Recently, it has also been shown that Snail is able to repress the expression of 





1.6.3 Twist family 
Twist family belong to the larger family of basic Helix-Loop-Helix (bHLH) 
transcription factors originally found to modulate the expression of various target 
genes through canonical E-box responsive elements of consensus sequence 
NCANNTGN (Ellenberger, Fass et al. 1994; Lee, Park et al. 1997; Yin, Xu et al. 
1997). In vertebrates, two Twist genes exist, namely Twist1 and Twist2. The Twist 
proteins display a high degree of sequence similarity in their C-terminal half, 
including the bHLH domain and a ‘TWIST-box’ protein interaction surface but are 
more divergent in their N-terminus (Li, Cserjesi et al. 1995; Bialek, Kern et al. 2004). 
Twist proteins can behave either as transcriptional repressors, recruiting histone 
deacetylases or inhibiting acetyl-transferases, or as transcriptional activators 
(Hamamori, Sartorelli et al. 1999; Gong and Li 2002; Pan, Fujimoto et al. 2009). Both 
Twist genes were found to be overexpressed in a large set of human and murine 
tumors including a variety of carcinoma as well as sarcomas, melanomas, gliomas and 
neuroblastomas (Puisieux, Valsesia-Wittmann et al. 2006; Ansieau, Bastid et al. 2008). 
Twist1 expression was found to correlate with metastatic potential in murine cell lines. 
In lung cancer progression, Twist1 depletion prevents metastasis without affecting 
primary tumor formation, hence suggesting that Twist1 specifically contributes to late 
cancer cell dissemination (Yang, Mani et al. 2004). This potential was suggested to 
depend on the ability of Twist1 to induce EMT and thereby promote motility, 
reminiscent of its embryonic biological properties. E-cadherin, encoded by the CDH1 
gene, is generally defined as a guardian of the epithelium phenotype and loss of its 
expression is associated with tumor invasiveness, metastatic dissemination and poor 
patient prognosis (Schipper, Frixen et al. 1991; Oka, Shiozaki et al. 1993; Umbas, 
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Isaacs et al. 1994). Repression of CDH1 gene by Twist is directly through 
transcriptional repression which may require Twist stabilization through 
heterodimmerization, potentially in response to environmental signals. This gives a 
rational to the detection of Twist-positive, E-cadherin-negative cells at the invading 
fronts of malignant parathyroid tumor (Fendrich, Waldmann et al. 2009). Interestingly, 
Twist was found to be activated following loss of E-cadherin expression (Onder, 
Gupta et al. 2008), raising the possibility that Twist contributed to EMT induction by 
inducing the expression of mesenchymal genes rather than repressing CDH1. 
Accordingly, a correlation between VIM, CDH2 and TWIST gene expressions was 
also observed in breast cancer cell lines (Lombaerts, van Wezel et al. 2006).  
 
In addition, Twist protein can override oncogene-induced senescence and apoptosis 
which are the natural barriers activated to constrain cell growth in pre-malignant 
lesions (Braig, Lee et al. 2005; Collado, Gil et al. 2005). By inhibiting both 
senescence and apoptotic programs, Twist proteins are suggested to promote 
malignant conversion and to provide cell with a growth advantage at the primary site. 
Accordingly, several studies reported the induction of Twist1 expression during the 
progression towards malignant stage in several cancer types including ovary, prostate, 
bladder, pancreas and hepatic carcinoma as well as melanomas and 
pheochromocytomas (Kwok, Ling et al. 2007; Ansieau, Bastid et al. 2008; Waldmann, 
Slater et al. 2009; Yoshida, Horiuchi et al. 2009). Associated-EMT might also 
contribute to Twist-induced chemoresistance. Growing evidence indeed support the 
assumption that EMT is as a transient state providing cells with higher stress tolerance 
threshold and could thereby constitute an escape route away from apoptosis. In vitro, 
oxaliplatin-resistant colorectal cancer cells, tamoxifen-resistant breast cancer cells, 
41 
 
gefintinib-resistant lung cancer cells as well as gemcitabine-resistant pancreatic 
cancer cells have all been shown to have undergone EMT (Hiscox, Jiang et al. 2006; 
Yang, Fan et al. 2006; Rho, Choi et al. 2009; Franco, Casasnovas et al. 2010). Twist 
acts upstream of Snail, Zeb1 acts downstream of Twist and Snail (Guaita, Puig et al. 
2002). 
 
1.6.4 Zeb1 and Zeb2 
Zeb1 (also known as TCF8 and δEF1) and Zeb2 (also known as ZFXH1B and SMAD 
interacting protein 1), are two members of the ZEB family. Zeb factors (Zeb1 and 
Zeb2, encoded by the ZFHX1a and ZFHX1b genes) are transcriptional repressors that 
comprise two widely separated clusters of C2H2-type zinc fingers binding to paired 
CAGGTA/G E-box-like promoter elements. They induce EMT by suppressing the 
expression of many epithelial genes, including E-cadherin (Vandewalle, Van Roy et 
al. 2009). Zeb1 expression has mainly been studied in colorectal tumors and uterine 
cancers, where it was associated with aggressive behavior. Zeb2 has higher 
expression pattern in ovarian carcinoma effusions than in solid metastases (Aigner, 




Goosecoid (Gsc) gene, which encodes a well conserved transcription factor that was 
first identified as the most highly expressed homeobox gene in the Spemann organizer. 
Gsc can recapitulate many of the properties of the organizer when ectopically 
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expressed in the amphibian embryo and is known to promote cell migration in 
xenopus laevis. Moreover, elements of the TGF-β superfamily and Wnt/β-catenin 
signaling pathways, which are known to be involved in tumor invasion and metastasis, 
can induce Gsc expression in embryonic cells and are required for Spemann organizer 
formation (Nakaya, Murakami et al. 2008). 
 
Recently, Hartwell and team extend Gsc functional study in human breasts (Hartwell, 
Muir et al. 2006). They found that Gsc expression was elevated in three prevalent 
pathological types of human breast tumors which are atypical ductal hyperplasia 
(ADH), ductal carcinoma in situ (DCIS), and invasion ductal carcinoma (IDC). 
Ectopic expression of Gsc in immortalized human mammary epithelial cells (HMECs) 
and in Madin-Darby canine kidney (MDCK) epithelial cells induced epithelial to 
mesenchymal transition and enhanced cell motility. In addition, Gsc is induced in 
TGF-β signaling pathway in adult breast epithelial cells. Ectopic expression of Gsc in 
MDA-MB-231 human breast cancer cells enhance the lung metastatic ability of these 
cells. 
 
1.6.6 Other molecules promoting EMT 
Recently, a large amount of research articles identified several novel molecules in 
regulating EMT. In breast carcinoma, forkhead factor FOXC1 and FOXC2 were 
shown to positively regulate EMT in human mammary epithelial cells, and also 
participated in the metastatic process of aggressive breast cancer (Mani, Yang et al. 
2007; Ray, Wang et al. 2010). In mammary epithelial cells, overexpression of LBX1 
(Ladybird homeobox 1), a developmentally regulated homeobox gene, led to EMT 
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with morphological transformation, expression of mesenchymal markers, enhanced 
cell migration, increased CD44+/CD24- progenitor cell population, and tumorigenic 
cooperation with known oncogenes. In human breast cancer, LBX1 upregulation is 
associated with basal-like subtype (Yu, Smolen et al. 2009). 
 
1.7 Forkhead box transcription factor family 
Forkhead box transcription factor family is evolutionary conserved and share a 
common 110-amino acid DNA-binding domain (DBD) termed forkhead or winged 
helix domain. The forkhead gene was first identified in Drosophila melanogaster 
where mutation in this gene gave rise to two spiked-head structures in the embryos of 
Drosophila. Results of this mutation led to a defect in the formation of the anterior 
and posterior gut. In addition, the forkhead DNA-binding domain was previously 
referred to as hepatocyte nuclear factor 3 α (HNF3α) in mammals (Weigel, Jurgens et 
al. 1989; Lai, Prezioso et al. 1990; Clark, Halay et al. 1993). 
 
After the first forkhead box member was discovered more than 20 years ago, a large 
number of forkhead gene families were subsequently identified. In order to streamline 
the nomenclature for the forkhead transcription factor family, an international 
conference was held in California, and a forkhead nomenclature committee was set up 
to standardize the nomenclature for these forkhead proteins. The name of ‘Fox’ which 
was adapted from ‘forkhead box’ was agreed upon and used to unify these proteins. 
Finally in the year 2000, Kaestner and colleagues finished the nomenclature of 
forkhead transcription factors. It provided an comprehensive and convenient 
classification for subsequent  research in this area (Kaestner, Knochel et al. 2000). 
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They established a Fox nomenclature web site that provided the latest nomenclature 
for forkhead box family (http://www.biology.pomona.edu/fox.html). 
 
As more and more forkhead factors were identified, some of them show functions in 
tumorigenesis, epithelial to mesenchymal transition, angiogenesis and apoptosis. In 
spite of the highly conserved DNA-binding domain, biological functions amongst this 
family display a large diversity. I shall be introducing several well-studied forkhead 
members especially relating to their functions in cancer. 
 
1.7.1 FOXC1 and FOXC2  
FOXC1 shares 85% homology with FOXC2, and similar functional roles in breast 
cancer progression. In particular, FOXC2 expression is necessary for metastasis of 
murine mammary carcinoma cells to the lung. Also, FOXC2 expression is 
upregulated following trigger by EMT signaling, and FOXC2 expression levels 
correlated positively with aggression levels of basal-like human breast cancers, hence 
suggesting that FOXC2 could be a specific molecular marker for this type of cancer 
(Mani, Yang et al. 2007). Moreover, in aggressive basal-like breast cancer subtype, 
FOXC1 was shown to be consistently overexpressed and its overexpression correlated 
with poorer overall survival, higher incidence of brain metastasis and shorter brain 
metastasis-free survival in lymph node-negative patients. Biologically, FOXC1 
promotes cancer cell proliferation, migration and invasion. Clinically, FOXC1 maybe 
useful as a potential prognostic marker and a molecular therapeutic target in the 




However, FOXC2 is not always coupled with promoting epithelial to mesenchymal 
transition. Endogenous FOXC2 expression in injured renal tubular cells was increased 
in the cytoplasm rather than in the nucleus, and elevated FOXC2 further activated 
epithelial cell differentiation during tissue repair. These findings suggested that 
FOXC2 may have novel functions besides nuclear transcriptional activity (Hader, 
Marlier et al. 2009). Both FOXC1 and FOXC2 have overlapping expression patterns 
and similar regulatory functions in mesoderm and neural crest derivatives during 
development. Other studies indicated that FOXC1 and FOXC2 were involved in 
cardiovascular development particularly arterial cell specification, lymphatic vessel 
formation, angiogenesis and cardiac outflow tract development (Seo, Fujita et al. 2006; 
Hayashi and Kume 2008; Kume 2009). 
 
1.7.2 FOXM1 
FOXM1 has a very important role in cellular development pathway including the 
maintenance of homeostasis between cell proliferation and apoptosis. Deregulated 
FOXM1 inhibits differentiation and finally lead undifferentiated cells towards 
malignant transformation. In many human malignancies, FOXM1 expression level is 
upregulated and is often linked to malfunction of this transcription factor. These 
malignancies include prostate cancer, basal cell carcinoma, hepatocellular carcinoma, 
lung cancer, glioblastoma, primary breast cancer, and pancreatic cancer. In molecular 
basis, FOXM1 is associated with multiple oncogenic pathways including PI3K/Akt 
signalling, NF-κB signalling, EGFR signalling, Raf/MEK/MAPK, ERK, sonic 
hedgehog signalling, estrogen receptor signalling, cyclooxygenase (COX2) pathway, 
MMP, reactive oxygen species (ROS), vascular endothelial growth factor, c-Myc, p53, 
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HIF-1, and proteasome pathway. Generally, FOXM1 participate in many oncogenic 
pathways in cancer cells with poor outcome. Hence, inactivation of FOXM1 as a 
novel therapeutic approach would have a significant impact for cancer therapy (Wang, 
Ahmad et al. 2009). 
 
FOXM1 has been reported to contribute to acute myeloid leukaemia (AML) cell 
proliferation. Aberrant FOXM1 expression results in AML cell proliferation through 
cell cycle progression while reduce FOXM1 expression in AML inhibits cell 
proliferation and colony formation. These findings suggested that FOXM1 could be a 
therapeutic target for AML treatment (Nakamura, Hirano et al. 2010). FOXM1 
overexpression in majority of human cancers suggested that FOXM1 may have 
functions in initiation of human tumorigenesis. Recently, this hypothesis was 
supported by observations that FOXM1 participated in early oncogenic pathways by 
expanding the number of stem/progenitor cells in the epithelial compartment, and 
inhibiting keratinocyte terminal differentiation. These findings may provide the basis 
for designing therapy to target tumorigenesis at its initiation stage (Gemenetzidis, 
Elena-Costea et al. 2010). FOXM1 regulates normal lung morphogenesis as well as 
development of lung cancer, and increased FOXM1 activity resulted in altered lung 
sacculation, and increased proliferation in the respiratory epithelium and accelerated 
lung tumor growth (Wang, Zhang et al. 2010). 
 
FOXM1 is involved in maintenance of stem cell pluripotency. In P19 cells 
(embryonal carcinoma cell line), FOXM1 was found to regulate Oct4 and knockdown 
of FOXM1 caused P19 cells to differentiate into mesodermal derivatives, such as 
muscle and adipose tissues. Maintaining FOXM1 expression in P19 cells prevented 
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down-regulation of pluripotency-related transcription factors such as Oct4 and Nanog 
during cell differentiation. Ectopic expression of FOXM1 in retinoic acid-
differentiated P19 cells reinstated the expression of Oct4, Nanog and Sox2. These 
results suggested that FOXM1 plays a critical role in maintenance of stem cell 
pluripotency (Xie, Tan et al. 2010). FOXM1 is essential for endothelial proliferation 
after vascular injury and it regulates endothelial barrier reformation through direct 
regulation of β-catenin transcription. These findings represented a new therapeutic 
idea for treatment of inflammatory vascular disease associated with persistent 
vascular barrier leakiness, such as acute lung injury (Mirza, Sun et al. 2010). In breast 
cancer cells, overexpression of FOXM1 resulted in resistance to Herceptin (human 
epidermal growth factor receptor 2 monoclonal antibody) and paclitaxel. Inhibition of 
FOXM1 expression may relieve therapeutic resistance in breast cancer and should be 
seen as a target for cancer therapy (Carr, Park et al. 2010). 
 
1.7.3 FOXF1 
FOXF1 expression is up-regulated in tumors with a constitutively activated Hedgehog 
signaling pathway (Wendling, Luck et al. 2008).  In the study of expression profile of 
normal prostate and diseased prostate, FOXF1 and FOXF2 were highly expressed in 
the normal prostate transition zone and benign prostatic hyperplasis (BPH), but 
decreased in prostate cancer (van der Heul-Nieuwenhuijsen, Dits et al. 2009). 
 
In breast cancer, the transcription factor nuclear factor 1-C2 (NF1-C2) is a negative 
regulator of EMT, motility, invasiveness and tumor growth. NF1-C2 directly 
represses FOXF1, its downstream target. Hence, FOXF1 positively regulates to 
48 
 
promote mesenchymal phenotype, invasion and metastasis in breast cancer (Nilsson, 
Helou et al. 2010). However in some breast cancer, FOXF1 is epigenetically silenced 
by promoter methylation. Pharmacologic approach can restore FOXF1 expression and 
result in cell growth arrest in vitro and in vivo. This suggests that FOXF1 is a 
potential tumor suppressor in breast cancer (Lo, Lee et al. 2010). In lung cancer 
FOXF1 regulates tumor-promoting properties of cancer-associated fibroblasts (Saito, 
Micke et al. 2010). 
 
1.7.4 FOXO family 
Among the different subclasses of FOX genes, FOXO subfamily is one of the largest. 
This subfamily contains four members (FOXO1, FOXO3, FOXO4 and FOXO6). 
Functions include activation or repression of multiple genes such as Bim and FasL in 
apoptosis process, p27kip and cyclin D in cell cycle regression, DADD45a in DNA 
damage repair, response to superoxide induced stress and glucose-6-phosphatase in 
metabolism (Weidinger, Krause et al. 2008; Yang and Hung 2009). 
 
FOXO activity is controlled at both the transcriptional and posttranscriptional levels. 
FOXO1 and FOXO3a were reported lately to be transcriptionally controlled by E2F1 
through binding to FOXO1 and FOXO3a promoter. In human glioblastoma cells, 
E2F1 promotes the transcription of FOXO1 and FOXO3a in vitro. The activity of 
FOXO is also controlled by posttranscriptional regulation including phosphorylation, 
acethylation and uniquitination, which provides evidence that forkhead members can 




The ability of FOXO to control cell survival and cell death suggests that FOXO may 
function as tumor suppressors, and loss of FOXO function has been observed in a 
number of human cancers. The loss of function maybe due to genetic defects and 
altered posttranslational modification. Several genetic defects were observed in 
human cancers. In human alveolar rhabdomyo-sarcoma FOXO1 C-terminal domain is 
fused with the N-terminal domain of PAX3 or PAX7. This resulted in activation of 
transcription   function to promote cell proliferation. The function of FOXO can also 
be lost. In PI3K/Akt cascade, tumor suppressor phosphatase PTEN could become lost 
due to genetic mutation. The decreased expression can lead to perpetual Akt 
activation. As a result, FOXO1 and FOXO3a are phoshorylated and translocate from 
nucleus into cytosol to abolish their inhibition of cell proliferation. Functionally 
impaired FOXO in cancer also can be found in other signaling pathways including 
NF-κB and RAS/ERK pathways. Again, FOXO can be a potential therapeutic target 
for cancer treatment (Weidinger, Krause et al. 2008; Yang and Hung 2009). 
 
1.7.5 FOXA1 and FOXA2 
FOXA1 is identified in breast, prostate and aggressive thyroid cancer (Nakshatri and 
Badve 2007; Nucera, Eeckhoute et al. 2009; Hu and Mackenzie 2010). FOXA1 is a 
marker of luminal cells in mammary gland and is associated with luminal type A 
(ER+) breast cancers. FOXA1 is a lineage-specific oncogene in proliferation of 
mammary cancer cells and could be a good candidate for prognosis (Badve, Turbin et 
al. 2007; Habashy, Powe et al. 2008; Thorat, Marchio et al. 2008; Yamaguchi, Ito et 
al. 2008; Albergaria, Paredes et al. 2009; Bernardo, Lozada et al. 2010; Liu, Niu et al. 
2010). FOXA1 is expressed in epithelia of the prostate gland and regulates the 
50 
 
transcription of prostate-specific genes. FOXA1 negatively regulates androgen 
receptor by physical interaction with the receptor (Yu, Gupta et al. 2005; Mirosevich, 
Gao et al. 2006; Sun, Yu et al. 2009). 
 
FOXA2 is expressed in many types of lung tumors including typical/atypical 
carcinoid, large cell NE carcinoma, small cell carcinoma, and adenocarcinoma, but 
not squamous cell carcinoma and (non-NE) large cell carcinoma (Khoor, Stahlman et 
al. 2004). In aggressive prostate cancer, FOXA2 forms a transcriptional complex with 
ubiquitin ligase Siah2 and HIF-1α to promote a transcriptional program to induce 
Hes6, Sox9 and Jmjd1a to facilitate the formation of aggressive prostate tumors (Qi, 
Nakayama et al. 2010). In human lung cancer cell lines, FOXA2 negatively regulate 
epithelial to mensenchymal transition through inhibition of slug expression by direct 
binding to slug promoter (Tang, Shu et al. 2010). In human pancreatic ductal 
adenocarcinoma, FOXA1 and FOXA2 expression occurred specifically in epithelial 
and well-differentiated cancer cells, but expression were lost in undifferentiated 
cancer cells. Ectopic expression of FOXA1 and FOXA2 is sufficient to reverse EMT 
phenotype by reactivating E-cadherin expression. In pancreatic ductal 
adenocarcinoma, suppression of FOXA1 and FOXA2 expression contributed to 
malignant progression (Song, Washington et al. 2010). In epithelial ovarian 
carcinoma, FOXA2 is downregulated in chemoresistant tumors (Ju, Yoo et al. 2009). 
In human embryonic stem cells overexpression of FOXA2 induced differentiation into 




1.7.6 FOXP1 and FOXP3  
FOXP1 is widely expressed in cardiac, lung and lymphocytic cells. FOXP1 may 
function as an oncogene or a tumor suppressor depending on the cell type.  FOXP1 
locates on 3p14 where many tumor suppressor genes are also found to be localised in 
various cancers. Loss of FOXP1 in breast cancers is associated with worse outcome, 
and hence, FOXP1 was suggested to function as a tumor suppressor. FOXP1 possibly 
serve as a tumor suppressor in gastrointestinal, lung, head, breast and neck cancers, 
and also genitourinary malignancies. However, FOXP1 function as oncogene in 
diffuse large B-cell lymphoma and mucosal associated lymphoid tissue lymphoma 
(Koon, Ippolito et al. 2007). 
 
FOXP3 expression is not only restricted to the lymphocyte lineage but also expressed 
in non-hematopoietic cells and cancer cells of a non-hematopietic origin. It seems that 
FOXP3 has roles in carcinogenesis and immune response in these different cell types. 
In prostate and breast cancers, downregulation of FOXP3 is associated with HER2 
and SKP2 (S-phase kinase-associated protein 2) or c-MYC overexpression. This 
suggest that FOXP3 may act as a tumor suppressor in prostate and breast cancers 
(Martin, Ladoire et al. 2010). 
 
1.7.7 FOXG1 
FOXG1 acts as an oncoprotein inhibiting TGF-β-mediated anti-proliferative 
responses in ovarian cancer cells through suppression of p21(WAF1/CIP1) transcription 
(Chan, Liu et al. 2009). In addition, FOXG1 has oncogenic potential through 
modulating FOXO1 expression by acting as a transcriptional repressor (Kim, Jo et al. 
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2009). In cells of hepatoblastoma, FOXG1 overexpression may contribute to the 
maintenance of the undifferentiated state and could be a potential target for molecular 
therapeutics (Adesina, Nguyen et al. 2007). 
 
1.7.8 FOXQ1 
FOXQ1 (Forkhead box, subclass q, member 1) was previously known as hepatocyte 
nuclear factor 3 forkhead homolog 1 (HFH1) before the unified nomenclature. 
FOXQ1 was first mapped in murine autosome (Avraham, Fletcher et al. 1995). 
Murine FOXQ1 is a 2.7kb transcript in the adult kidney and stomach and was later 
revealed that it was most likely intronless and located within chromosome 13. The 
gene expression pattern was examined and results suggested that FOXQ1 gene is 
involved in the development of kidney in mice (Frank and Zoll 1998). Other 
laboratories reported that FOXQ1 mRNA expression is highest in stomach and 
bladder, especially in epithelial cells. The expression of FOXQ1 strongly repressed 
telokin promoter activity in A10 vascular smooth muscle cells by binding to the 
forkhead consensus sequence located within an AT-rich region of telokin promoter. 
Also FOXQ1 is able to repress other smooth muscle-specific promoter such as 
SM22α promoter (Hoggatt, Kriegel et al. 2000). FOXQ1 is involved in hair 
differentiation in Satin mice. Satin (Sa) homozygous mice carry a silky coat with high 
sheen because of the structurally abnormal medulla cells and defects in differentiation 
of hair shaft. This phenotype arises from FOXQ1 mutation in Sa mice, which 
suggested that FOXQ1 displayed a function in differentiation and development of hair 
shaft (Hong, Noveroske et al. 2001). Further study demonstrated that mice carrying a 
homozygous deletion of FOXQ1 developed a silky shiny coat and a defect in gastric 
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acid secretion even when exposed to secretagogue stimuli (Goering, Adham et al. 
2008). FOXQ1 has been suggested to be a downstream mediator of Hoxa1 in 
embryonic stem cells and shown to be regulated by Hoxc13 during hair follicle 
development (Martinez-Ceballos, Chambon et al. 2005; Potter, Peterson et al. 2006).  
 
FOXQ1 is predominantly expressed in the abundant mucin-producing cells called 
fovelar or pit cells that line the stomach’s mucosal surface.  Defective FOXQ1 in the 
stomach resulted in lose of mRNA and protein expression of gastric MUC5AC 
synthesis. These findings suggested that a function of FOXQ1 is in promoting major 
stomach mucin MUC5AC formation (Verzi, Khan et al. 2008). The functions of 
FOXQ1 in mouse mammary gland cell line NMuMG was lately revealed. In this 
heterogeneous epithelial cell line, FOXQ1 was found to be transcriptionally up-
regulated in response to TGF-β1 signalling. They further utilized the morphological 
homologous subclone of NMuMG cell line (NM18) to demonstrate that FOXQ1 has a 
functional impact on epithelial differentiation (Feuerborn, Srivastava et al. 2011). 
 
The human FOXQ1 gene was finally isolated and characterized by Bieller in 2001. 
They found that the human FOXQ1 gene is located on chromosome 6p23-25 and 
encodes a protein of 403 amino acids. The human FOXQ1 gene was expressed 
predominantly in the stomach, trachea, bladder and salivary gland. Additionally, the 
expression status of FOXQ1 in colorectal adenocarcinoma and lung carcinoma cell 
lines were very high. There is 82% homology between mouse and human FOXQ1 
with an updated rat FOXQ1 gene. The DNA-binding motif is extremely conserved 
whether in humans, mice or rats. The putative trans-activation domain of human 
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FOXQ1 shares a high degree of similarity in amino acid sequences with murine in 
matching domains (Bieller, Pasche et al. 2001).  
 
In addition to its role in development, FOXQ1 was identified to be expressed in 36% 
(5 out of 14) of pancreatic cancer cell lines via bioinformatic analysis of microarray 
assays using expressed sequence tags. These findings suggested that FOXQ1 might 
contribute to pancreatic cancer development (Cao, Hustinx et al. 2004). Recently, 
FOXQ1 was reported to be overexpressed in human colorectal cancer which is similar 
to my own observations. In their study, they have identified that p21 is one of the 
downstream targets of FOXQ1, and overexpression of FOXQ1 in lung carcinoma cell 
line H1299 have increased tumorigenicity. Furthermore, the increased tumorigenicity 
is independent of p21 levels. In addition, they found that overexpression of FOXQ1 in 
H1299 cells resulted in reduced apoptotic signal in response to adriamycin 
(doxorubicin) treatment. They also showed that FOXQ1 promoted angiogenesis in 
tumor growth. The above results are quite consistent and in parallel with my own 




1.8 Study objectives and rationale 
My aim in this study is to discover new biological roles of FOXQ1 in human cancers 
(breast and colorectal cancers), and to delineate underlying molecular mechanism 
associated with observed phenotypes. Before this study, FOXQ1 was a novel member 
of the forkhead family and not linked to any published functional reports relating to 
cancer. In view of the expressed status of FOXQ1 in basal-like breast cancer and most 
of colorectal cancers discovered at the start of this project, my starting hypothesis is 
FOXQ1 has an oncogenic role to play. Other forkhead members such as FOXC1 and 
FOXC2 were recently reported to influence basal-like breast cancer progression 
through promotion of EMT during invasion and metastasis. In this study, my 
hypothesis is FOXQ1 may have similar function roles in cancer progression. The 
principle strategy in this project uses an ectopic expression system and RNAi 
knockdown system to study FOXQ1 in human cancer cells and immortalized 
epithelial cell lines. Furthermore, the transcriptional network modulated by FOXQ1 





























2.1 Cell lines 
The cell lines used in this study were purchased from American Type Culture 
Collection (Manassas, VA) unless otherwise stated. Colorectal cancer cell lines 
include HCT116, SW480, SW620, HT29, HT15 and DLD1; breast cancer cell lines 
include MCF7, T47D, MDA-MB-361, MDA-MB-415, BT549, BT474, SKBR3, 
MDA-MB-468, MDA-MB-436 and MDA-MB-231; other epithelial-like cell lines 
include SAOS2, U2OS, and A549. Non-cancerous human mammary epithelial cell 
lines include MCF10A, HMEC (human mammary epithelial cell immortalized with 
hTERT), and HMLER (HMEC cells further transfected with SV40 LT and H-Ras). 
HMLER cells were a generous gift from Dr. W.C. Hahn of Dana-Farber Cancer 
Institute. 
 
2.2 Cell culture conditions 
MCF10A, HMEC and HMLER were cultured in DMEM/F12 medium supplemented 
with 5% horse serum, 1% penicillin and streptomycin (PS), 20 ng/ml epidermal 
growth factor (EGF) (PeproTech, NJ), 0.5 mg/ml hydrocortisone (cat#H0888, Sigma-
Aldrich), 100 ng/ml cholera toxin (cat#C8052, Sigma-Aldrich), and 10 µg/ml insulin 
(cat#I1882, Sigma-Aldrich). All other cell lines were maintained in DMEM 
supplemented with 10% fetal bovine serum (FBS) and 1% PS. In Tet-on inducible 
system, Tet system approved FBS was used (Clontech, Mountain View, CA) to 
replace normal FBS. All cell lines were maintained in logarithmic growth as a 
monolayer in 75 cm2 flask at 37ºC in a humidified atmosphere containing 5% CO2. 
Cell lines were regularly subcultured when cell density reached 80-90% confluence. 
Subculture procedure began with aspiration of existing culture medium followed by 
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rinsing with phosphate buffer saline (PBS) once, and then incubated with 0.25% 
trypsin in PBS with 0.02% (w/v) EDTA. After incubation at 37ºC for 5-10 minutes, 
the cells will detach from the flask. The detached cells were transferred into a fresh 15 
ml tube with 5 ml culture medium. Cells were collected by centrifuge at 1000 rpm for 
4 minutes, and then cell pellets were suspended in 10 ml fresh culture medium. 30% 
of the cell suspension was seeded into 75 cm2 flask. All cell culture process and 
materials were carried out under sterile conditions. All cell culture materials were 
purchased from Invitrogen (Carlsbad, CA) unless otherwise stated. 
 
2.3 Cryogenic preservation 
All experiments have been done using cell lines that were passaged less than 20 times. 
Hence, the cell lines were frozen down regularly. The freezing progress is described 
below. Cells were harvested as usual, and then suspended in specific medium 
containing 90% culture medium and 10% DMSO for MCF10A, HMEC, and HMLER 
cell lines. The rest of cell lines were frozen down using 90% FBS together with 10% 
DMSO. The density of frozen cells was about 1 × 106 cells/ml, and cryovials were 
placed into Mr. Frosty freezing container (NALGENE, NUNC) at -80ºC overnight, 
and then transferred to liquid nitrogen for longer storage. To thaw frozen cells from 
cryo-preservated condition, cryovial was removed from liquid nitrogen and quickly 
thawed in 37ºC water bath. The cell suspensions were then neutralized by adding pre-
warmed culture medium and centrifuged at 1000 rpm for 4 minutes. Cells were finally 





5-Flurouracil (5FU), paclitaxel (Taxol), camptothecin (CPT), adriamycin (ADR), 4-
hydroxytamoxifen (OHT) and doxycycline (DOX) were purchased from Sigma-
Aldrich (St. Louis, MO). HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) 
was purchased from Enzo Life Science. 5FU, Taxol, ADR, and SAHA were dissolved 
in DMSO in concentrations of 375 mM, 10 mM, 10 mM, and 10 mM, respectively. 
CPT and DOX were dissolved in MilliQ water filtered by Millipore and sterilized by 
passage through 0.2 µm filter unit (Millipore, Singapore). Concentrations were 10 
mM and 1 mg/ml respectively. CPT was freshly prepared every two weeks. All drugs 
were stored at -20ºC in 50 µl aliquots. 
 
2.5 Expression plasmid construction and molecular cloning 
procedure 
Full-length FOXQ1 coding region containing 1212 base pairs (bp) was downloaded 
from NCBI database (http://www.ncbi.nlm.nih.gov). The forward and reverse primers 
were designed by Vector NTI advance 10.3.0 software (Invitrogen) with Kpn I and 
EcoR I restriction enzyme sites at 5’ and 3’ respectively. Normal colon tissue cDNA 
was used as the template, and FOXQ1 fragment was isolated by PCR program based 
on the manufacturer’s instruction of FailSafeTM PCR system (EPICENTRE 
Biotechnologies). The size of PCR product was subsequently verified using DNA 
agarose gel electrophoresis. The DNA fragment was viewed under ultra-violet light, 
and the correct band was excised and then subjected to gel extraction and the DNA 
fragment was eluted into 30 µl RNAse-free water. 
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TOPO TA cloning was carried out to ligate gel purified FOXQ1 fragment into the 
TOPO2.1 vector (Figure 2.1). In detail, 4 µl FOXQ1 fragment was mixed with 1 µl 
TOPO2.1 vector and 1 µl salt solution and the mixture was incubated for 15 minutes 
at room temperature. Volume ranging from 2 to 3 µl of ligated product was used in 
transformation into One Shot® TOP10 chemically competent E. coli cells according to 
manufacturer’s instruction (Invitrogen). The cultured bacteria were spread and 
incubated overnight at 37ºC on the LB agar plate containing 100 µg/ml ampicillin and 
80 µl of 20 mg/ml X-gal (cat#R0941, Fermentas) for growing single colonies. 
Positive clones appeared white while negative clones appeared blue. Positive clones 
were amplified and plasmid DNA was eluted into 30 µl RNAse-free water using 
QIAGEN Miniprep kit followed by Kpn I and EcoR I double restriction enzyme 
digestion. In digestion process, 10 µl of Miniprep products was mixed with 1 µl Kpn I 
and EcoR I enzyme each, 0.2 µl 100× BSA, NEB buffer 2 and incubated for 1 hour at 
37ºC. Digested products were separated by 1.2% agarose DNA gel electrophoresis. 
According to weight separation, the correct inserts were identified, excised, purified 
and finally ligated into pcDNA4.0/myc-His-B expression vector (Figure 2.2) with 
myc-tag at the C-terminus of FOXQ1. A mixture comprising of 4 µl DNA fragment, 2 
µl pcDNA4.0/myc-His-B pre-digested by Kpn I and EcoR I enzyme, 1 µl T4 ligase 
and 1 µl T4 ligation buffer were prepared and incubated at room temperature for 1 
hour for use in ligation. The resulting ligation product was transformed into One 
Shot® TOP10 chemically competent E. coli as described in section 2.10 and spreaded 
onto ampicillin LB agar plate and incubated at 37ºC overnight for growing single 
colonies. The content of the resulting plasmids was verified by DNA sequencing. 
Next, the plasmid with the correct DNA sequence was amplified using QIAGEN 
Midiprep kit. FOXQ1 deletions (D1-D8) were cloned into pcDNA4.0/myc-His-B 
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expression vector using full-length FOXQ1 as the template with the same 
experimental procedures but using different designated forward and reverse primers. 
For the Tet-on inducible expression system, FOXQ1 fragment was obtained from 
pcDNA4.0/myc-FOXQ1 after double digestion by Kpn I and EcoR I restriction 
enzymes, and then ligated into pcDNA4.0/TO/myc-His-B inducible vector (Figure 2.4) 
within the same restriction enzyme sites using T4 ligase. For the retroviral expression 
system, myc-tagged FOXQ1 was cloned into pMN GFP/IRES retroviral vector 
(Figure 2.5) (a gift from Dr Linda Penn’s lab). Primers used for expression plasmid 














Figure 2.1 Map of TA cloning vector pCR® 2.1-TOPO®. 
PCR product was ligated into this vector, and correct sequence was verified by 








Figure 2.2 Map of mammalian expression vector pcDNA4/myc-His®. 
Type B was used in this thesis. Gene of interest was ligated into multicloning sites 






Figure 2.3 Map of pcDNA6TM/TR vector of Tet-on inducible system. 
It expresses Tet repressor which will bind to the Tet operator in pcDNA4TM/TO/myc-












Figure 2.4 Map of pcDNA4TM/TO/myc-His B expression vector in Tet-on 
inducible system. 
This vector shares the same MCS with vector pcDNA4/myc-His®. The mammalian 














2.6 Site-directed mutagenesis 
Site-directed mutagenesis was performed using QuikChange® Multi Site-Directed 
Mutagenesis Kit (Stratagene). Primers for designated site mutation were designed by 
the QuikChange® primer design program provided online by Agilent Technologies 
(Table 2.6). pcDNA4.0/myc-FOXQ1 plasmid DNA was used as template and diluted  
into 100 ng/µl and 1 µl of it was mixed with 2.5 µl of 10× QuikChange buffer, 0.75 µl 
QuikSolution, 1 µl of 100 ng/µl primer, 1 µl dNTP mix, 1 µl QuikChange enzyme 
blend and it was topped up with water to final volume of 25 µl. The mixture was next 
incubated in thermal cycler with following program. Step one is 95ºC for 1 minute, 
step two is 95ºC for 1 minute, step three is 55ºC for 1 minute, and step four is 68ºC 
for 13 minutes. Step two to step four were then repeated for 30 cycles, and after that, 
step five operated at 37ºC for 2 minutes. The resulting 25 µl PCR product was mixed 
with 1 µl Dpn I restriction enzyme and incubated at 37ºC for one hour for digesting 
unmethylated parental single strand plasmid DNA. The 26 µl digested product 
containing single-stranded site-mutated plasmid DNA was then precipitated with 74 
µl isopropanol and centrifuged at 14680 rpm for 15 minutes at room temperature. 
Pellet was washed with 100 µl of 70% ethanol, and centrifuged at 14680 rpm for 15 
minutes at room temperature. Pellet containing plasmid DNA was air-dried, then 
dissolved in 5 µl of water, and finally ready for transformation into bacteria. XLGold-
ultracompetent cell was used for this transformation and in that single-stranded site-
mutated plasmid DNA was converted into double-stranded DNA. 45 µl competent 
cell was mixed with 2 µl β-BE and incubated on ice for 10 minutes with swirl every 2 
minutes. 5 µl plasmid DNA was then added into the previous mixture and incubated 
on ice for 30 minutes. After that, the mixture was heat-shocked at 42ºC for 30 seconds, 
68 
 
and incubated with 500 µl pre-warmed LB medium containing 100 µg/ml ampicillin 
at 37ºC shaker for one hour. The resulting product was spreaded onto LB agar plate 
containing 100 µg/ml ampicillin and incubated at 37ºC overnight. Positive clones 
were verified by double restriction enzyme digestion with EcoR I and Kpn I, and 
correct sequences were confirmed by sequencing. 
2.7 Construction of RNAi-Ready pSIREN-RetroQ vector 
expressing FOXQ1 shRNA 
2.7.1 shRNA oligonucleotide design 
FOXQ1 siRNA sequence containing 19bp nucleotides were input into online shRNA 
sequence designer provided by Clontech (Mountain View, CA) 
(http://bioinfo.clontech.com/rnaidesigner/oligoDesigner.do). Restriction enzyme sites 
5’ BamH I and 3’ EcoR I overhangs were added to the insert fragment for directional 
cloning into RNAi-Ready pSIREN vector (Figure 2.6). Additional Mlu I site was 
added to verify the positive clone. The designed end products contain 65bp 
nucleotides. shRNA sequences are listed in Table 2.5. 
 
2.7.2 Annealing the oligonucleotides 
PAGE-purified oligonucleotides were synthesized by 1st Base (Singapore) and diluted 
in TE buffer at a concentration of 100 µM. Top and bottom strands were mixed in a 
ratio of 1:1 to give a final concentration of 50 µM. The mixture were heated at 95ºC 
for 30 seconds, 72ºC for 2 minutes, 37ºC for 2 minutes and finally 25ºC for 2 minutes 




2.7.3 Ligation of double stranded oligonucleotide into RNAi-Ready 
pRIREN vector 
The annealed oligos were first diluted into TE buffer at a concentration of 0.5 µM. 
After that, 1 µl of 0.5 µM annealed oligos and 2 µl of 25 ng/µl linearized pSIREN 
vector were mixed with 1.5 µl 10× T4 DNA ligase buffer, 0.5 µl BSA (10mg/ml), 9.5 
µl nuclease-free water, and 0.5 µl T4 DNA ligase (400 unit/µl). The mixture was 
incubated at room temperature for 3 hours for ligation to take place. For 
transformation, 5 µl of the ligated products were inserted into One Shot® TOP10 
competent E. coli as described in section 2.10. Positive clones were selected by single 

























Figure 2.6 Map of RNAi-Ready pSIREN-RetroQ vector. 
shRNA sequence was ligated between BamH I and EcoR I sites. The antibiotic 









2.8 DNA agarose gel electrophoresis 
Fermentas 6× loading dye was added into DNA to obtain a final concentration of 1× 
mixture. The mixture was loaded onto solidified agarose gel dissolved in TAE buffer 
with 0.5 µg/ml ethidium bromide and electrophoresed at constant voltage of 120V in 
1× TAE buffer for 30 minutes at room temperature. After the electrophoresis was 
completed, the migrated DNA bands can then be viewed under ultra-violet light 
(GeneGenius Gel Imaging System from Syngene). 
 
2.9 DNA gel extraction 
DNA gel extraction was performed using QIAquick® Gel Extraction Kit. In detail, 
DNA fragments were excised under ultra-violet light and weighed. 3 volumes of QG 
buffer were added into the weighed gel slice and the mixture were incubated on a heat 
block at 50ºC for 10 minutes until the agarose gel is completely melted into the QG 
buffer. 1 volume of isopropanol was next added and mixed properly. The mixture was 
then transferred into a filter column and centrifuged at 13000 rpm for 30 seconds to 
allow the DNA materials to bind to the filter. 750 µl of PE buffer was used to wash 
the filter column once and DNA fragments were eluted into 30 µl RNAse-free water. 
 
2.10 One Shot® TOP10 chemically competent E. coli transformation 
Volume ranging from 2 to 6 µl of plasmid DNA product was mixed into one vial of 
One Shot® TOP10 chemically competent E. coli cells (Invitrogen) and incubated on 
ice for 30 minutes. The mixture was then subjected to heat shock at 42ºC in a water 
bath for 30 seconds and then transferred onto ice for 2 minutes. 150 µl SOC medium 
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was added to the mixture and cultured at 37ºC on a shaker operating at 280 rpm for 1 
hour. 100 µl of cultured product was spreaded onto LB agar plate containing 100 
µg/ml of ampicillin and incubate at 37ºC overnight for growing single colonies. 
 
2.11 Plasmid amplification and preparation 
Plasmids were extracted from bacteria (E.coli) through Mini- and Midi-prep method. 
Single bacterial colony was amplified into 2 ml LB medium containing 100 µg/ml 
ampicillin with shaking at 280 rpm for overnight at 37ºC. The next day, 1 ml of the 
cultured bacteria was used for plasmid purification using QIAprep® spin Miniprep kit. 
Firstly, bacteria were spun down by centrifuge at 3000 rpm for 3 minute at room 
temperature. The pellet was resuspended in solution using 250 µl of Buffer 1, and 
lysed by 250 µl of Buffer 2 followed by neutralization with 350 µl of Buffer 3. The 
neutralized mixture was centrifuged at 13000 rpm for 10 minutes. After that, 800 µl 
of supernatant was transferred into a filter column and further centrifuged at 13000 
rpm for 30 seconds followed by one wash with 750 µl of PE buffer. The Miniprep 
products were finally eluted into 30 µl of RNAse-free water. 
 
Midiprep was carried out using 50 ml bacterial culture material and QIAprep® spin 
Midiprep kit. Bacteria were first spun down by centrifuge at 4000 rpm for 15 minutes 
at 4ºC. The pellet was then resuspended with 4 ml of buffer P1, and lysed for 5 
minutes with 4 ml of buffer P2 followed by neutralization with 4 ml of chilled buffer 
P3. The neutralized bacterial lysate was transferred into a filtered cartridge and 
incubated for 10 minutes at room temperature. Meanwhile, QIAGEN-tip was 
equilibrated with 10 ml QBT buffer. After 10 minutes, the bacterial lysate was filtered 
73 
 
through the cartridge into the QIAGEN-tip, and the clear lysate was allowed to go 
through the QIAGEN-tip by gravity flow. Next, the QIAGEN-tip was washed twice 
with 10 ml of QC buffer, and the plasmid DNA was eluted with 5 ml of QF buffer. 
The 5 ml of elution which contained DNA was precipitated with 3.5 ml of 
isopropanol by centrifuged at 13200 rpm for 30 minutes at 4ºC. The precipitated DNA 
was washed once with 2 ml of 70% ethanol and then centrifuged at 13200 rpm for 10 
minutes at 4ºC. The DNA pellet was air-dried and reconstituted with 100 µl of 
RNAse-free water. The quality and concentration of DNA was measured by 
Nanodrop. 
 
2.12 Sequences and plasmids for RNA interference 
siRNA FOXQ1 sequences was designed and synthesized by 1st Base (Singapore), (#2 
siRNA: AGATCAACGAGTACCTCAT). Another siRNA FOXQ1 oligos which 
contain three different siRNA oligos targeting human FOXQ1 were purchased from 
Santa Cruz. In addition, the FOXQ1 shRNA and negative control lentiviral particles 
with the same targeting site were purchased as well. PLKO.1-E-cadherin shRNA and 
PLKO.1-control plasmid, psPAX2 packaging plasmid and pMD2.G envelope plasmid 
were purchased from Addgene (Cambridge, MA). 
 
2.13 Transient transfection 
Target cell lines were seeded into 6-well plate at a density of 3 to 4 × 105 cells/well at 
18 hours before transfection. Transfection mixture was prepared in 100 µl DMEM 
only medium at the ratio of 1 µg plasmid DNA to 3 µl Fugene 6, Fugene 6 HD 
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(Roche) or Lipofactamine 2000 (Invitrogen) for each well respectively. The mixture 
was incubated at room temperature for 20 minutes prior to adding into the cell culture 
plate which contained 1 ml PS-free DMEM. The DMEM was used without PS 
because PS can adversely affect the transfection efficiency. 
 
To deliver siRNA sequence efficiently and firmly, LipofectamineTM RNAiMAX 
reagent was used and siRNA was transfected twice. 5 µl of 20 nM siRNA oligos and 
6 µl LipofectamineTM RNAiMAX reagent were added into 100 µl OPTI-MEM® 
medium separately and incubated at room temperature for 5 minutes before mixing 
together. 20 µl mixtures were evenly dropped into cell culture well containing 800 µl 
OPTI-MEM® medium. After 6 hours incubation, OPTI-MEM® medium was changed 
to 2 ml PS-free DMEM to reduce the toxicity of the transfection reagent. The 
following day, transfected cells were trypsinized and reseeded into 6-well plate in 
preparation for the second transfection. The siRNA transfection procedure was 
repeated 18 hours later. The transfected cells were incubated for 48 hours prior to 
harvesting. 
 
2.14 Generation of stable cell lines 
2.14.1 Tet-on inducible expression system 
To generate stable HCT116 Tet-on expression system, HCT116 epithelial colorectal 
cancer cell line was first transfected with pcDNA6.0/TR, followed by selection using 
10 µg/ml blasticidin antibiotic. After selection for two weeks, the surviving colonies 
were pooled together and sequentially transfected with pcDNA4.0/TO/myc-FOXQ1 
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or empty vectors. Successfully transfected cells were selected, this time using 100 
µg/ml zeocin antibiotic. After selection for two weeks, single colonies were picked 
and first seeded into 96-well plate after which the populations were further expanded. 
To examine for FOXQ1 expression, 2 µg/ml doxycycline (DOX) was introduced into 
the culturing medium. After 48 hours of treatment, the cellular proteins were 
harvested and immunoblotting for myc-tagged FOXQ1 were carried out using anti-
myc antibody. Positively identified clones with myc-tagged FOXQ1 expression were 
expanded and maintained under conditions of 10 µg/ml blasticidin and 100 µg/ml 
zeocin which were added into the culturing medium. 
 
2.14.2 Retroviral expression system 
To generate retroviral expression system, platinum-A retroviral packaging cell line 
(CELL BIOLAB, INC., San Diego, CA) was seeded into collagen I coated 6-well 
plates (BD, BIOCOAT) at a density of 7 × 105 cells/well for 18 hours prior to 
transfection. At the start of the transfection process, 4 µg pMN-FOXQ1 or pMN 
empty plasmids were added into each well with 10 µl Lipofectamine 2000 (Invitrogen) 
transfection reagent. After 6 hours, transfection mixtures were replaced by DMEM 
cell culture medium with 10% FBS and 1% PS, and left aside for 48 hours to allow 
the packaging cells to express FOXQ1 or control retroviral particles. Target cell lines 
were seeded into 6-well plates at a density of 3 × 105 cells/well for 24 hours prior to 
introduction of the retroviral particles. At the start of the infection process, 
supernatants of retroviral packaging cells containing FOXQ1 or control retroviral 
particles were filtered through 0.45 µm filter unit to get rid of cell debris, and the 
resulting 1 ml of filtered retroviral supernatant were then added into each well of 
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target cells contained 1 ml of culturing medium. The 6-well plate, each well 
containing 2 ml mixture of retroviral supernatant plus culture medium and 8 µg/ml 
polybrene, was then centrifuged at 1800 rpm for 45 minutes to strengthen the 
efficiency of infection. Another 1 ml retroviral supernatant was sequentially added 
and the 6-well plate again centrifuged at 1800 rpm for another 45 minutes. The plates 
were then incubated at 37ºC for 48 hours after which the target cells were sorted for 
GFP expression. The retroviral expression system was generated in cells of HCT116, 
A549, SAOS2, MCF7, MCF10A, HMEC, and HMLER. 
 
2.14.3 Stable RNA interference system 
To generate FOXQ1 RNA interference system, cells were seeded into 6-well plate at a 
density of 3 × 105 cells/well. After 18 hours, either 10 µl shFOXQ1 or negative 
control lentiviral particles were added into the culture medium of each well with 8 
µg/ml polybrene followed by 1800 rpm centrifuge for 45 minutes. After infection for 
48 hours, positive cells were selected by exposure to 2 µg/ml puromycin for 2 weeks, 
following which single colonies were picked for knockdown efficiency validation by 
means of RT-PCR. 
 
To generate E-cadherin RNA interference system, the human embryonic kidney 
(HEK) 293T cells were used for production of lentivirus. HEK 293T cells were 
seeded into collagen I coated 6-well plate at a density of 7 × 105 cells/well. After 18 
hours, either 4 µg of PLKO.1-E-cadherin or PLKO.1-control was transfected into the 
cells along with 3 µg psPAX2 packaging plasmid, 1 µg pMD2.G envelope plasmid 
and 20 µl Lipofectemin 2000. The transfection medium was changed after 6 hours, 
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and then the 6-well plate incubated at 37ºC for 48 hours to allow for generation of 
lentiviral particles in the supernatant. Target cells were seeded at 24 hours before 
introduction of the lentiviral particles. The procedure for infection is the same as 
previously mentioned. After infection for 48 hours, selection for HMLER cells was 
carried out using 4 µg/ml puromycin for 2 weeks. The selected colonies were then 
pooled together and verified by immunoblotting with E-cadherin antibody. 
 
2.15 Western blot analysis 
Cells were harvested using trypsin and washed twice with cold PBS. The cell pellet 
was lysed using 30 µl of radioimmunoprecipitation assay lysis buffer [50 mmol/L 
Tris-HCl (pH7.4), 1 mmol/L EDTA, 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, and proteinase inhibitors] for 60 minutes on ice. During the 
lysis process, the sample was vortexed for 15 seconds at 10 minutes interval. 
Subsequently, the cell lysate was sonicated 3 times at 5 seconds interval. After 
centrifuge at 132000 rpm for 15 minutes at 4ºC, the resulting supernatant was 
collected. Protein concentrations in the supernatant were determined with the 
Bradford protein assay kit (Bio-Rad, Hercules, CA). Protein samples (20-30 μg) were 
separated by 10% SDS-PAGE, transferred onto a PVDF immobilon membrane 
(Millipore), and blotted with specific primary antibodies followed by HRP-labelled 
secondary antibodies. The following primary antibodies were used in this study: E-
cadherin (cat#610182, BD Biosciences), Vimentin (cat#6260, Santa Cruz), Myc-tag 
(9E10, Roche), CD44 (cat#550392, BD Biosciences), CD24 (cat#555426, BD 
Biosciences), FOXQ1 (AV39755, Sigma-Alrich), cleaved-PARP (cat#D214, Cell 
Signalling, Danvers, MA) and actin (Roche). ECL anti-rabbit (NA934V, GE 
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Healthcare) and ECL anti-mouse (NA931V, GE Healthcare) horseradish peroxidise-
linked whole antibodies were used as secondary antibodies. 
 
2.16 Immunofluorescence confocal microscopy 
Stable cell lines were seeded at a density of 1.5 × 105 cells/well on 8 mm coverslips in 
12-well plates under conditions with or without 2 µg/ml doxycycline treatments for 
48 hours. For transient transfection, target cells were seeded under the same condition, 
which is with or without doxycycline treatment for 18 hours prior to transfection, and 
2 µg plasmid DNA was transfected into each well with the experimental procedure 
previously mentioned. After 48 hours, cell coated coverslips were rinsed once with 
PBS and then fixed by ice-cold methanol for 5 minutes at -20ºC. After that, it was 
rehydrated with 3 washes of PBS at 10 minutes interval at room temperature. Fixed 
cells were permeabilized with 0.2% Triton-X-100 for 15 minutes at room temperature. 
After blocking with 10% FBS for 1 hour at room temperature, cell coated coverslips 
were probed with primary anti-myc-tag (9E10, Roche), E-cadherin (cat#610182, BD 
Biosciences) or Vimentin (cat#6260, Cell Signalling) antibodies in a 1/1000 dilution 
at room temperature for 1 hour followed by 3 washes with PBS. Next, the coverslips 
were probed with florescent-labelled secondary antibodies (Alexa Fluor®546 or Alexa 
Fluor®488) (Invitrogen, Molecular Probes, Eugene, Oregon) in a 1/2000 dilution at 
room temperature for 1 hour followed by 3 washes with PBS in subdued light. Finally, 
nuclei were stained with DAPI and coverslips were mounted with FluorSave™ 
reagent (CALBIOCHEM®). Flurorescence images were taken using Zeiss Meta 
upright microscope (LSM510 DUO system, Carl Zeiss) under 63×/1.40 oil DIC 
immersion objective with 488 nm (Argon) and 633 nm (Hene) wavelength lasers. 
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2.17 Promoter construction 
The upstream promoter region for genes of interest was downloaded from UCSC 
database (http://genome.ucsc.edu/), and consensus transcription binding motifs were 
predicted by online software Genomatix MatInspector (http://www.genomatix.de). In 
this study, luciferase promoter activity assay was performed on three selected genes 
(CDH1, SLUG and CTGF) and tested genomic regions were shown in Table 2.1. 
Each gene was constructed in various fragments into the pGL3 reporter system 
depending on the consensus transcription binding motifs prediction. Primers used for 
promoter construction are listed in Table 2.4. 
 
The procedure of promoter construct is described as follows. Human genomic DNA 
was used as the template for PCR amplification of specific promoter region, and PCR 
programme was run according to manufacturer’s instruction for HotStarTaq 
(cat#203445, QIAGEN). In particular, the PCR master mix included 100 ng genomix 
DNA, 10 µM forward and reverse primer mix, 10 µl HotStarTaq master mix and it 
was topped up with water to final volume of 20 µl. PCR amplification was performed 
on peltier thermal cycler machine (DNA engine DYADTM). The machine operated in 
the following programme: step one is 95ºC for 15 minutes, step two is 94ºC for 30 
seconds, step three is 68ºC for 30 seconds, and step four is 72ºC for 1 minute. Step 
two to step four were then repeated for 35 cycles, and after that, step five operated at 
72ºC for 10 minutes. Finally, the samples were incubated at 4ºC for short-term storage. 















2.18 Luciferase reporter assay 
To perform luciferase reporter assay, desired target cell lines were seeded onto 12-
well plates at a density of 1 × 105 cells/well. The target cells were transfected with 
various promoter or control plasmids according to procedures described for transient 
transfection. In particular, (i) the ratio of pGL3-basic promoter plasmid (firefly signal) 
to PRL-null (renilla signal) is 100/1, (ii) 500ng of pGL3-basic promoter plasmid was 
added to each well, and (iii) duplicates were carried out. Forty-eight hours after 
transfection, the luciferase activities were analyzed using the Dual Luciferase system 
according to manufacturers’ instruction (Promega). Luciferase signals were measured 
by TriStar LB941 machine (BERTHOLD TECHNOLOGIES). Three independent 
experiments were performed.  
 
2.19 Cell viability 
Cell viability was measured using CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, Madison, WI). This assay is a homogeneous method of determining the 
number of viable cells in culture based on quantification of the ATP present, which 
signals the presence of metabolically active cells. This assay procedure involves 
addition of a single reagent named CellTiter-Glo® reagent which is a mixture of 
CellTiter-Glo® substrate and CellTiter-Glo® buffer. Adding CellTiter-Glo® reagent to 
cell culture medium result in cell lysis and generation of luminescent signal. This 
signal is proportional to the amount of ATP present, and the amount of ATP is 
directly proportional to the number of cells (Crouch, Kozlowski et al. 1993). In detail, 
cells were seeded at a density of 500-1000 cells/well in 96-well optical bottom plates 
with 100 µl medium. After indicated days, cells were lysed by 100µl of CellTiter-
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Glo® reagent for 10 minutes with gentle shaking, and then incubated another 5 
minutes to allow luminescence signal to stabilize. These luminescence signals 
generated were measured by MicroLumat Plus LB96V system (BERTHOLD 
TECHNOLOGIES). Six replicas were performed for each sample. 
 
2.20 Anchorage-independent growth by soft agar colony formation 
assay 
Soft agar colony formation assay was used to measure the ability of anchorage 
independent growth in vitro. It consists two layers of agar (base layer and top layer) 
with different agar concentrations. Base layer does not contain cells, but it has higher 
percentage of agar. Top layer is the cell layer, and contains lower percentage of agar. 
This assay was performed as follow: mixture comprising 3% agar in sterilized PBS 
was heated up in a microwave oven to dissolve the mixture homogenously. 6-well 
plates were pre-coated with 2 ml of 0.6% agar diluted with pre-warmed medium from 
3% agar stock for each well as the base layer. Approximately 1000-3000 single cells 
were seeded into 0.3% agar for each well as the upper layer. After two weeks, formed 
colonies were stained with 4 µg/ml p-Iodonitrotetrazolium Violet (INT) overnight and 
photographed to produce phase contrast images. Duplicates were carried out for each 




2.21 Flow Cytometry/PI staining and active Caspase-3 activity 
through FACS analysis 
Cells were seeded into 6-well plate at a density of 3 × 105 cells/well, and treated with 
indicated drugs for various time durations. At the end of the drug treatment, cells were 
harvested by trypsin, washed once by 1 ml cold PBS, and then fixed by 70% ethanol 
for 1 hour at 4ºC. After fixing, the cells were washed twice with cold PBS, treated by 
100 ng/µl RNase for 5 minutes, and stained with 400 µl of 50 mg/ml propidium 
iodide (PI) for 30 minutes in subdued light. The DNA contents were measured by 
FACS analysis (Becton Dickson), and 10000 cells were analyzed for each sample. 
 
Active Caspase-3 activities were measured by FACS analysis using BD 
cytofix/cytoperm fixation/permeabilization kit with FITC rabbit anti-active Caspase-3 
antibody (cat#559341, BD Biosciences) based on the manufacturer’s instruction. In 
particular, cells were harvested by trypsin, washed once by 1 ml cold PBS, fixed and 
permeabilized by 800 µl Cytofix buffer for 20 minutes at room temperature, and 
washed twice using 1ml 1× Cytoperm buffer. 20 µl FITC rabbit anti-active Caspase-3 
antibody was used for each sample and cells were incubated for 1 hour at room 
temperature in subdued light.  Stained cells were washed once with 1 ml 1× Cytoperm 
buffer, and resuspended in 300 µl of the same buffer for FACS analysis. 
 
2.22 Invasion and migration assay 
Analysis of cell invasion and migration was performed using 24-well BD Falcon 
FluoroBlokTM transwell insert (cat#351152, BD Biosciences) with 8 µm pore size and 
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special 24-well plates (cat#353504, BD Biosciences). For the purpose of invasion 
assay, inserts were prepared by coating the upper surface with 80 µl of 250 ng/ml 
growth factor reduced matrigel (cat#356231, BD Biosciences). The coatings were 
then incubated for 4 to 6 hours at 37ºC in a cell culture incubator prior to seeding of 
cells. For migration assay, the inserts remained un-coated. Cells (approximately 2.5 to 
5 × 104) were seeded into the upper compartment of each insert with 200 µl DMEM 
containing 0.25% FBS. A chemoattractant consisting of 750 µl DMEM with 10% 
FBS were deposited into the bottom wells to allow the invading and migrating cells to 
penetrate through the insert. After 24 hours incubation at 37ºC, inserts were fixed with 
3.7% formaldehyde for 20 minutes, and stained with 25 µg/ml propidium iodide for 
30 minutes at room temperature in subdued light. Invaded and migrated cells beneath 
the inserts were scanned and counted using high content screening machine Cellomics 
ArrayScan VTI (Thermo Scientific Inc.). 10 individual fields were scanned for each 
insert and the result was presented as the sum of 10 fields. Triplicates were carried out 
for each sample, and at least three independent experiments were repeated. 
 
2.23 Three-dimensional matrigel culture 
The three-dimensional culture of mammary epithelial cells on a reconstituted 
basement membrane (matrigel) has been widely accepted to recapitulate various 
features of breast epithelium in vivo. Unlike monolayer culture, mammary epithelial 
cells grown in three-dimension display the formation of acini-like spheroids with a 
hollow lumen and these acini were made up of apicobasal polarized cells. This 
structure mimics glandular epithelium in vivo. In the presence of oncogenes, the 
morphogenesis of glandular architecture by mammary epithelium became disrupted. 
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Thus, three-dimensional epithelial culture provides the appropriate structural and 
functional context fundamental for examining the biological activities of cancer genes 
(Debnath, Muthuswamy et al. 2003). 
 
For three-dimensional culture of cells on matrigel, 8-well chamber slide (cat#384118, 
BD Biosciences) was used, and 7.6 mg/ml growth factor reduced matrigel 
(cat#356231, BD Biosciences) was thawed on ice and 50 µl matrigel was spread out 
evenly in each well. The matrigel coated culture slide was placed in 37ºC incubator to 
solidify the matrigel layer. The matrigel layer measured approximately 1-2 mm in 
thickness. MDA-MB-231 FOXQ1 knockdown and control cells were plated (5000 
cells/well) in 8-well chamber slide on a solidified layer of matrigel. Each well was 
filled with 400 µl DMEM containing 2% FBS and 2-4% matrigel. For MCF10A cells, 
special assay medium was used for three-dimensional matrigel growth. The medium 
contained DMEM/F12 supplemented with 2% horse serum, 1% PS, 5 ng/ml EGF, 0.5 
mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 µg/ml insulin and 2% matrigel. 
The medium in wells were replaced with fresh medium every four days. Phase 
contrast images of the three-dimensional structure were taken on indicated days. 
 
2.24 Mammosphere formation assay 
Mammosphere formation assay was developed by Dontu and Wicha to allow in vitro 
culture of undifferentiated human mammary epithelial cells in suspension. When 
cultured on non-adherent surfaces in the presence of growth factors, human mammary 
epithelial cells form spherical colonies termed ‘non-adherent mammospheres’. They 
have demonstrated that these non-adherent mammospheres are enriched in cells with 
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functional traits of stem/progenitor cells. This in vitro assay is suitable for testing self-
renewal and differentiation of all three lineages present in the mammary gland, and it 
also facilitates the isolation and characterization of human mammary stem cells and 
the related pathway (Dontu, Abdallah et al. 2003). 
 
To perform mammosphere formation assay, single cell suspension of target cells were 
plated at a density of 5000 cells/well in 6-well ultra-low attachment plates (Corning) 
containing 2 ml MammoCult medium with hydrocortisone and heparin (STEMCELL 
technologies) and cultured for a period of 7 days. For mammosphere numbers 
calculation, single cell suspension (100 cells/well) was plated in 96-well ultra-low 
attachment plates under the same conditions. Mammosphere sizes more than 100 µm 
were counted under microscope (Nikon ECLIPSE TS100). The data calculated for the 
number and size of mammosphere is the average of three independent experiments.  
 
2.25 Total RNA extraction 
Total RNA was isolated using Trizol (Invitrogen) and purified with the RNeasy Mini 
Kit (QIAGEN). First, 106 cells were lysed with 1 ml Trizol and 200 µl chloroform. 
The RNA layer was separated by centrifuge at 12000 rpm for 15 minutes at 4ºC. The 
upper layer containing RNA was transferred to a fresh RNAse-free tube and 
neutralized with equal volume of 70% ethanol. The mixtures were purified through 
filter column provided in the kit and washed once with 750 µl RW1 buffer followed 
twice with 500 µl RPE buffer based on manufacture’s instruction. Finally, the RNAs 
were eluted into 30 µl RNAse-free water. The RNA quantity and concentration were 




To perform RT-PCR, total RNA was diluted to a concentration of 125 ng/µl based on 
TITANIUM One-Step RT-PCR Kit (Clontech). 1 µl of the diluted total RNA was 
used for each reaction together with 1× one step buffer, 1× dNTP mix, 0.4 unit 
RNAse inhibitor, 0.5× thermostabilizing reagent, 0.2× GC-melt, 0.4 µM oligo(dT) 
primer, 1× RT-titanium Taq enzyme mix, 0.9 µM specific PCR primer mix and 
finally topped up with RNAse-free water to 25 µl volume. The PCR mixture was 
amplified in the PCR machine (DNA Engine DYADTM, MJ Research) programmed to 
run step one at 50ºC for 1 minute, step two at 94ºC for 5 minutes, step three at 94ºC 
for 30 seconds, step four at 60ºC for 30 seconds, and step five at 68ºC for 30 seconds. 
Steps three to five were then repeated for indicated cycles. Step six ran at 68ºC for 2 
minutes, and finally the mixture was incubated at 4ºC. GAPDH was used as internal 
control. The RT-PCR results were visualized by 2% DNA agarose gel electrophoresis. 
RT-PCR primers are listed in Table 2.3. 
 
2.27 Semi-quantitative RT-PCR 
In order to carry out semi-quantitative real-time PCR, total RNAs were converted into 
cDNA first. In this converting experiment, 1-2 µg of total RNA was diluted into 25 µl 
RNAse-free water for preparing cDNA according to protocols of the High-Capacity 
cDNA Reverse Transcription Kits (Applied Biosystems). In detail, 25 µl of diluted 
RNA was mixed with PCR master mix comprising 5 µl 10X reverse transcription 
buffer, 2 µl 25X dNTPs, 5 µl 10× random primers, and 2.5 µl MultiScribeTM reverse 
transcriptase. This mixture was finally topped up with RNAse-free water to 50µl. This 
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50 µl mixture was fed into the PCR machine which was ran using the programme of 
25ºC for 10 minutes, 37ºC for 2 hours, and the sample finally incubated at 4ºC. 
 
Semi-quantitative real-time PCR was performed using PRISM 7900 Sequence 
Detection System (Applied Biosystems). 2 to 4 ng cDNA were amplified using 
FOXQ1, E-cadherin, Vimentin, CD44, CD24 and GAPDH Taqman probes (Applied 
Biosystems) with Taqman fast universal PCR master mix (cat#4352042, Ambion, 
Applied Biosystems). Three independent experiments were performed for quantitative 
real-time PCR. Results were normalized to reflect fold changes of target genes with 
respect to internal control GAPDH. 
 
2.28 Microarray gene expression profiling 
Gene expression profiling was performed on the platform of Illumina Gene 
Expression Sentrix® BeadChip HumanRef-8_V2 and V3 (San Diego, CA). The 
procedure is described as follows. 
 
2.28.1 RNA amplification and labeling 
Total RNA was extracted using method as described in section 2.25. Illumina® 
TotalPrepTM-96 RNA Amplification Kit was used for RNA amplification and labeling. 
For each sample, 500 ng RNA was diluted in 11 µl nuclease-free water, and 9 µl 
reverse transcription master mix [2 µl 10× first strand buffer, 4 µl dNTP mix, 1 µl T7 
oligo(dT) primer, 1 µl RNAse inhibitor, and 1 µl ArrayScriptTM reverse transcriptase]. 
This mixture was incubated at 42ºC for 2 hours in thermocyclers (DNA Engine 
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DYADTM, MJ Research) to synthesize first strand cDNA. In order to generate second 
strand cDNA, 80 µl second strand master mix (63 µl nuclease-free water, 10 µl 
second strand buffer, 4 µl dNTP mix, 2 µl DNA polymerase and 1 µl RNase H) was 
combined with the previous product, and incubated at 16ºC for 2 hours. To eliminate 
excess primers, salt and enzymes, 100 µl cDNA product was purified by adding 180 
µl cDNAPure first. The cDNA became bound to the magnetic beads in the cDNA 
Pure buffer. cDNA binding beads were captured by magnetic stand, and these beads 
were washed twice with 150 µl cDNA wash buffer. cDNA was eluted with 20 µl 
preheated Nuclease-free water, and 17.5 µl eluted cDNA was transferred to a fresh 
PCR plate for labeling. In order to produce biotin-labeled cRNA, 7.5 µl IVT master 
mix (2.5 µl biotin-NTP mix, 2.5 µl T7 10× reaction buffer, and 2.5 µl T7 enzyme mix) 
was added into 17.5 µl purified cDNA and incubated at 37ºC for 14 hours. The 
mixture was then used to transcript biotin-labeled cRNA in vitro. On the next day, 
transcripted cRNA was added into 70 µl cRNA binding buffer that contained 
magnetic beads and further mixed with 95 µl 100% ethanol. cRNA binding beads 
were captured by magnetic stand, and washed twice with 100 µl cRNA wash solution. 
Finally, purified cRNA was eluted with 40 µl preheated cRNA elution buffer. cRNA 
concentration was measured with NanoDrop spectrophotometer. The biotin-labeled 
and purified cRNA was stored at -20ºC for further hybridization. 
 
2.28.2 Hybridization 
Illumina 8-sample Sentrix® BeadChip was used for hybridization. Before the samples 
were hybridized, buffer GEX-HYB and GEX-HCB were pre-warmed in 58ºC 
Illumina hybridization oven (San Diego, CA) until all salts were dissolved. For each 
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sample, 750 ng cRNA was diluted in 5 µl RNase-free water and 10 µl GEX-HYB, 
and incubated at 65ºC for 5 minutes. Illuminal Hyb camber gasket was placed into 
BeadChip Hyb chamber, and 200 µl GEX-HCB was added into each of the two 
humidifying buffer reservoirs in each Hyb chamber. BeadChip was placed into the 
Hyb chamber insert, and barcode was oriented to match the symbol on the insert. 15 
µl of each pre-heated cRNA samples were loaded into BeadChip. The Hyb chamber 
insert containing samples was loaded into BeadChip Hyb chamber, and chamber was 
sealed with lid. The sealed Hyb chamber was baked in Illumina Hybridization oven at 
58ºC for 18 hours to complete hybridization. 
 
2.28.3 Wash and imaging BeadChip 
After hybridization, on the next day, Hyb chamber was removed from oven and 
disassembled. The coverseal on top of the BeadChip was peeled off, and BeadChip 
was transferred to sliding rack submerged in diluted E1BC wash buffer for staining. 
The sliding rack with BeadChip was next transferred into the Hybex waterbath insert 
containing High-Temp wash buffer and incubated for 10 minutes at 55ºC. The 
BeadChip was washed at room temperature with 250 ml E1BC for 100 minutes 
followed by a 10 minutes wash with 100% ethanol. A second wash at room 
temperature with another 250 ml E1BC buffer, and BeadChip was then incubated 
with 4 ml E1 buffer for blocking. After blocking, BeadChip was detected with 2 ml 
buffer E1 at 1/1000 dilution of steptavidin-Cy3 for 10 minutes. The BeadChip was 
finally washed with 250 ml E1BC buffer. After wash, BeadChip was dried 
immediately by centrifuge at 100×g for 4 minutes at 25ºC. The dried BeadChip was 
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scanned using Illumina BeadArray Reader, and images were stored with indicated 
barcodes for further analysis. 
 
2.28.4 Gene expression profiling and Gene ontology analysis 
The scanned BeadChip images were processed through Illumina GenomeStudioTM 
first and the generated data were imported into GeneSpringGXTM (Agilent 
Technologies) software for further analysis. To do GeneSpringGX analysis, Illumina 
single color was selected for experimental type and signals were normalized to 
median of all samples in the same BeadChip. To achieve a meaningful gene 
expression profile, samples were numbered and grouped with experimental design. 
Fold changes were calculated by comparison of paired samples. Cluster heat map was 
generated by hierarchical analysis and the distance metric was set to Pearson centered. 
The analyzed gene sets by GeneSpring were next subjected to Ingenuity Pathway 
Analysis (IPA) (www.ingenuity.com) for gene ontology analysis. Gene name and fold 
changes were imported into IPA, and analyzed results showed the potential signalling 
pathways involved and related biological functions. 
 
2.29 Clinical relevance and survival analysis 
To get the information of gene expression pattern on published databases, I examined 
FOXQ1 expression in web-based cancer microarray database i.e. Oncomine 
(www.oncomine.org). Oncomine provides cancer microarray data in a variety of 
cancer subtypes and clinical-based as well as pathology-based analyses (Rhodes, Yu 




In the breast cancer data set of Vande Vijver, the expression of probes for each 
FOXQ1 gene was averaged and transformed to z-score. The positive z-score was 
treated as higher expression and the negative z-score was treated as lower expression. 
Kaplan-Meier survival analysis was used for the analysis of clinical outcome. 
 
2.30 Statistical analysis 
Statistical analysis was done using Prism (GraphPad software Inc., San Diego, CA) 
for three independent experiments. T-test was carried out for p-value calculation. 
Error bar was plotted with SEM (standard error of mean).  
 
Table 2.1 Genomic region of CTGF, SLUG, and CDH1 promoters 
 
Promoter name Genomic region Product length (bp) Restriction enzyme site 
CTGF-P1 (-2000 to -797bp) 1205 KpnI and BglII 
CTGF-P2 (-874 to +195 bp) 1069 KpnI and BglII 
SLUG-P1 (-2000 to -800 bp) 1200 KpnI and XhoI 
SLUG-P2 (-900 to +100 bp) 1000 KpnI and XhoI 
SLUG-P3 (-400 to -50 bp) 350 KpnI and XhoI 
SLUG-P4 (- 400 to +100 bp) 500 KpnI and XhoI 
SLUG-P5 (-900 to -400 bp) 500 KpnI and XhoI 
CDH1-P2 (-1000 to +200 bp) 1200 MluI and BglII 















Table 2.2 Oligonucleotide primers for expression vector construction 
 Name Direction Sequence 
Full length-FOXQ1 forward 5' GGTACCCCACCATGAAGTTGGAGGTGTTCGTCC 3' 
  reverse 5' GAATTCCAGGCTAGGAGCGTCTCCAC 3' 
D1-FOXQ1 forward 5' AGGTACCACCATGAAGTTGGAGGTGTTCGTC 3' 
 
reverse 5' AGAATTCTTCTTGCGCAGGATGCTG 3' 
D2-FOXQ1 forward 5' AGGTACCACCATGAAGTTGGAGGTGTTCGTC 3' 
  reverse 5' AGAATTCATGCTGTCGATGGCG 3' 
D3-FOXQ1 forward 5' GGTACCACCATGAAGTTGGAGGTGTTC 3' 
 
reverse 5' GAATTCCCGTCGGCGAAGGTGTAC 3' 
D4-FOXQ1 forward 5' GGTACCCCACCATGCTCAACCCCAACAGCGAG 3' 
  reverse 5' GAATTCCAGGCTAGGAGCGTCTCCAC 3' 
D5-FOXQ1 forward 5' GGTACCATGAAGCGCCTCAGCCAC 3' 
 
reverse 5' GAATTCCAGGCTAGGAGCGTCTCCAC 3' 
D6-FOXQ1 forward 5' GGTACCACCATGAAGTTGGAGGTGTTC 3' 
  reverse 5' GAATTCCGCGTATATGGCTTGCT 3' 
D7-FOXQ1 forward 5' GGTACCACCATGAAGTTGGAGGTGTTCGTCCCT 3' 
 
reverse 5' GAATTCCGCTTGCGGCGGCGGCGGAAGACCCC 3' 
D7/NLS mut-FOXQ1 forward 5' GGTACCACCATGAAGTTGGAGGTGTTCGTCCCT 3' 
  reverse 5' GAATTCCGGGCGCGGGCGCGGGCGAAGACCCC 3' 
D8-FOXQ1 forward 5' GGTACCACCATGCGCCGCCGCCGCAAG 3' 
 
reverse 5' GAATTCCAGGCTAGGAGCGTCTCCAC 3' 
FOXQ1/pMN forward 5' TCCCGCACTCTGTTCGCCGTCGCC 3' 
  reverse 5' CCCGGCGGCGGCCCCCGCCAAGCC 3' 94
 
Table 2.3 Oligonucleotide primers for RT-PCR  
 Name Direction Sequence 
CTGF forward 5' GCACAAGGGCCTCTTCTGTGA 3' 
  reverse 5' TGTCTTCCAGTCGGTAAGCCG 3' 
FOXQ1 forward 5' ATGAAGTTGGAGGTGTTCGT 3' 
 
reverse 5' TGAGCGCGATGTACGAGTAG 3' 
GAPDH forward 5' ATGGGGAAGGTGAAGGTCGG 3' 
  reverse 5' AAGACGCCAGTGGACTCCACGA 3' 
ACTIN forward 5' GTGGGGCGCCCCAGGCACCA 3' 
 
reverse 5' CTCCTTAATGTCACGCACGATTTC 3' 
VIM forward 5' ATGTCCACCAGGTCCGTGTC 3' 
  reverse 5'GCGGGTGTTCTTGAACTCGG3' 
CDH1 forward 5' CTGCTGCTGCTGCAGGTCTCCTCTT 3' 
 
reverse 5' TTCTGAGGCCAGGAGAGGAGTTGGG 3' 
SLUG forward 5' CGCGCTCCTTCCTGGTCAAGAA 3' 
  reverse 5' GGCATGGGGGTCTGAAAGCT 3' 
SNAIL forward 5' ATGCCGCGCTCTTTCCTCGT 3' 
 
reverse 5' AAGGACGAAGGAGCCGGTGA 3' 
TWIST forward 5' ATGATGCAGGACGTGTCCAG 3' 
  reverse 5' TCGTAAGACTGCGGACTCCC3' 95
 
Table 2.4 Oligonucleotide primers for promoter construction 
Name Direction Sequence 
CDH1-P1 forward 5' ACGCGTTGGCTCATGCCTGTAAT  3' 
 reverse 5' AGATCTCCCTCGCAAGTCAGGGG 3' 
CDH1-P2 forward 5' ACGCGTATTAGGCCGCTCGAG 3' 
 reverse 5' AGATCTCCCTCGCAAGTCAGGGG  3' 
SLUG-P1 forward 5' GGTACCGATCTGTGCAGTGCACC 3' 
 reverse 5' CTCGAGTCTCTCACACTTTTGACAAGAGAT   3' 
SLUG-P2 forward 5' GGTACCATAATTGTCTCTAAAGACCCATACAACC  3' 
 reverse 5' CTCGAGCTACAGCATCGCGGC 3' 
SLUG-P3 forward 5' GTACCTAACACCAGAGGCTGGCCT 3' 
 reverse 5' CTCGAGATCCAATCACAGCTGAGAGG 3' 
SLUG-P4 forward 5' GGTACCTAACACCAGAGGCTGGCCT 3' 
 reverse 5' CTCGAGCTACAGCATCGCGGC 3' 
SLUG-P5 forward 5' GGTACCATAATTGTCTCTAAAGACCCATACAACC 3' 
 reverse 5' CTCGAGATGAGAGCCTATATTTGGAAGTGG 3' 
CTGF-P1 forward 5' GGGGTACCTCTTGAAAGGTTTCACTGTGG 3' 
 reverse 5' GAAGATCTGTGGCCATCAATGTTTCCAG 3' 
CTGF-P2 forward 5' GGGGTACCAGCCCCTACCTACCCAACACA 3' 






Table 2.5 Oligonucleotide for FOXQ1 shRNA construction 
Name Target sequence Direction Sequence Oligo length 
 





















































Table 2.6 Oligonucleotide primers for site-directed mutation vector construction 
Name Sequence 
S18A 5' GGACAAGCAGGGCGCTGACCTGGAGGGC 3' 
S217A 5' CGCAAGCGCCTCGCCCACCGCGCGCC 3' 
T115A 5' CACGCAGCAAGCCATATGCGCGGCGGC 3' 
































Recent evidence has shown that forkhead transcription factor family members such as 
FOXC1 and FOXC2 are associated with EMT and tumor progression in aggressive 
basal-like breast cancer (Mani, Yang et al. 2007; Ray, Wang et al. 2010). However, it 
is not clear whether other forkhead family members also have roles in breast cancer 
progression. FOXQ1 is the only member that has been identified so far in the ‘Q’ 
subgroup of the forkhead family, and its biological functions in breast cancer have not 
been previously studied. In this study, I investigated the functional role of FOXQ1 in 
breast cancer, in particular with respect to EMT. 
3.1 FOXQ1 expression is associated with aggressive breast cancer 
phenotypes 
In order to identify additional EMT regulators within the forkhead transcription factor 
family, microarray gene expression analysis was performed to compare the expression 
levels of forkhead transcription factor members between the highly invasive 
mesenchymal-like breast cancer MDA-MB-231 and non-invasive epithelial-like 
breast cancer MCF7 cells using Illumina Beadchip gene expression array. The results 
showed that among all 49 array detectable forkhead genes, FOXQ1 was identified as 
the most highly overexpressed in MDA-MB-231 cells relative to MCF-7 cells (Figure 
3.1A). Notably, the differential expression of other established forkhead EMT 
inducers including FOXC1 and FOXC2 were less prominent. This finding was further 
confirmed by quantitative RT-PCR in a panel of breast cancer cell lines including 
luminal and basal-like subtypes and non-cancerous breast cell lines. The results 
showed the higher levels of FOXQ1 mRNA in basal-like breast cancer cell lines 
MDA-MB-231, MDA-MB-468, MDA-MB-436, and BT549 subtype as compared to 
luminal cell lines (MCF-7, T47D, SKBR-3, BT474, MDA-MB-361, and MDA-MB-
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415) as well as non-cancerous mammary epithelial MCF10A and HMLER cells 
(Figure 3.1B).  The endogenous protein levels of FOXQ1 in the above breast cancer 
cell lines were examined as well. Except for MDA-MB-468, all other basal-like breast 
cancer cell lines BT549, MDA-MB-436 and MDA-MB-231 expressed high levels of 
FOXQ1 protein (Figure 3.1C). Interestingly, MDA-MB-468 cell which is 
characterized as basal A, while the others (BT549, MDA-MB-436 and MDA-MB-231) 
are defined as basal B breast cancer. Clinically, basal B breast cancers are more 
representative of triple-negative breast cancer subtype, and displayed stem cell gene 
expression profile as shown by microarray analysis (Neve, Chin et al. 2006). The 
discrepancy between FOXQ1 protein level and mRNA level in MDA-MB-468 cells 
could be caused by posttranslational modification. In general, FOXQ1 expression 
seems to correlate with basal B (also known as triple-negative) breast cancer which 




















Figure 3.1 FOXQ1 is highly expressed in invasive breast cancer cells. 
A, Relative gene expression levels of forkhead family members in MDA-MB-231 
compared to MCF7 cells, based on Illumina gene expression array data from the 
respective two cell lines. 
B, Quantitative RT-PCR analysis of FOXQ1 mRNA in indicated cell lines. 







































































































































































































































































































































To seek clinical evidence linking FOXQ1 expression to breast cancer, the FOXQ1 
expression was examined in Oncomine data sets (www.oncomine.com).  The data 
from various breast cancer cohorts showed that the FOXQ1 expression correlated 
with not only a higher tumor grade (P=0.0007) in VantVeer database (Figure 3.2A), 
but also metastasis (P=0.003) in VandeVijver database (Figure 3.2B). Especially 
FOXQ1 is highly enriched in unfavorable estrogen receptor (ER)/progesterone 
(PR)/HER2 triple-negative basal-like subtype (P=0.008) revealed in Richardson 
database (Figure 3.2C). Moreover, higher FOXQ1 expression is also associated with 
poor clinical outcomes (P=0.002) in VandeVijver database (Figure 3.2D). The 
patients with high FOXQ1 expression have less overall survival. These results from 
both in vitro and clinical data suggested a potential oncogenic role of FOXQ1 in a 
















Figure 3.2 FOXQ1 expression is associated with aggressive breast cancers in 
clinical databases. 
A, FOXQ1 expression level in breast cancer is associated with high grade in the Vant 
Veer cohort. 
B, FOXQ1 expression level in breast cancer is associated with metastatic status in the 
Vande Vijver cohort. 
C, FOXQ1 expression level in breast cancer is associated with basal-like disease type 
in the Richardson cohort. 
D, Higher level of FOXQ1 expression is associated with poorer survival. Kaplan-
Meier survival plots of overall survival from the Vande Vijver cohort. Patients with 
higher levels of FOXQ1 are highlighted in red, while patients with lower levels of 









3.2 FOXQ1 depletion reduces mesenchymal phenotype and 
invasive ability of MDA-MB-231 cells in vitro 
To functionally validate the role of FOXQ1 in regulating aggressive breast cancer 
phenotype, triple-negative breast cancer cell line MDA-MB-231 was used. MDA-
MB-231 is a mesenchymal-like aggressive breast cancer cell line and is often used to 
study breast cancer invasion and metastasIs. In order to investigate the role of FOXQ1 
in MDA-MB-231 cells, several FOXQ1 shRNA sequences were introduced into 
MDA-MB-231 cells to establish stable FOXQ1 knockdown cell lines. A total of three 
FOXQ1 depletion clones were generated in MDA-MB-231 cells. One stable cell line 
was generated to express a pool of three individual FOXQ1 shRNA sequences which 
was purchased from Santa Cruz (designated as shFOXQ1-SC). Another two clones 
were derived from the same single FOXQ1 shRNA sequence with different single 
clones (designated as shFOXQ1 #2-9, #2-12). These stable FOXQ1-depleted MDA-
MB-231 cell lines and their respective control cells were maintained under puromycin 
containing medium. 
 
Typically, the morphology of MDA-MB-231 cells displays an elongated and spindle-
like phenotype associated with invasive ability. Notably, FOXQ1 ablation induced a 
change from spindle-like mesenchymal morphology of MDA-MB-231 cells into 
epithelial-like morphology by manifesting an increased cell-to-cell adhesion in all 


















Figure 3.3 Morphological change of MDA-MB-231 cells after depletion of 























Coupled with the loss of spindle-like phenotype and acquired pronounced cell-cell 
interaction and adhesion, related EMT markers E-cadherin and vimentin were then 
examined in protein and mRNA levels. E-cadherin serves as an epithelial marker 
which strengthens the bond between cells much like a glue. On the other hand, 
vimentin is a mesenchymal marker which indicates whether epithelial cells have 
acquired mesenchymal features. The mRNA level and protein level of these EMT 
markers were examined in three different FOXQ1 shRNA MDA-MB-231 cell lines. 
Consistent with the phenotypic change associated with FOXQ1-depletion was an 
increased expression of epithelial marker E-cadherin (CDH1) and a concomitant 
down regulation of mesenchymal marker vimentin (Vim) in all three FOXQ1 
depletion cell lines (Figure 3.4). However, depending on the levels of FOXQ1 
knockdown in the various established cell lines, changes to the EMT markers can be 
different. Cells expressing shFOXQ1-SC have greater knockdown efficiency than the 
other two cell lines and also, shFOXQ1-SC cells have more pronounced CDH1 
mRNA and protein expression than others. Consistent with E-cadherin changes 
observed in these three cell lines, vimentin decreased largely in shFOXQ1-SC cells 
when compared to other cell lines. These E-cadherin and vimentin changes correlated 
with the degree of FOXQ1 knockdown in MDA-MB-231 cells. Therefore, FOXQ1 
depletion could have resulted in a reversal of EMT in MDA-MB-231 cells. In addition, 
immunofluorescent confocal imaging shown in Figure 3.5 indicated similar alterations 



















Figure 3.4 mRNA and protein levels of EMT markers and FOXQ1 in MDA-MB-
231 FOXQ1 depleted cell lines. 
A, Quantitative RT-PCR of CDH1 (E-cadherin), Vim (vimentin), and FOXQ1 mRNA 
levels in MDA-MB-231 FOXQ1-SC depleted cells. 
B, Levels of the indicated proteins in MDA-MB-231 FOXQ1-SC depleted cells. 
C, Quantitative RT-PCR of CDH1 (E-cadherin), Vim (vimentin), and FOXQ1 mRNA 
levels in two other clones of MDA-MB-231 FOXQ1 depleted cells. 































































































Figure 3.5 Immunofluorescent confocal images of E-cadherin and vimentin in 
MDA-MB-231 FOXQ1-SC depleted cells. 
A, Vimentin (red) is detected by Alexa Fluor 546 and nucleus (blue) is detected by 
DAPI. 






















In addition to loss of epithelial marker E-cadherin and gain of mesenchymal marker 
vimentin upon depletion of FOXQ1 in MDA-MB-231 cells, there is also a functional 
impact associated with FOXQ1 depletion upon analysis of these cells. In order to 
assess the invasion ability of MDA-MB-231 cells after FOXQ1 depletion, I used the 
in vitro transwell invasion assay technique. The representative images in Figure 3.6A 
indicated that FOXQ1 depletion markedly reduced the invasive ability of MDA-MB-
231 cells in terms of number of cells which have crossed through the matrigel-coated 
membrane. The quantitative result showed that depletion of FOXQ1 in MDA-MB-
231 cells attenuated its invasion ability by more than 50% in shFOXQ1-SC cells 
(Figure 3.6B), as well as two other FOXQ1 shRNA #2-9 and #2-12 expressing cell 
lines (Figure 3.6C). This reduction of invasion should not be due to reduced cell 
proliferation rate as FOXQ1 ablation did not change the proliferation rate of 

















Figure 3.6 FOXQ1 depletion reduced the invasive ability of MDA-MB-231 cells 
in vitro. 
A, Representative view of invaded cells beneath the matrigel-coated membrane for 
the indicated cell lines. 
B, Invaded cells were quantified in FOXQ1-SC cells. 
C, Invaded cells were quantified in another two FOXQ1 depleted clones. 






















































































The ability to differentiate was measured under in vitro condition of 3D matrigel 
culture. MCF10A, a non-cancerous human mammary epithelial cell line, was able to 
differentiate into spheroid structure with a lumen which mimics acinar tissue structure 
in vivo (Figure 3.7C). The black arrow indicates the luminal space of MCF10A tissue 
cells. The acinar tissue structure will be disrupted in the presence of oncogenic signals 
such as Ras. Figure 3.7 B shows the 3D tissue structure of MCF10A cells transformed 
with Ras oncogene relative to an empty vector control. Ras expressing MCF10A cells 
displayed a spread and aggressive morphology compared to its empty vector (pBabe) 
control. To assess 3D growth potential in FOXQ1 depleted cells, three different 
shFOXQ1 MDA-MB-231 cell lines were cultured under conditions of 3D matrigel. 
The control MDA-MB-231 cells displayed aggressive phenotype by showing highly 
disorganized structures of cell cluster lacking basal polarity (Figure 3.7A). This 
aggressive phenotype is similar with the Ras oncogene transformed MCF10A cells 
(Figure 3.7B). In contrast, MDA-MB-231 cells depleted of FOXQ1 showed more 
uniform and polarized acinar structures in all three cell lines (Figure 3.7A). Therefore, 
FOXQ1 depletion in MDA-MB-231 breast cancer cells may attenuate the aggressive 
















Figure 3.7 3D matrigel growth of MDA-MB-231 FOXQ1 depleted cells. 
A, 3D matrigel growth of three MDA-MB-231 FOXQ1 depleted cell lines. 
B, MCF10A cells transfected with vector control pBabe or Ras oncoprotein were 
grown on matrigel. 





























3.3 Ectopic FOXQ1 expression in human mammary epithelial cells 
induces EMT and mammosphere formation 
After showing that FOXQ1 has functional regulation of EMT in aggressive MDA-
MB-231 cells, I next examined whether ectopic expression of FOXQ1 is able to 
trigger mesenchymal phenotype in immortalized human mammary epithelial cells. To 
achieve this, I used a semi-transformed human mammary epithelial cell line (HMLER) 
as a model which has been previously shown to undergo EMT upon overexpression of 
EMT regulator such as Snail or Twist. A stable HMLER cell line expressing FOXQ1 
was established through retroviral induction (designated as HMLER-FOXQ1). The 
validation of FOXQ1 expression in cell lines with the appropriate matching controls is 
shown in Figure 3.9 by RT-PCR and quantitative PCR. While the HMLER cells 
expressing a control vector (HMLER-pMN) retained an epithelial morphology with 
tight cell-to-cell adhesion, in contrast, HMLER-FOXQ1 cells displayed an elongated 
morphology typically associated with mesenchymal phenotype (Figure 3.8). These 
morphological changes in HMLER-FOXQ1 cells were accompanied by a marked 
reduction of E-cadherin (CDH1) expression and increased expression of vimentin 
(Vim) at both mRNA and protein levels (Figure 3.10). The immunofluorescent 
confocal imaging showed the loss of E-cadherin at the cell boundary and gain of 
vimentin in HMLER-FOXQ1 cells (Figure 3.11) at single cell level. These findings 














Figure 3.8 Ectopic expression of FOXQ1 in HMLER cells led to gain of 













Figure 3.9 Validation of ectopic FOXQ1 expression in HMLER cells. 
A, RT-PCR using FOXQ1 specific primers in vector control cells HMLER-pMN, and 
FOXQ1 expressing cells HMLER-FOXQ1. 

























































Figure 3.10 Changes in the level of EMT markers which accompanied FOXQ1-
induced EMT in HMLER cells. 
A, Quantitative PCR of CDH1 (E-cadherin) and Vim (vimentin) in HMLER cells, 
carrying empty vector pMN or FOXQ1 overexpression vector. 




















































Figure 3.11 Immunofluorescent confocal images of EMT markers in HMLER 
cells expressing control vector or FOXQ1. 
Both E-cadherin and vimentin were stained with Alexa Fluor 546 in red color, and 













Recent studies have shown that human mammary epithelial cells undergoing EMT 
often exhibit a gain of stem cell-like characteristics, including increased expression of 
breast stem cell marker CD44, and reduced expression of CD24, as well as enhanced 
capacity to form spherical colonies in suspension cultures, termed tumor 
mammospheres. To test whether FOXQ1 overexpression in HMLER cells can also 
result in similar stem cell-like properties, I assessed the alterations in expression of 
CD44 and CD24 in HMLER-FOXQ1 cells as well as the cell’s capacity to form 
mammospheres. Indeed, HMLER-FOXQ1 cells expressed increased levels of CD44 
and reduced CD24 as compared to the control cells (Figure 3.12) in both mRNA and 
protein levels and formed significantly larger numbers of mammospheres when 
cultured in suspension using a mammosphere formation assay (Figure 3.13A and B). 
The formed mammosphere populations were found to be further enriched in protein 
levels of FOXQ1 as well as CD44, which supports a role of FOXQ1 in driving the 
formation of mammosphere (Figure 3.13C). Taken together, I propose that FOXQ1 
induced EMT in HMLER cells endowed these cells with breast cancer stem cell-like 





















Figure 3.12 Breast cancer stem cell marker changes in HMLER cells expressing 
either vector control or FOXQ1. 
A, Quantitative PCR measuring CD24 and CD44 mRNA levels in HMLER cells 
expressing either control vector or FOXQ1. 























































Figure 3.13 Ectopic expression of FOXQ1 in HMLER cells led to gain of stem 
cell-like characteristics. 
A, Mammosphere formation in indicated cultured cell lines at day 7. 
B, Quantification of formed mammosphere in indicated cell lines. 































Consistent with an established role of E-cadherin depletion in EMT induction in 
mammary epithelial cells, I showed that E-cadherin knockdown in HMLER cells led 
to the establishment of a mesenchymal-like morphology (Figure 3.14A).  Depletion of 
E-cadherin was sufficient to induce EMT and mammosphere formation (Figure 
3.14B), with corresponding changes in levels of vimentin, CD44 and CD24 (Figure 
3.15B). Thus, the deletion of E-cadherin could be a functionally relevant target of 
FOXQ1 in EMT induction. Collectively, these findings suggested that FOXQ1 is able 
to induce EMT and stem cell-like characteristics, further supporting an oncogenic role 


















Figure 3.14 Morphology and mammosphere formation of E-cadherin 
knockdown HMLER cells. 
A, Morphological change in control (shCtrl) and E-cadherin knockdown (shEcad) 
HMLER cells. 





























Figure 3.15 E-cadherin knockdown in HMLER cells induces EMT and stem cell-
like traits. 
A, Quantification of mammospheres formed in HMLER cells in vector control (shCtrl) 
and E-cadherin knockdown (shEcad) samples. 




















3.4 Depletion of FOXQ1 expression in MDA-MB-231 cells 
increases sensitivity to chemotherapy-induced apoptosis 
Cancer cells undergoing EMT has recently been connected to chemoresistance, which 
has been observed in FOXQ1 overexpressing colon cancers in Chapter 4. Hence I 
next investigated whether FOXQ1 has a role to play in apoptosis induced by DNA-
damaging agents in shFOXQ1-SC MDA-MB-231 breast cancer cells. I found that 
FOXQ1 depletion in MDA-MB-231 cells resulted in increased apoptotic response 
(more than 50%) to a series of chemotherapeutic drugs, including 5-Flurouracil (5FU), 
paclitaxel (Taxol) and camptothecin (CPT) in a dose-dependant manner, as assessed 
by Caspase 3 activation assay through FACS analysis (Figure 3.16). Hence, these 
results showed that FOXQ1 deregulation not only induced EMT but also could be a 













Figure 3.16 FOXQ1 depletion in MDA-MB-231 cells increases their drug 
sensitivity in a dose-dependent manner. 
Active Caspase 3 activity was measured after treatment using 375 µM of 5FU; 0.5 






























3.5 FOXQ1 mediated transcription network in breast cancer cells 
Since EMT regulation by transcription factor FOXQ1 has been observed in both 
FOXQ1 overexpression and knockdown system, therefore, I sought to identify the 
transcriptional network regulated by FOXQ1. 
 
Microarray gene expression analysis was performed in both FOXQ1 overexpression 
(HMLER) and knockdown (MDA-MB-231) systems. I planned to identify two set of 
genes in which one is positively regulated by FOXQ1, and the other is negatively 
regulated by FOXQ1. To achieve this, genes upregulated in HMLER-FOXQ1 as 
compared to HMLER-pMN control were overlapped with those that were 
downregulated upon FOXQ1 knockdown in MDA-MB-231 cells. Using this method, 
I was able to identity the gene set positively regulated by FOXQ1. Conversely, those 
FOXQ1 negatively regulated gene set can then be obtained by using reverse analysis. 
The Venn Diagram in Figure 3.17A shows the gene sets upregulated and 
downregulated by FOXQ1 respectively. Among the genes upregulated in HMLER-
FOXQ1 versus HMLER control (a) and genes downregulated in MDA-MB-231 
shFOXQ1 versus MDA-MB-231 shControl (b), there are a total of 63 genes that co-
presented in both parts, and these 63 genes were designated as ‘set I’ which is 
positively regulated by FOXQ1 (Figure 3.17A left panel). In the right panel of Figure 
3.17A, the genes downregulated in HMLER-FOXQ1 versus control (c) and the genes 
upregulated in MDA-MB-231 shFOXQ1 versus shControl (d) (using 5-fold cut off) 
were over lapped and it turns out there were 206 genes that co-presented in both parts, 
and these 206 genes were designated as ‘set II’ which is negatively regulated by 
FOXQ1. Next, these two sets of genes were clustered by GeneSpring (Figure 3.17B), 
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and the full list of genes was subjected to pathway analysis by Ingenuity Pathway 
Analysis (IPA) and their top function affected by FOXQ1 is listed in the lower panel 
of Figure 3.17B. After comparing the two sets of genes, I found there were more 
FOXQ1 negatively regulated genes than positively regulated ones, suggesting that the 
main role of FOXQ1 in breast cancer regulation could be to repress certain gene 
expressions rather than to activate gene expressions. In the list of functions affected, 
cell morphology was at the top which is consistent with my observation of EMT 
phenotype induced by FOXQ1. Gene Ontology (GO) analysis revealed that genes 
downregulated by FOXQ1 were most enriched for gene sets related to cell 
morphology or migration and motility, thus supporting a functional role of FOXQ1 in 

















Figure 3.17 Gene expression program associated with FOXQ1 expression. 
A, Venn Diagram showing the gene sets upregulated and downregulated by FOXQ1 
respectively. a, genes upregulated in HMLER-FOXQ1 versus HMLER control; b, 
genes downregulated in MDA-MB-231 shFOXQ1 versus MDA-MB-231 shControl; c, 
genes downregulated in HMLER-FOXQ1 versus HMLER control; d, genes 
upregulated in MDA-MB-231 shFOXQ1 versus MDA-MB-231 shControl. 
B, Gene clustering showing two sets of genes that are upregulated (I) and 
downregulated (II) by FOXQ1, respectively (upper panel). The lower panel shows the 
Gene Ontology (GO) analysis of the two gene sets by Ingenuity Pathway Analysis. 





3.6 FOXQ1 represses E-cadherin transcription in breast cancer 
cells 
The gene network among the cell morphology subset were extracted from IPA and 
shown in Figure 3.18. Interestingly, the network showed that CDH1 (E-cadherin) is 
located in the centre. CDH1 is also found to be transcriptional regulated in FOXQ1-
induced EMT, further confirming the importance of E-cadherin-associated gene 



















Figure 3.18 Ingenuity Pathway Analysis (IPA) showing the top network of 










To determine whether FOXQ1 inhibits E-cadherin transcription, a promoter region of 
CDH1 (encoding E-cadherin) is cloned and reporter assays were performed (Figure 
3.19A) in both HMLER overexpression and MDA-MB-231 knockdown systems. As 
expected, CDH1 promoter activity is repressed in HMLER-FOXQ1 cells, and 
increased in MDA-MB-231 FOXQ1 knockdown cells. This indicated that CDH1 
transcription activity is repressed during FOXQ1-induced EMT process. However, the 
question of whether CDH1 is directly regulated by FOXQ1 still remains. In HMLER 
overexpression system, chromatin immunoprecipitation (ChIP) was preformed using 
anti-myc antibody to precipitate ectopically expressed myc-tag FOXQ1 protein, and 
its binding to different CDH1 promoter regions were examined. However, ChIP 
results did not show any convincing binding between FOXQ1 and CDH1 promoter 
(Figure 3.20). This suggested that E-cadherin is not a direct transcriptional target of 
FOXQ1, and the downregulation of E-cadherin in FOXQ1-induced EMT could be 
















Figure 3.19 CDH1 promoter activity is negatively regulated by FOXQ1. 
A, Schematic structure of CDH1 promoter region. 
B, E-cadherin (CDH1) promoter reporter activities were measured in HMLER control 
or FOXQ1 expressing cells. 
C, E-cadherin (CDH1) promoter reporter activities were measured in MDA-MB-231 































































































































Figure 3.20 ChIP assay of FOXQ1 on the promoters of CDH1 in HMLER 












































 In breast cancer, FOXQ1 is found to be correlated with its aggressive basal-like 
subtype. FOXQ1’s expression is associated with worse tumor grade, more metastasis, 
and poor survival outcomes. Among various breast cancer cell lines, FOXQ1 
expression is coupled with basal-like aggressive mesenchymal-like MDA-MB-231 
cells. Therefore, FOXQ1 should have significant clinical relevance to aggressive 
basal-like subtype of breast cancers. In this study, the functional role of FOXQ1 in 
breast cancer was investigated in both the knockdown and overexpression system. 
 
In MDA-MB-231 cells, depletion of FOXQ1 is able to attenuate the mesenchymal 
phenotype in terms of increased cell-cell connection and decreased spindle shapes. 
This phenotypic change results in impaired invasive ability in vitro. In addition, 
knockdown of FOXQ1 in MDA-MB-231 cells sensitized these cells to 
chemotherapeutic drug induced apoptosis. Considering the expression profile of 
FOXQ1 in aggressive breast cancer and the sensitization effect observed in FOXQ1 
depleted cells, I propose that FOXQ1 could be a potential drug target against breast 
cancer, and may serve as a biomarker specifically for potentially invasive breast 
cancers. In the ectopic HMLER overexpression system, FOXQ1 successfully 
triggered the EMT phenotype in these cells. Together with EMT, HMLER-FOXQ1 
cell gained the ability to form mammosphere, and also expressed breast cancer stem 
cell markers CD44+/CD24-. These pointed out that ectopic expression of FOXQ1 in 
HMLER induce these cells to de-differentiate and become breast cancer stem cells. 
My results are consistent with current literature on EMT induction of cancer stem cell 
formation. Moreover, direct E-cadherin knockdown in HMLER also showed a similar 
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outcome with respect to HMLER-FOXQ1 cells. Together, FOXQ1 is believed to be 
an important gene in regulating breast caner progression and metastases by triggering 
EMT process and development of gain breast cancer stem cell characteristics. 
 
The transcriptional network mediated by FOXQ1 in breast cancer was analyzed. From 
gene ontology analysis, CDH1 was shown to play an important functional role in 
FOXQ1-induced EMT network. However, other well-known EMT inducers are not 
significantly affected. At the transcriptional level, CDH1 promoter activity was 
upregulated in HMLER-FOXQ1 cells, and downregulated in FOXQ1 depletion 
MDA-MB-231 cells. However, the chromatin immunoprecipitation analysis did not 
show pronounced binding between FOXQ1 and CDH1 promoter. Hence, whether or 
not CDH1 is directly transcriptional regulated via transcription by FOXQ1 or 
regulated via other novel intermediate players during FOXQ1-induced EMT remains 
to be elucidated. 
 
However, the observed EMT phenotype and stem cell-like traits driven by FOXQ1 
were not seen in other normal human mammary epithelial cell lines such as MCF10A 
and HMEC. In MCF10A and HMEC cells, ectopic overexpression of FOXQ1 by 
using the same retroviral expression system did not result in any visible mesenchymal 
morphology as compared with the empty vector control (Figure 3.20). Besides the 
absence of EMT, ectopic overexpression of FOXQ1 in MCF10A cells also did not 
change protein levels of epithelial marker E-cadherin and mesenchymal marker 
vimentin. Finally, there was no significant change observed in breast cancer stem cell 
markers CD44 and CD24. In HMEC cells, ectopic FOXQ1 overexpression also did 
not trigger EMT phenotype. In contrast, HMEC FOXQ1 overexpressing cells showed 
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elevated E-cadherin protein and decreased vimentin expression, both of which are 
enhanced epithelial traits. CD44 was found increased and CD24 decreased in HMEC. 
However, these changes in CD44 and CD24 were not coupled to increased 















Figure 3.21 Morphology of MCF10A and HMEC cells with ectopic expressing 


















Figure 3.22 Protein levels of EMT and breast cancer stem cell markers in 






















































In the previous chapter, I have shown evidence to suggest that FOXQ1 was capable of 
regulating human mammary epithelial cell plasticity. In addition, FOXQ1 was also 
required for maintenance of mesenchymal phenotype linked to MDA-MB-231 cell 
invasion. In the following chapter, I shall investigate the function of FOXQ1 in 
colorectal carcinoma cells. 
 
4.1 FOXQ1 is overexpressed in colon cancer 
Exploring our previously published data on microarray gene expression profiling of 
24 pairs of clinical human colon tumor and matched normal mucosa tissue samples 
(Jiang, Tan et al. 2008), FOXQ1 was found to be highly expressed in colon tumors 
compared with paired normal tissues. As shown in gene clustering analysis of 
microarray data, FOXQ1 together with CCND1 and MYC were overexpressed in 
tumor samples compared to normal counterparts (Figure 4.1A). To further validate the 
array data, RT-PCR analysis was performed in 8 randomly selected pairs. The DNA 
agrose gel electrophoresis results in Figure 4.1B indicated that FOXQ1 gene is 
overexpressed in all 8 paired tumor samples. Together with microarray gene 
expression analysis, overall results indicated that expression of FOXQ1 in human 
colon tumors was elevated. The expression status of FOXQ1 in colon tumors suggests 
that this gene may play an oncogenic role. To further validate the expression level of 























Figure 4.1 FOXQ1 gene is highly expressed in 24 pairs of clinical colon tumor 
samples. 
A, Heatmap extracted from microarray gene expression analysis shows that FOXQ1 is 
the most highly expressed gene in clinical colon tumors as compared to normal 
controls.  
B, RT-PCR performed on 8 randomly selected colon tumor RNA samples and their 
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After showing FOXQ1 overexpression status in clinical samples, I proceeded to 
examine the FOXQ1 expression level in colon cancer cell lines including HCT116, 
DLD1, SW480, SW620, HT29, and HT15 cells by quantitative RT-PCR using 
FOXQ1 Taqman probe (Figure 4.2A). However, the protein analysis of FOXQ1 by 
western blot as shown in Figure 4.2B indicated that the protein levels of FOXQ1 do 
not always correlate with its mRNA expression amongst the various colon cancer cell 
lines which have been examined. One possible explanation for this inconsistency may 
be due to posttranslational modification which is a common feature associated with 
the forkhead box transcription factor family. 
 
According to the results shown in Figure 4.2, HCT116 cell line is consistently 
expressing very low level of FOXQ1. After checking the promoter methylation 
database available in our lab, the promoter of FOXQ1 in HCT116 cells is 
hypermethylated which likely resulted in silencing of FOXQ1 in these cells. In view 
of this silencing, I opportunistically planned for ectopic overexpression of FOXQ1 in 
this cell line. In addition to the very low endogenous expression of FOXQ1, HCT116 
cells present a typical epithelial morphology, which provided further possibility to 

















Figure 4.2 FOXQ1 expression status in various human colon cancer cell lines. 
A, Quantitative real-time PCR by FOXQ1 Taqman probes in indicated colon cancer 
cell lines. 























































4.2 Generation of Tet-on inducible FOXQ1 cell line system 
In order to further assess the functional role of FOXQ1, an inducible and reliable 
ectopic expression system, that is the Tet-on inducible system, was established in 
HCT116 cells. In Tet-on expression system, the expression of myc-tagged FOXQ1 
depended on the presence of doxycycline (DOX) in the cell culture medium. The 
principle of Tet-on inducible system is described in Figure 4.3. 
 
In order to generate an optimal and stable expression system for FOXQ1, single 
clones were picked after antibiotic selection. After screening a number of stable 
clones by western blot analysis for myc-tagged FOXQ1 expression using anti-myc 
antibody, clone 1 and clone 5 (designated as C1 and C5) were identified to have the 
desired doxycycline inducible expression of FOXQ1 (Figure 4.4A). In order to 
optimize the induction by doxycycline, its kinetics has to be taken into consideration. 
Therefore, I examined the expression pattern of FOXQ1 levels upon doxycycline 
treatment at different time intervals. From the results of western blot analysis in 
Figure 4.4B and C, the doxycycline-induced FOXQ1 expression was shown to be 
time dependent, reaching its peak level at 48 hours after doxycycline treatment, and 
returning to nearly its basal level at 72 hours. Hence, in this study, cells were treated 
with doxycycline for 48 hours to induce optimal FOXQ1 expression, and clone 5 was 


























Figure 4.3 Workflow of Tet-on inducible expression system. 
A, Tet repressor (tetR) protein is expressed from pcDNA6/TR in established host cells. 
B, TetR homodimers bind to Tet operators (TetO2) sequences in the FOXQ1 inducible 
expression vector which was sequentially transfected into host cells, repressing 
transcription of FOXQ1. 
C, Addition of tetracycline (tet) that binds to tetR homodimers. Tetracycline was 
replaced by doxycycline to relief the tet repressor. 
D, Binding of tet to tetR homodimers causes a conformational change resulting in the 
















Figure 4.4 Screening for functional Tet-on inducible FOXQ1 expression in six 
HCT116 cell lines. 
A, FOXQ1 protein levels were measured in different clones by western blot analysis 
upon 2µg/ml DOX (doxycycline) treatment for 24 hours. Myc-tagged FOXQ1 protein 
is detected by anti-myc antibody.  
B, Two FOXQ1 expressing clones (FOXQ1-C1 and FOXQ1-C5) and empty vector 
cells were treated with DOX for indicated time points. FOXQ1 expressions were 
detected with anti-myc antibody. 
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As FOXQ1 belongs to the forkhead transcription factor family, it is expected to 
translocate into the nucleus where it exerts its effect on target gene expression. To 
investigate nuclear localization of full-length FOXQ1 in HCT116 Tet-on inducible 
cell line, the doxycycline induced FOXQ1 was visualized by confocal 
immunoflurorescence microscopy. The results shown in Figure 4.5 demonstrated that 
ectopic FOXQ1 located in the nucleus when HCT116-FOXQ1 cells were treated with 
doxycycline. These results not only confirmed the validity of the Tet-on FOXQ1 
















Figure 4.5 Confocal imaging of FOXQ1 expression in HCT116 Tet-on inducible 
cell lines. 
Immunofluorescence of HCT116 vector cell line detected using an anti-myc 
monoclonal antibody, in the absence (A) or presence (B) of DOX (doxycycline). A 
selected clone of HCT116 expressing FOXQ1 (FOXQ1-C5) stained with an anti-myc 
monoclonal antibody for detecting ectopic myc-tagged FOXQ1, in the absence (C) or 
in the presence (D) of DOX. The color theme is shown below. Red color indicated the 
ectopic expression of myc-tagged FOXQ1 protein which is stained with anti-myc 














4.3 Ectopic FOXQ1 expression induces epithelial to mesenchymal 
transition in epithelial-like HCT116 colon cancer cells 
I made an interesting observation in HCT116-FOXQ1 inducible cells that have been 
subjected to long-term doxycycline treatment. The original typical cuboidal-shape 
epithelial morphology of HCT116 cells became elongated and spindle mesenchymal-
like. 
 
HCT116 cells are known to exhibit epithelial characteristics and carry silenced 
FOXQ1 expression. My results demonstrated that consistent overexpression of 
FOXQ1 for a period of 1-2 weeks in doxycycline-induced cells indeed caused 
HCT116 cells to exhibit morphological changes characteristic of epithelial to 
mesenchymal transition, namely the loss of cell-cell interaction and gain of spindle-
like phenotype (Figure 4.6). However, this morphological transition is reversible and 
the cells will revert back to epithelial phenotype after doxycycline is withdrawn from 
cell culture to switch off FOXQ1 expression. My hypothesis is that the change from 
epithelial to mesenchymal-like morphology may be caused by ectopic FOXQ1 
expression in HCT116 cells. The HCT116 vector control did not show any of the 
mentioned phenotype changes upon doxycycline treatment for the same length of time, 
eliminating the possibility that the morphological changes of FOXQ1 expressing cells 
were due to the side effect of doxycycline. 
 
To further look into the biological function of FOXQ1 in HCT116 cells, I have 
generated an additional Tet-on inducible cell line using a FOXQ1 deletion mutant D6 
(designated as HCT116 FOXQ1-D6). The rationale of selecting D6 is based on the 
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observation that D6 can not transcriptionally activate potential transcriptional target 
CTGF promoter activity by FOXQ1 shown in Chapter 5. D6 seems to have less 
transactivation ability than full-length FOXQ1 on CTGF promoter in the genomic 
region of upstream 874bp to downstream 195bp (CTGF-P2). I next examined the 
ability of inducing EMT in these FOXQ1 mutant expressing cells. By contrast, this 
EMT phenotype also did not occur in D6 truncated FOXQ1 mutant expressing cells 
(Figure 4.7) suggesting that wild type full-length FOXQ1 is a pre-requisite for such 














Figure 4.6 Morphologic change of HCT116-FOXQ1 cells. 
Phase contrast images of HCT116 vector control and FOXQ1 cells either treated with 
or without DOX for over two weeks period. FOXQ1 expressing cells exhibit a 
phenotypic change resembling EMT. This mesenchymal morphology was reverted 

















Figure 4.7 Morphology of HCT116 cells expressing indicated FOXQ1 deletion. 
HCT116 cells with FOXQ1-D6 truncated deletion mutant were treated with or 




















As its name suggests, EMT is a transition process that resulted not only in 
morphological changes in the cells but also gaining the ability of migration and 
invasion. In this process it is usually coupled with decreased expression of epithelial 
markers such as E-cadherin, and increased expression of mesenchymal markers such 
as vimentin. In order to confirm the morphologic changes which have occurred in 
FOXQ1 expressing HCT116 cells were indeed EMT related, I proceeded to test for 
such EMT markers. 
 
Since EMT morphologic changes were not observed in short-term doxycycline 
treatment, that is to say short-term FOXQ1 induction may not be sufficient to trigger 
this phenotype. Hence, both long-term and short-term FOXQ1 inductions were 
examined for EMT markers using RT-PCR, quantitative PCR, and western blot 
analysis. In FOXQ1 expressing cells exposed to long-term doxycycline treatment, the 
mRNA and protein levels of E-cadherin were both decreased accompanied by loss of 
characteristic epithelial traits (Figure 4.8). The mRNA and protein levels of vimentin 
were both increased upon long-term FOXQ1 induction. Besides the expected changes 
in EMT markers, I also found that the mRNA level of the metastasis related gene 
CTGF was upregulated in response to long-term FOXQ1 induction, and it could be a 
potential FOXQ1 target (Figure 4.8A). Next, I tested two well established EMT 
triggers Slug and Snail. Interestingly, the mRNA level of Slug is enriched in FOXQ1 
expression cells but not Snail (Figure 4.8A). In addition, the Slug protein level was 
also elevated as shown in Figure 4.8B. However, no changes were observed with 
another EMT trigger Snail. In addition, changes in these EMT markers were not seen 
in cells whereby FOXQ1 were overexpressed for a short period of time (Figure 4.9). 
Although increase in CTGF mRNA level can be detected shortly after 24 hours, 
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changes in Slug level was not detected (Figure 4.9A). The results demonstrated a 



















Figure 4.8 Long-term and steady FOXQ1 expression induced morphological 
change in HCT116 associated with EMT. 
A, RT-PCR analysis of HCT116 vector cells and two clones of FOXQ1 expressing 
cells for epithelial marker E-cadherin, mesenchymal marker vimentin, CTGF, EMT 
inducers Slug and Snail. Actin was used as internal control. 
B, Western blot analysis for myc-tagged FOXQ1, EMT markers (E-cadherin and 
vimentin) and inducer (Slug). 
C, Quantitave PCR of EMT markers and inducer in HCT116 vector and FOXQ1-C5 




















































































Figure 4.9 Short-term FOXQ1 expression in HCT116 is not sufficient to trigger 
EMT morphological change and there were no changes in EMT markers at both 
mRNA and protein levels. 
A, RT-PCR analysis in HCT116 FOXQ1-C5 treated with DOX for indicated time 
duration did not induce changes in the EMT marker, and Slug expression. 
Nevertheless, CTGF was upregulated 24 hour after treatment with DOX. 
B, Western blot analysis for the EMT markers E-cadherin and vimentin in HCT116-
FOXQ1-C5 cells. 
C, Quantitative PCR of EMT markers and inducer in HCT116 vector and FOXQ1-C5 

































































Next, I checked for any alterations in levels of E-cadherin and vimentin in single cell 
level following long-term FOXQ1 expressions as well as cells that have FOXQ1 
withdrawn. The preparations were visualized by confocal microscopy with staining of 
E-cadherin and vimentin expression. Figure 4.10A shows that loss of E-cadherin is 
only detected in doxycycline treated FOXQ1 expressing population, but not in 
FOXQ1 withdrawn cell population and without doxycycline treated control cells. The 
response of vimentin to FOXQ1 was opposite to the response of E-cadherin as shown 
in Figure 4.10B. 
 
In summary, prolonged and consistent FOXQ1 overexpression in HCT116 cells 
























Figure 4.10 Immunofluroscent confocal images of EMT markers in HCT116-
FOXQ1 cells with or without DOX and DOX withdrawn population. 
A, E-cadherin is stained with Alexa Fluor 488 appearing green. Myc-tagged FOXQ1 
is stained with Alexa Fluor 546 appearing red. Nucleus is stained with DAPI 
appearing blue. 
B, Vimentin is stained with Alexa Fluor 488 appearing green. Myc-tagged FOXQ1 is 
stained with Alexa Fluor 546 appearing red. Nucleus is stained with DAPI appearing 
blue. 
Vimentin FOXQ1 DAPI Merge

















4.4 Effect of FOXQ1 on proliferation rate in HCT116 cells 
To understand the biological function of FOXQ1, I examined the effect of FOXQ1 
induction on cell proliferation. Cell growth and colony formation assay were 
performed in Tet-on inducible cell lines including vector control, full-length FOXQ1 
and D6 deletion mutant. In addition, the inducible protein expression and subcellular 
localization were viewed by confocal microscopy. As expected, the wild type FOXQ1 
was detected in the nucleus (Figure 4.12A), whereas the D6 was detected only in the 
cytoplasm (Figure 4.13A). These data are consistent with the transient transfection 
experiments. The growth rate was reduced only in full-length FOXQ1 cells when 
treated with doxycycline for 11 days. The doxycycline was replaced every two days 
(Figure 4.12B). However, this cell growth inhibition was not observed in cells 
expressing D6 mutant as well as vector control cells (Figure 4.11B, 4.13B). These 
findings suggested that wild type full-length FOXQ1 has the ability to reduce 
HCT116 cell proliferation in vitro. However truncation of FOXQ1 protein impaired 
its ability to retain HCT116 cancer cell growth and proliferation. In addition, colony 
formation assay showed that ectopic expression of FOXQ1 in HCT116 cells inhibited 
colony formation. This phenomenon is consistent with results obtained in cell 
proliferation assay. Whereas, HCT116 expressing D6 deletion mutant did not show 
any cell growth inhibition, neither in colony formation nor cell proliferation assay. 
The functional results of FOXQ1-D6 in cell proliferation and colony formation ability 
are correlated with the loss of transactivation ability on reporter assay of CTGF-P2. 
Hence, the growth arrest caused by wild type FOXQ1 might be affected through 















Figure 4.11 Proliferation rate of HCT116 vector control cell lines in conditions of 
with or without DOX (doxycycline) treatment. 
A, Immunofluroscent confocal staining with anti-myc antibody in HCT116 vector 
control cells. 
B, Proliferation rate of HCT116 vector control cells. 
















































Figure 4.12 Proliferation rate of full-length FOXQ1 expressing HCT116 cell lines 
in conditions of with or without DOX (doxycycline) treatment. 
A, Immunofluroscent confocal staining for myc-tagged FOXQ1 expressing cell line.  
B, Proliferation rate of FOXQ1 expressing cell line. 

















































Figure 4.13 Proliferation rate of D6 truncated FOXQ1 expressing HCT116 cell 
lines in conditions of with or without DOX (doxycycline) treatment. 
A, Immunofluroscent confocal staining for myc-tagged D6 truncated FOXQ1. 
B, Proliferation rate of D6 truncated FOXQ1. 















































4.5 Identified transcriptional target of FOXQ1 that associated with 
epithelial to mesenchymal transition 
A protein called Slug which is a known EMT trigger was strongly upregulated 
together with CTGF in HCT116 cells. The other known EMT triggers, namely, Twist 
and Snail, however, did not show any changes. Notably, Twist is known to be 
silenced by DNA methylation in HCT116 cells. These changes of EMT triggers have 
been consistently observed in two FOXQ1 clones examined.  This suggested that 
FOXQ1-induced EMT is linked to transcriptional upregulation of CTGF and Slug as 
well as downregulation of E-cadherin. 
 
To further verify CTGF as a potential target of FOXQ1, I isolated two genomic 
regions upstream of CTGF transcription start site (TSS). The two regions are the 
CTGF-P2 promoter region (-874 to +195bp) and a more distal region CTGF-P1 (-
2000 to -797bp) (Figure 4.14A). The two fragments of CTGF promoter regions were 
subcloned into pGL3 luciferase reporter plasmid individually. Co-transfection of 100 
ng of FOXQ1 and 1 µg of pGL3 reporter plasmid into HCT116 cells resulted in a 
strong induction of reporter activity containing the CTGF-P2 promoter region, but had 
no effect on reporter plasmid containing a more distal region CTGF-P1 (Figure 
4.14B). These results indicated that FOXQ1 did activate CTGF promoter activity in 
the region of -874 to +195bp, further proof that CTGF is a potential transcriptional 





Figure 4.14 Identification of promoter region of CTGF in response to FOXQ1 in 
HCT116. 
A, CTGF promoter construct designs. Two fragments of CTGF promoter regions: 
upstream 2000bp to 797bp (CTGF-P1) and upstream 874bp to downstream 195bp 
(CTGF-P2) were constructed into pGL3 luciferase reporter system. 























































To investigate whether Slug is transcriptionally regulated by FOXQ1, several 
promoter regions of Slug were cloned in to pGL3 luciferase vector including SLUG-
P1 (-2000 to -800bp), SLUG-P2 (-900 to +100bp), SLUG-P3 (-400 to -50bp), SLUG-
P4 (-400 to +100bp), SLUG-P5 (-900 to -400bp) (Figure 4.15A). The reporter 
luciferase assay was performed by co-transfection of FOXQ1 and Slug promoter 
plasmids. The information in Figure 4.15B indicated that SLUG-P4 is the response 
element to FOXQ1, and it contains the region of nt-400 to +100 of the Slug promoter. 
It suggested that FOXQ1 can transcriptionally activate Slug promoter activity in this 
specific region. 
 
The above results demonstrated that FOXQ1 has the potential to transcriptionally 
activate both CTGF and Slug promoter regions. Since the different enrichment of the 
promoter activity of CTGF and Slug by FOXQ1 (5-fold and 2-fold respectively), it is 
assumed that FOXQ1 may control these two potential targets by different ways and 
strength. In Chapter 4.3, CTGF was shown to be upregulated by FOXQ1 in 24 hours, 
however, Slug enrichment can be seen only when EMT phenotype appeared. These 
suggested CTGF activation through FOXQ1 is faster than Slug, hence, CTGF could 




















Figure 4.15 Schematic structure of Slug promoter regions and luciferase 
reporter activity of Slug promoter regions in response to FOXQ1. 
A, View of schematic structures of 5 fragments of Slug promoter regions which were 
constructed in pGL3 vector.  




















































































4.6 FOXQ1 induced EMT in HCT116 cells is independent of TGF-
β signalling pathway 
TGF-β signalling pathway in colon cancers is distinct from other types of cancer. In 
colon cancer TGF-β receptor is mutated, hence, as a result, colon cancer cells became 
unresponsive to TGF-β signalling. In order to better understand the relationship 
between FOXQ1 and TGF-β pathway, I have chosen a non-cancerous cell line HEK-
TERV in addition to HCT116 cells which have functional TGF-β receptors. Slug and 
CTGF were assayed after treatment with TGF-β1 for different time points, because 
Slug and CTGF were reported as downstream targets of TGF-β signalling pathway. 
Figure 4.16 demonstrated that after treatment with TGF-β1 for 4 hours, Slug and 
CTGF were increased and remain elevated for 72 hours in HEK-TERV cells. 
However, a similar response to TGF-β1 was not seen in HCT116 cells. This finding 









Figure 4.16 RT-PCR images of Slug, CTGF and actin after HCT116 and HEK-
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4.7 Ectopic FOXQ1 expression in HCT116 cells confers resistance 
to apoptosis induced by chemotherapeutic drugs 
I further investigated whether ectopic expression of FOXQ1 in HCT116 will alter the 
responses to apoptosis. Two methods were used to induce stress. One method is 5-
Flurouracil (5FU) treatment, because 5FU is a first line chemotherapeutic drug used 
in clinic for the treatment of colorectal cancers. The other method is to subject 
cultured cells to serum starvation. 
 
Interestingly, both methods showed similar results. In Figure 4.17A, phase contrast 
images indicated that HCT116-FOXQ1 expressing cells upon doxycycline treatment 
have more surviving cells compared with non doxycycline condition, following 5FU 
treatment at a concentration of 375µM for 5 days. Similarly, under condition of serum 
starvation for 60 hours, HCT116-FOXQ1 expressing cells with doxycycline treatment 
remained intact and maintained its normal morphology, whereas, in the absence of 
























Figure 4.17 Phase contrast images of HCT116-FOXQ1 cells in response to stress 
under conditions with or without DOX treatments. 
A, HCT116-FOXQ1 cells were treated with 375 µM of 5FU for 5 days with or 
without DOX treatment. 
B, HCT116-FOXQ1 cells were cultured in serum starved (-Serum) or 10% serum 
















The anti-apoptotic effect of FOXQ1 in HCT116 cells was further examined by 
measuring SubG1 DNA contents using FACS analysis following 5FU treatment at 
different time intervals. The results showed that HCT116-FOXQ1 cells induced to 
express FOXQ1 by doxycycline have reduced SubG1 phase, thus suggesting that 
these cells were resistant to 5FU-induced apoptosis (Figure 4.18A). Meanwhile, 
HCT116 FOXQ1-D6 deletion mutant cells were used to perform the same 
experiments, and results showed that there was no significant difference in apoptosis 
in conditions with or without doxycycline treatment (Figure 4.18B). Together, the 
observed anti-apoptotic effect is likely associated with the wild type full-length 





Figure 4.18 Overexpression of FOXQ1 decreased apoptotic responses to 5FU 
treatment (as measured by subG1 population) in HCT116 cells. 
A, Apoptotic rates were measured by FACS for PI staining in HCT116 FOXQ1 full-
length cells with or without DOX treatment for indicated time points in response to 
375 µM of 5FU. 
B, Apoptotic rates were measured by FACS for PI staining in HCT116 FOXQ1-D6 
deletion mutant cells with or without DOX treatment for indicated time points in 


































We know that PARP cleavage occurs downstream of Caspase 3 activation in the 
apoptosis cascade. In this case, I decided to use cleaved-PARP to measure the 
apoptotic response. Western blot analysis showed that the protein levels of cleaved-
PARP decreased in HCT116-FOXQ1 expressing cells after treatment with 375µm of 
5FU for the indicated time intervals (Figure 4.19A). Similar results were also 
observed in serum starvation condition, and the amount of cleaved-PARP was 
decreased in HCT116-FOXQ1 expressing cells (Figure 4.19B). However, in HCT116-
FOXQ1-D6 cells, the amount of cleaved-PARP was not significantly different in 5FU 
or serum starved conditions following 48 hours of treatment with or without 
doxycycline (Figure 4.19C). In addition, FOXQ1 overexpression also confered 
reduced PARP cleavage by other chemotherapeutic drugs including camptothecin 
(CPT), adriamycin (ADR) and etoposide (VP16) (Figure 4.19D). Active Caspase 3 
activity was also measured by FACS in samples treated with different dosages of drug 
for 48 hours (Figure 4.20). FACS data showed that FOXQ1 expression in HCT116 
cells resulted in less than 50% of active Caspase 3 activities after 5FU, CPT, ADR, 
and SAHA treatments. Taken together, these data proved that FOXQ1 may attenuate 














Figure 4.19 Ectopic expression of FOXQ1 in HCT116 cells confers resistance to 
PARP cleavage induced by chemotherapeutic drugs. 
A, Western blot analysis of PARP cleavage by using antibody specific for cleaved 
PARP. Cells were treated with 5FU (375µM) for indicated times. 
B, Protein levels of PARP cleavage were measured in HCT116 FOXQ1 cells with or 
without DOX after incubation under serum starved culture condition for indicated 
time points. 
C, Protein levels of PARP cleavage were measured in HCT116-FOXQ1-D6 cells with 
or without DOX for 48 hours of treatment by either 375 µM 5FU or incubation under 
serum starved condition. 
D, Protein levels of PARP cleavage were measured in HCT116 FOXQ1 cells with or 


















Figure 4.20 FACS analysis of Caspase 3 activity of HCT116 FOXQ1 cells treated 
with various drugs in the presence or absence of DOX. 
Active caspase 3 activities were measured by FACS, and the percentage of active 
Caspase 3 is shown after treatment with various chemotherapeutic drugs at different 









In clinical colorectal tumors, FOXQ1 expression is highly upregulated. In Tet-on 
FOXQ1 inducible system in HCT116, the EMT phenotype was observed in the 
presence of ectopic wild type full-length FOXQ1 expression, but not in cells 
expressing truncated FOXQ1. Moreover, this change is reversible and is coupled with 
biochemical changes of EMT markers including upregulation of epithelial marker E-
cadherin, and downregulation of mesenchymal marker vimentin. By examining other 
known EMT triggers, Slug was found to be increased upon FOXQ1 expression 
together with CTGF. Simultaneously with the EMT phenotype triggered by FOXQ1 
expression in HCT116 cells, these cells became chemoresistant to several DNA 
damaging drugs. Overall, FOXQ1 may contribute to colon cancer progression through 
protecting DNA from damages, and FOXQ1 could be a potential therapeutic target to 















CHARACTERIZATION OF FUNCTIONAL DOMAINS 












Having demonstrated the functional role of FOXQ1 in breast and colon cancers, the 
functional domains of FOXQ1 protein were investigated in the following chapter 
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5.1 Mapping the transactivation domain of FOXQ1 
The FOXQ1 protein contains a conserved DNA binding domain (DBD) and a 
predicted putative nuclear localization signal (NLS) as well as a predicted 
transactivation domain in the C-terminus. In order to map the protein sequence 
required for directing FOXQ1 activity, a series of myc-tagged FOXQ1 deletion 
mutants were generated as schematically presented in Figure 5.2A. The ability of 
FOXQ1 mutants to activate CTGF-P2 promoter was used as an indicator of 
transactivation ability of FOXQ1 measured by a luciferase reporter assay system. 
 
As summarized in Figure 5.2B, deletion of FOXQ1’s C-terminal region reduced its 
ability to transactivate CTGF promoter. To establish whether the drop in reporter 
activity reflected the removal of the transactivation domain or is simply caused by 
instability of truncated proteins, I performed western blot analysis for these deletion 
mutants. The results in Figure 5.2C showed that the expression of these FOXQ1 
deletion mutants, as detected using anti-myc antibody, were expressed in similar 
levels, thus showing that the drop of CTGF promoter activity was due to the removal 
of transactivation domain of FOXQ1. D1 (1-279aa) showed an activity of 
approximately half the potency of the full-length FOXQ1, and additional deletions 
from 279 to 275aa (D2), and 275 to 213aa (D7) did not further reduce its activity. 
This indicated that the region from 279 to 403aa contains a transactivation domain 
required for a fully functional of FOXQ1. However, further removal of 213 to 207aa 
(D3) or 207 to 114aa (D6) resulted in a nearly complete loss of FOXQ1 activity on 
CTGF promoter, suggesting that the region from 114 to 213aa contain both conserved 
DBD and a predicted NLS that is critical for its activity. Notably, consistent with a 
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loss of predicted NLS from 207 to 213aa, D3 (1-207aa) completely lost its activity 
similar to D6 (1-114aa) although still retaining a DBD domain. This suggests that 
FOXQ1 without the NLS should be located in the cytoplasm and thus cannot gain 















Figure 5.2 Identification of transactivation domain of FOXQ1. 
A, Schematic structures of full-length FOXQ1 and a series of C-terminal deletion 
mutants. DBD (DNA binding domain); NLS (nuclear localization signal)  
B, CTGF-P2 promoter activities responded to various deletion mutants of FOXQ1 
compared with full length.  
C,Western blot analysis shows myc-tagged FOXQ1 deletion mutants detected by anti-
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5.2 Validation of nuclear localization signal of FOXQ1 
The main function of nuclear localization signal is to determine the ability of the 
protein to translocate from cytosol to nucleus, and whether its biological function can 
be exerted in the nucleus. In order to do so, I used confocal immunofluorescent 
microscopy to visualize the cellular localization of FOXQ1 deletion mutants and also 
to measure its functional ability by reporter assay.  
 
In the confocal microscopy experiment, FOXQ1 deletion mutants tagged with myc 
peptide were labelled red color, and the nucleus was stained blue. Hence, by judging 
the degree of co-localization of these two colors, I can accurately tell the distribution 
of the protein either in cytoplasm or nucleus or both. In the absence of any structural 
modification, full-length (FL) FOXQ1 is perfectly localized in the nucleus, thus 
reflecting the function role of FOXQ1 as a transcription factor. As expected, the D3 
(1-207aa) and D6 (1-114aa) truncated proteins that do not contain the nuclear 
localization signal (NLS) did not locate in the nucleus (Figure 5.3), whereas D7 (1-
213aa) that retains the NLS remained in the nucleus (Figure 5.4B). These results 
demonstrated that the amino acid region of 207 to 213aa of FOXQ1 contained a 
























Figure 5.3 Localization of truncated FOXQ1 deletion mutants visualized by 
immunofluroscent confocal microscopy. 
Indicated FOXQ1 deletion mutants were transiently transfected into HCT116 cells. 
Myc-tagged FOXQ1 proteins were detected by primarily anti-myc antibody and 












To further identify the crucial amino acid residues functionally required for the NLS 
activity in the region of 207 to 213aa, I performed the site-directed mutagenesis 
analysis in D7 through mutation of the amino acid sequence from RRRRRK domain 
to ARARAR (designated as D7 NLS mut) (Figure 5.4A). The generated D7 NLS 
mutant was found predominantly in the cytoplasm (Figure 5.4B) and therefore, this 
mutant’s reporter activity to CTGF-P2 became indistinguishable from the background 
level as shown in Figure 5.4C. Taken together, these findings supported that the 
sequence of RRRRRK had a functional nuclear localization signal targeting FOXQ1 















Figure 5.4 Identification of nuclear localization signal of FOXQ1. 
A, Schematic structures of FOXQ1 deletion mutants D7 and D7 NLS mutant. 
B, Localization of indicated FOXQ1 deletion mutants by immunofluroscent confocal 
microscopy. Myc-tagged FOXQ1 detected by anti-myc primary antibody and 
subsequently with Alexa Fluor 546 that appears red. Blue indicate nucleus stained 
with DAPI. 
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5.3 The N-terminal region of FOXQ1 contains an inhibitory 
domain 
To define the functions of N-terminal region, I further constructed a series of N-
terminal deletion mutants of FOXQ1 which were summarized in Figure 5.5A. 
Intriguingly, I found that the D4 (196-403aa) and D8 (210-403aa) exhibited a higher 
activity on CTGF promoter (1.5 and 1.2 fold higher respectively) than that of full-
length FOXQ1. In addition, the D5 (214-403aa) had no activity due to the loss of NLS 
as anticipated (Figure 5.5B). The data suggested that the N-terminal region of FOXQ1 
protein might contain an inhibitory domain to restrain the FOXQ1 transcription 
activity. The confocal microscopy images showed that D4 and D8 were located in 
















Figure 5.5 Identification of inhibitory domain of FOXQ1. 
A, Schematic structures of a series of N-terminal deletion mutants of FOXQ1.  
B, Luciferase reporter activity of CTGF-P2 in response to indicated FOXQ1 deletion 
mutants. 
C, Localization of indicated FOXQ1 deletion mutants by immunofluroscent confocal 
microscopy. Myc-tagged FOXQ1 is detected by anti-myc primary antibody and 
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Previous reports showed that the activity of transcription factors of FOXO family 
member is often regulated by phosphorylation. I hypothesized that the inhibitory 
activity of N-terminal region might be mediated by aberrant phosphorylation signals 
in colon cancer cells. Protein sequence analysis of N-terminus of FOXQ1 with Motif 
Scan (http://hits.isb-sib.ch/cgi-bin/index) revealed the presence of multiple consensus 
phosphorylation sites for several protein kinases, including PKC, PKA (CAMP-
dependent) and CK2. To determine whether these phosphorylation sites are important 
to mediate the inhibitory activity of N-terminal region, I have conducted site-directed 
mutagenesis and generated several mutants to remove one or more concomitant 
multiple phosphorylation sites and analyzed their activity using CTGF reporter assay. 
These mutants include replacing PKC phosphorylation site (TRR) at Threonine-115 
with Alanine, and (SVR) Serine-166 with Alanine, CAMP phosphorylation site 
(KRLS) Serine-217 with Alanine, and CK2 phosphorylation site (SDLE) Serine-18 
with Alanine in the N-ternimus (Figure 5.6A). 
 
I found that abrogation of either one (T115) (M1) or both (T115 and S166) (M2) of 
PKC sites slightly increased the transcription activity of FOXQ1 compared with the 
wild type counterpart. However, concomitant abrogation of all 4 phosphorylation sites 
of PKC, PKA, CK2 (T115, S166, S18, and S217) resulted in a marked increase in 
activity (Figure 5.6B). These findings suggested that phosphorylation of these sites 
might inhibit FOXQ1 activity in colon cancer. I therefore proposed that oncogenic 
















Figure 5.6 Potential phosphorylation sites of FOXQ1. 
A, Structures of site-directed mutations. 
B, Transcription activity of wild type and mutant FOXQ1. 
C, Localization of indicated FOXQ1 deletion mutants by immunofluroscent confocal 
microscopy. Myc-tagged FOXQ1 is detected by anti-myc primary antibody and 
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In this area of research, forkhead family FOXQ1 was found to be highly expressed in 
human clinical colon tumor samples and most of colon cancer cell lines except 
epithelial-like colon carcinoma cell line HCT116. Hence, HCT116 was used as a cell 
line model to study the functional impact of FOXQ1 in colon cancers. In ectopic 
FOXQ1 expression system in HCT116, I first identified CTGF as a potential 
transcription target of FOXQ1, and in turn used reporter luciferase assay to zoom in 
on the responsive region of CTGF believed to be regulated by FOXQ1.  This region 
of CTGF was further used as an indicator for searching FOXQ1 protein functional 
domains in HCT116 cells. By constructing different truncated FOXQ1 deletion 
mutants, the transactivation domain was identified to be located in the C-terminus 
region of 279 to 403 amino acid (aa). The inhibitory region is contained in the N-
terminal region of 1 to 196aa. In addition, located near the end of the DNA binding 
domain (210 to 213aa) is the nuclear localization signal which directs the FOXQ1 
protein to the nucleus. These findings are based on the reporter activity of CTGF 




















The present study aims to delineate the cellular functions of FOXQ1 in breast and 
colorectal carcinoma, including mechanisms behind the induction of mesenchymal-
like phenotype by FOXQ1 in epithelial cells. The important and previously unknown 
role of FOXQ1 in cellular pathogenesis of invasion, migration and metastasis has 
been studied here. The evidence presented in this study supports a novel role of 
FOXQ1 as a critical participant in tumor progression through epithelial to 
mesenchymal transition (EMT), cancer stem cells, and anti-apoptotic ability. As a 
forkhead factor, FOXQ1 shares functional and structural similarities with some other 
forkhead family members. 
 
6.1 The potential of FOXQ1 in modulating epithelial plasticity 
Our understanding of EMT have greatly benefited from the discovery that some 
transcriptional factors and members of the TGF-β family can induce EMT both in 
vitro and in vivo which led to the establishment of cell culture models. These 
discoveries have generated great impetus and momentum to further dissect the 
signaling pathways which drive or contribute to EMT. The identification of distinct 
families of transcription factors, whose expression is activated during EMT, has 
provided greater insight into the transcription programs that are driving EMT. 
Interestingly, the signaling mechanisms and transcription programs that characterize 
EMT under physiological conditions appear to be largely recapitulated during EMT 
processes under pathological conditions. Although EMT has been well documented 
under physiological condition, there is much debate and discussion about its role and 
contribution under pathological conditions. The transient and reversible nature of 
EMT in cancer progression may contribute to some aspects of this debate, as cells that 
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have undergone EMT may revert to their differentiated epithelial state and are 
therefore not easily isolated for scrutiny. Another aspect of the debate centred around 
the acquisition of mesenchymal properties, especially since mesenchymal 
characteristics are ill-defined. Furthermore, in many cases epithelial cells lose 
epithelial characteristics and become migratory without acquiring mesenchymal 
features. These observations suggest there is a spectrum of epithelial plasticity 
changes that can occur, which will result in downregulation of epithelial 
differentiation and integrity to varying extents, and therefore in the end, may or may 
not qualify as EMT. By considering EMT as the most striking manifestation of 
epithelial plasticity, much debate on the relative contribution of EMT to cancer 
pathology maybe mooted in different degrees of observed epithelial plasticity. Finally, 
the realization that EMT provided a basis for cell invasion, leading to metastasis of 
carcinomas in different organs have also stimulated interest to find therapeutic 
modalities which will inhibit EMT, hence interfere with or prevent the progression of 
metastases. 
 
In this study, I have extended our knowledge on forkhead box transcription factor 
family and its impact on regulating EMT. Among this family, FOXQ1 was found to 
be highly expressed in most of colorectal cancer, and in particular aggressive basal-
like breast cancer subtype. The expression pattern of FOXQ1 suggested that it may 
have a potential oncogenic role to facilitate tumor progression in many types of 
cancers. By examining the biological role of FOXQ1 in ectopic overexpression 
system in both epithelial-like colon cancer HCT116 cells, and immortalized human 
mammary epithelial cells, prolonged and consistent FOXQ1 expression induced a 
phenotypic change from epithelial towards mesenchymal. Reflecting the 
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morphological changes are corresponding switches in markers of epithelium to 
mesenchyme. The results, as demonstrated in both colon and breast cancer cells, 
support the capability of FOXQ1 in regulation of epithelial plasticity and 
manifestation of EMT. 
 
The human FOXQ1 gene was isolated almost a decade ago by a team in Göttingen 
university (Bieller, Pasche et al. 2001). However, the biological function of this gene 
in human remained elusive until now. Several discoveries about the function role of 
FOXQ1 only emerged recently in year 2010. When this project started, there were no 
literature describing the role of FOXQ1 in regulation of epithelial plasticity nor its 
relationship with human malignancies. In 2010, Kaneda and colleagues were the first 
to link the expression status of FOXQ1 with colon cancer and concluded that FOXQ1 
played a positive role in colon cancer progression (Kaneda, Arao et al. 2010). Their 
results are consistent with my own findings in colon cancer. However, I went several 
steps further with my discovery that FOXQ1 has the ability to repress epithelial 
morphology by promoting mesenchymal-like phenotype in colon carcinoma cells. The 
role of FOXQ1 in regulating epithelial plasticity has also been recognised in mouse 
mammary gland epithelial cells by Feuerborn and team. They found that FOXQ1 is 
upregulated by TGF-β treatment in normal mouse mammary epithelial cell (NMuMG) 
and the level of FOXQ1 influenced the outcome of TGF-β signalling pathway 
(Feuerborn, Srivastava et al. 2010). What’s more, they showed that FOXQ1 has the 
ability to regulate epithelial plasticity in morphologically homogenous subclone of the 
parental NMuMG cell line (NM18). However, there was no mention in their paper 




The impact of FOXQ1 in modulating epithelial plasticity is not limited only to colon 
cancer. Its impact also extends over breast cancer. In this study, I have shown that 
FOXQ1 expression level played a pivotal role in breast cancer especially the basal-
like subtype. My results indicated that FOXQ1 is required to maintain the aggressive 
phenotype of basal-like human breast cancer cell MDA-MB-231 through promoting 
EMT processes, while depletion of FOXQ1 expression is sufficient to reverse the 
mesenchymal-like morphology of these cells, resulting in impaired ability to invade in 
vitro. In my ectopic expression system, FOXQ1 successfully triggered EMT in human 
mammary epithelial cells (HMLER). At the same time, Zhang and team have also 
revealed a similar finding on FOXQ1 in their experiments on mouse breast cancer 
cells (Zhang, Meng et al. 2011). They demonstrated that FOXQ1 contributed to the 
metastatic ability of 4TI mouse breast cancer cells in vivo. In FOXQ1 expressing 4TI 
cancer cells, FOXQ1 knockdown in these cancer cells reduced the long-distance 
metastasis when injected into fat pads of BALB/c mice. In their ectopic expression 
system, they claimed that FOXQ1 can trigger EMT morphology in human mammary 
epithelial cell (HMLE) and MDCK cell line. In addition, reversal of EMT due to 
FOXQ1 knockdown in 4TI cancer cells has also been observed. Taken together, the 
capability of FOXQ1 in regulating epithelial plasticity is believed to occur in a wide 
range of mammalian cells.  FOXQ1 also played an active role in metastasis of both 
colon and breast carcinoma through positive regulation of EMT processes. 
Investigation into the role of FOXQ1 in malignancies will help us to better understand 





In both Feuerborn’s and Zhang’s publications which I have mentioned earlier, they 
have showed that FOXQ1 is responsive to TGF-β signalling pathway in murine 
mammary epithelial cell line systems, such as EpRas and NMuMG. In their 
experimental systems, FOXQ1 was observed to be upregulated upon TGF-β1 
treatment. In contrast, there was no observable change in FOXQ1 level when I treated 
HCT116 cells with TGF-β1. This could be due to mutation in the TGF-β receptor 
which is common in colon cancer, and hence, the negative response to TGF-β1 in my 
setup. Despite the probable mutant status of TGF-β receptor in HCT116 colon 
carcinoma cell, FOXQ1 was able to successfully induce EMT in the cells and 
moreover, the acquired EMT morphological changes were reversible depending on 
the FOXQ1 levels. Therefore, FOXQ1 may have the potential to trigger EMT 
processes but independent of TGF-β signalling. 
 
The induction of EMT by FOXQ1 in vitro appeared to be specific to certain cell lines. 
EMT is a key developmental process during cancer progression, invasion and the 
metastatic cascade. From my observation, ectopic FOXQ1 expression in several 
epithelial cell lines namely A549, SAOS2, U2OS, MCF7, MCF10A, and HMEC did 
not trigger the cells to exhibit EMT phenotype. However, FOXQ1 was able to induce 
EMT in HMLER and HCT116 cell lines. HMLER is a semi-transformed 
immortalized human mammary epithelial cell line and widely used as a model system 
to study EMT. HMLER cell line has been engineered on the basis of HMEC with the 
simian virus 40 large-T oncoprotein and low expression level of H-Ras oncogene. 
HMEC is human mammary epithelial cell which was immortalized by telomerase 
catalytic subunit (hTERT). The findings presented herein describes that FOXQ1 is 
able to promote EMT in semi-transformed HMLER cells and also enable these cells 
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to express stem cell-like traits. However, I failed to note a similar phenotype in non-
transformed normal human mammary epithelial cells with ectopic overexpressed 
FOXQ1. On the other hand, FOXQ1 alone is sufficient to provoke EMT in epithelial 
colon cancer cells albeit over an extended period of time. The EMT induced by 
FOXQ1 is reversible upon withdrawn of FOXQ1 induction, which suggests that 
FOXQ1 could be a potential target to overcome EMT in cancer metastasis. These 
evidence favours a relatively weak oncogenic signalling role for FOXQ1, which is 
dependent on other low level oncogenic signal to exert a combined synergistic effect 
of inducing human mammary epithelial cells to progressively acquire mesenchymal-
like phenotypes. To better understand the role of FOXQ1 in cancer, immortalized 
cells are increasingly used as experimental models for research (Boehm and Hahn 
2004). The above-mentioned role of FOXQ1 in modulating EMT shed new light on 
understanding of novel functions of FOXQ1 in various human cancers. 
 
6.2 The transcriptional network mediated by FOXQ1 during EMT 
In my study, I discovered the EMT phenotypic changes induced by FOXQ1 in both 
colon and breast epithelial cells, but the transcriptional network governing this 
morphological change remain unclear. Since the forkhead family is a group of 
transcriptional factors, I therefore dissected the potential transcriptional network 
regulated by FOXQ1 in both colon and breast carcinomas. CDH1, CTGF and Slug 




Protein E-cadherin encoded by CDH1 gene is expressed on cell junction of epithelial 
cells and functions as glue which holds adjacent cells together thus inhibiting 
individual cell movement. During EMT processes, E-cadherin plays a downstream 
role and its mRNA counterpart is a transcriptional target of several well-known EMT 
inducers. These EMT inducers regulate E-cadherin expression either by binding to E-
box of CDH1 promoter region to directly repress CDH1 transcription or indirectly 
inhibit E-cadherin expression. As a result of EMT, E-cadherin expression is reduced 
at cell junctions which leads to weaken intercellular binding. Thus, the epithelial cells 
become freed from adjacent cells. I have observed that E-cadherin mRNA and protein 
expressions are inversely correlated with FOXQ1 level in both breast and colon 
carcinomas. However, in breast carcinoma, the well-known EMT inducers did not 
show any significant changes in gene expression assay using microarray analysis. 
Hence, the acquired EMT induced by FOXQ1 in breast epithelial cells maybe due to 
direct or indirect repression of CDH1 transcriptional activity. As an example of 
forkhead family transcription factor, FOXC2 was shown to regulate breast carcinoma 
EMT through indirect repression of CDH1 and resulting in the relocation of E-
cadherin protein from cell junction to cytosol (Mani, Yang et al. 2007). Such 
translocation of E-cadherin partially releases epithelial cells to become individual 
units with increased mobility. In order to further understand relationship between 
CDH1 and FOXQ1, the promoter region of CDH1 was cloned and reporter activity 
was measured in stable ectopic FOXQ1 expressing HMLER cells as well as MDA-
MB-231 cells with FOXQ1 knockdown. Reporter activity of CDH1 is inversely 
correlated with FOXQ1 levels, but the chromatin immunoprecipitation (ChIP) assay 
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did not detect any pronounced binding between CDH1 promoter region and FOXQ1 
in vivo. Hence, FOXQ1 may regulate EMT processes by indirectly repressing CDH1 
transcriptional activity. The difference between FOXQ1 and FOXC2 in regulating 
CDH1 is that FOXQ1 can fully repress E-cadherin protein and mRNA expression, but 
FOXC2 can only partially repress its expression and also result in its translocation. 
The gene ontology analysis revealed that CDH1 is a key player in FOXQ1 mediated 
EMT transcriptional network in breast carcinoma. I propose that FOXQ1 does not 
modulate E-cadherin directly and therefore I believe that some intermediate players 
exist between them. 
 
6.2.2 CTGF 
The other potential transcriptional targets of FOXQ1 identified in this study are CTGF 
and Slug, both established EMT inducers (Kurrey, K et al. 2005; Liu, Zhang et al. 
2006). In colon carcinoma cells, CTGF and Slug were detected to be transcriptionally 
activated by FOXQ1. In order to identify the transcriptional target of FOXQ1 in 
mediating EMT process, microarray gene expression profiling was analyzed. In colon 
carcinoma HCT116 cells, CTGF and Slug were observed to be upregulated in 
response to FOXQ1 overexpression at different time points. CTGF was elevated 
rapidly only after 24 hours of FOXQ1 induction. However, Slug upregulation was 
only detected upon prolonged FOXQ1 overexpression for a period of at least two 
weeks. These suggest that FOXQ1 may activate CTGF and Slug expression via 
different mechanisms. In addition, following my observation, I decided to map out the 
CTGF and Slug promoter responsive region which can be activated by FOXQ1 in a 
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transient co-transfection system performed in HCT116 cell line. However, whether 
CTGF or Slug are direct transcriptional targets of FOXQ1 remain to be determined. 
 
Because current knowledge for FOXQ1 is limited, an alternative albeit indirect way is 
to understand the biological function of CTGF. CTGF (connective tissue growth 
factor) also known as CCN2 is a member of the CCN protein family (Bork 1993). 
Other members of this family are cycteine-rich 61 (CYR61/CCN1), nephroblastoma 
overexpressed (NOV/CCN3), WISP-1/elm1 (CCN4), WISP-2/rCop1 (CCN5), and 
WISP-3 (CCN6) (Perbal 2004). Members of the CCN protein family are involved in 
various biological functions including stimulating cellular proliferation, migration, 
adhesion, formation of extracellular matrix, as well as regulation of angiogenesis and 
tumorigenesis. CTGF is a secreted growth factor that can bind to integrins on cell 
surface. It can also serves as an angiogenic factor in collaboration with matrix 
metalloproteinase (Lau and Lam 1999; Kondo, Kubota et al. 2002). Elevated CTGF 
expression has been observed in breast cancers, pancreatic cancers, melanomas, and 
chondro-sarcomas (Kubo, Kikuchi et al. 1998; Wenger, Ellenrieder et al. 1999; 
Shakunaga, Ozaki et al. 2000; Xie, Nakachi et al. 2001). Specifically, in breast 
cancers, CTGF overexpression has been linked to increase of tumor size and lymph 
node metastasis (Chen, Wang et al. 2007). Microarray analysis indicated that CTGF is 
critically involved in the formation of osteolytic bone metastasis in breast cancer 
(Kang, Siegel et al. 2003; Minn, Kang et al. 2005). The paper published by Min-Liang 
Kuo and team in 2009 showed that CTGF promote breast cancer cell metastasis 
through an integrin αvβ3-extracellular signal–regulated kinase (ERK)-1/2–dependent, 
S100A4-upregulated pathway. This group further studied the CTGF mediated 
chemoresponse in breast cancers, and their results showed that CTGF overexpression 
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resulted in greater resistance to apoptosis induced by doxorubicin (adriamycin) and 
paclitaxel. The resistance was believed to be due to upregulation of Bcl-xL and 
cellular inhibitor of apoptosis protein 1 (cIAP1). Therefore, CTGF expression 
conferred resistance against apoptosis induced by chemotherapeutic agents via 
increasing a survival pathway through ERK1/2-dependent Bcl-xL/cIAP1 up-
regulation (Wang, Chen et al. 2009). On the other hand, CTGF may act in a positive 
way to promote invasion and metastasis in lung adenocarcinoma and colorectal 
cancers (Chang, Shih et al. 2004; Lin, Chang et al. 2005). Therefore, the biological 
function of CTGF can change depending on the cellular environment. Furthermore, 
CTGF is regulated by TGF-β signalling in fibroblast. CTGF was first identified in 
conditioned medium collected from cultured human vascular endothelial cells, whose 
gene expression is strongly induced by TGF-β in fibroblast. In fibroblast, CTGF is a 
downstream mediator of TGF-β activity. Indeed, CTGF is known to mediate key 
cellular events in response to TGF-β including migration, proliferation, matrix 
production and contraction, and differentiation of fibroblast into myofibroblasts. 
CTGF induction by TGF-β is not limited to connective tissue cells. During TGF-β 
induced EMT in epithelial cells, CTGF can also be produced and played an important 
role. In human corneal epithelial cells (HCEC), CTGF is required for TGF-β-
stimulated epithelial cell migration. This CTGF signalling occurred through ERK-p38 
MAPK pathway to induce migration in epithelial cells derived from stratified 
epithelium. TGF-β cannot induce epithelial cell migration in the absence of CTGF 
(Bradham, Igarashi et al. 1991; Brigstock 1999; Secker, Shortt et al. 2008). In my 
study, CTGF was found to be upregulated by FOXQ1 expression in HCT116 colon 
carcinoma cells, and FOXQ1 then induced EMT phenotype in these cells. It seemed 




Slug is the next potential transcriptional target of FOXQ1 identified in colon cancer. It 
belongs to the same family as Snail. Slug was detected to be upregulated after 
prolonged FOXQ1 expression in HCT116 cells. However, no significant changes 
were detected with other well-known EMT inducers such as Snail and Twist. 
Furthermore, luciferase reporter assay revealed that certain region of Slug promoter 
can be transactivated by full-length FOXQ1 expression. This suggested that Slug 
could be the FOXQ1 responsive element to induce EMT in HCT116 cells. 
Unfortunately, the ChIP assay did not detected any binding between FOXQ1 and Slug 
promoter region from 400bp upstream to 100bp downstream. Due to the absence of 
commercially available FOXQ1 antibody and the customized antibody was not 
optimal, I therefore detected FOXQ1 protein with anti-myc antibody which not only 
recognized the myc tag, but also endogenous Myc. Hence, the outcome of the ChIP 
assay should not be accurate. Notwithstanding the failure of ChIP assay to detect any 
direct binding between FOXQ1 and its proposed target Slug, Slug is still believed to 
be an effecter in FOXQ1-induced EMT. Since Twist represses E-cadherin expression 
indirectly which in turn facilitate EMT induction process, in colon cancer, Twist 
promoter is frequently hypermethylated (Okada, Suehiro et al.). In colon cancer, the 
TGF-β signalling pathway which is a well-known mediator of EMT, invasion and 
metastasis becomes malfunction due to mutation of the TGF-β receptor II (Samowitz 
and Slattery 1997). Hence, Slug is postulated as the effecter of FOXQ1-induced EMT 




It is believed that FOXQ1 trigged EMT in breast and colorectal carcinomas through 
different molecular mechanisms. There were no significant changes on CTGF and 
Slug mRNA levels in breast carcinoma FOXQ1 was either overexpressed or knocked 
down, on the other hand, significant changes were observed in colorectal carcinoma. 
However, in both breast and colon cancers, E-cadherin protein and mRNA levels are 
inversely correlated with FOXQ1 consistently. This suggests that FOXQ1 induced 
EMT through different mechanisms in colorectal and breast carcinomas. 
 
6.3 FOXQ1-induced EMT in human mammary epithelial cells 
results in generation of cancer stem cells 
Compelling evidence exists that relates EMT to the emergence of cancer stem cell 
(CSC)-like phenotype, which may be a prerequisite for cancer cell metastasis 
(Sheridan, Kishimoto et al. 2006). Experimental evidence that showed a direct 
connection between EMT and cancer stem cells was recently reported (Mani, Guo et 
al. 2008; Morel, Lievre et al. 2008). These characteristic phenotypes have also been 
observed through the same HMLER cell system with FOXQ1 overexpression in my 
research. In addition, a growing number of evidence suggested that certain 
subpopulation of cells in primary breast cancers maybe endowed with self-renewal 
ability which enabled these subpopulations to initiate metastasis of the tumor to a 
distant site. The subpopulation of breast cancer cells express special cell surface 
antigens CD44+/CD24(-/low), which distinguished breast cancer stem cells from the 
bulk of the breast tumor. In addition, the concept of breast cancer stem cell is also 
applicable to laboratory cultured breast cancer cell lines, for example, in MDA-MB-
231 cells which have at least 80% of population expressing CD44+/CD24- which are 
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considered as breast cancer stem cells. Besides the self-renewal ability of cancer stem 
cells, they also possess other stem cell characteristics such as indefinite proliferation, 
the ability to differentiate (developing into functional cells), and resistance to 
chemotherapy. Others reported that surviving residual breast cancer tissue cells after 
conventional therapy also have cancer stem cell properties by expressing cell surface 
markers CD44+/CD24-. In addition to the cancer stem cell traits, the CD44+/CD24- 
subpopulation of breast cancer cells also exhibited unique ability to invade matrigel in 
vitro and expressed higher levels of proinvasive genes such as IL-1α, IL-6, and IL-8. 
However, CD44+/CD24- phenotype alone is not sufficient for metastasis, then 
followed by proliferation at distant site (Sheridan, Kishimoto et al. 2006). Moreover, 
consistent with the high level of expression of FOXQ1 in MDA-MB-231 cells, these 
cells consist a high percentage of breast cancer stem cell population displayed 
CD44+/CD24(-/low) phenotype. Therefore, these findings may indicate a role of 
FOXQ1 in cancer EMT and possible cancer stem cell regulation. The evidence 
provided so far suggests that FOXQ1 is a multifunctional factor with the ability to 
induce EMT and regulate metastatic program in breast cancers. During the EMT 
processes, FOXQ1 likely transformed these cells to display breast cancer stem cell 
properties as shown by increased population of staining with tumor surface antigens 
CD44+/CD24-. 
 
Identification of cells with cancer stem cell properties or factors that promote 
formation of this population will help to improve therapeutic opportunity. Currently, 
chemotherapy and radiotherapy only kill the bulky mass of cancerous tissue, while the 
remaining cancerous cells may still retain the capability to form recurrent malignancy 
in the future and even in distant sites. The remaining cells after chemo- or 
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radiotherapy share similarities with cancer stem cell. They are characterized by well-
known cell surface markers CD44+/CD24- in breast cancers. In ovarian cancer, EMT 
inducer Snail and Slug also contribute to cancer stem cell formation. Transfection 
with Snail and Slug led to derepression of ‘stemness’ genes, including Nanog and 
KLF4, as well as four to five-fold increases in the size of CD44+ CD117+ cancer 
stem cell population that was resistant to chemo- and radiotherapy. This revolutionary 
finding highlighted the heterogeneity of cancer cells, of which only certain 
subpopulation has the ability to give rise to tumor formation. Due to the heterogeneity 
of tumors, they likely contain a subpopulation of self-renewing and expanding stem 
cells, known as cancer stem cells. EMT is an increasingly recognized mechanism to 
further generate cancer stem cells endowed with a more invasive and metastatic 
phenotype (Kurrey, Jalgaonkar et al. 2009). 
 
6.4 Chemoresistance mediated by high level of FOXQ1 in colon 
carcinomas 
Growing evidence is showing that one of the outcomes of EMT process is acquired 
chemoresistance ability. In this study, FOXQ1 not only has functions in promoting 
EMT in breast epithelial cells but also conferring cancer stem cell properties upon 
them. In colon epithelial cells, FOXQ1 initiates EMT to make them more 
chemoresistance. In colon cancer epithelial cell line HCT116, besides the EMT 
morphology displayed, ectopic expressing FOXQ1 also confers chemoresistance to a 
panel of DNA toxic drugs. Another unrelated research group simultaneously 
published similar findings with regards to FOXQ1-mediated chemoresistance in colon 
cancer (Kaneda, Arao et al. 2010). They demonstrated that p21 is a downstream target 
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of FOXQ1 in colon cancer, and overexpression of FOXQ1 in H1299 (a non-small cell 
lung carcinoma cell line) led to reduced apoptotic signal in terms of Annexin V and PI 
staining in response to both doxirubicin (Adriamycin) and CPT treatments. They 
concluded that the acquired chemoresistance after FOXQ1 overexpression could 
partially be due to upregulation of p21. However, there is no evidence to show direct 
connection of p21 to FOXQ1 mediated anti-apoptotic effect. Similar to my own 
findings, FOXQ1 was shown to mediate apoptosis resistance. However, the result 
from Kaneda’s research was achieved using ectopic overexpressing FOXQ1 in a 
model of non-small cell lung carcinoma cell line (H1299). Thus, even though their 
results can provide a clue about FOXQ1 in regulating anti-apoptotic effect, further 
direct demonstration on colon cancer cell lines would be useful indeed. Considering 
the high expression level of FOXQ1 in most colon cancers, FOXQ1 is postulated to 
have functions in promoting tumorigenicity and to enable cells to bypass apoptotic 
signals. Hence, targeting FOXQ1 could be a practical idea to increase chemo-
responsiveness of cancer cells. FOXQ1 may also be useful in the future as a 
biomarker of colon cancers. 
 
Cancer therapy has often been associated with acquired resistance. An increasing 
body of literature now suggests that acquired resistance to chemotherapy is likely to 
be linked to acquired EMT (Voulgari and Pintzas 2009). For instance, elevated E-
cadherin expression or increased mesenchymal phenotype can result in resistance to 
EGFR kinase inhibitor (Cano, Perez-Moreno et al. 2000) or DNA damaging agent-
induced apoptosis (Comijn, Berx et al. 2001). Moreover, chemotherapy leading to an 
increase in the number of CD44+/CD24(-/low) cancer stem cells (Hajra, Chen et al. 
2002) may represent a potentially important mechanism of acquired drug resistance. 
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Therefore, in addition to gaining self-renewal ability by cancer cells undergoing EMT, 
they also become chemoresistant at the same time. Consistent with this reasoning, I 
have shown that FOXQ1 depletion in MDA-MB-231 cells can result in sensitization 
to a variety of chemotherapeutic agents while enforced expression of FOXQ1 in 
epithelial cancer cells can induce chemoresistance. Therefore, FOXQ1 may play a 
broader role with respect to multiple drug resistance in human cancer and this is likely 
to be achieved through more than one single mechanism. 
 
Recently, accumulating evidence has implicated the close relationship between EMT, 
cancer stem cells and chemoresistance (Singh and Settleman 2010). From the effect of 
ectopic expressing FOXQ1 in colon cancer and immortalized mammary epithelial 
cells, FOXQ1 indeed has biological function in manipulating epithelial plasticity, 
gaining chemoresistant ability, and acquiring stem cell traits. Although I could not 
provide direct evidence for chemoresistance and stem cell-like properties, there is a 
growing amount of literature on this topic of cancer stem cell and its role in response 
to chemotherapy. Regardless of the lack of direct evidence, EMT processes still 
promote tumor progression, contribute to cancer relapses and chemoresistance. EMT 
not only contributes to tumor progression, subsequent invasion and metastasis, but 
also enables tumor cells to acquire chemoresistance. In ovarian cancers, 
overexpression of EMT inducers Slug and Snail in epithelial ovarian caner cell line 
triggered EMT phenotype while enabling these cells to have enhanced survival and 
resistance to radiotherapy.  On the other hand, paclitaxel resistant ovarian cell line 
was established by exposure to paclitaxel for a certain period of time. These paclitaxel 
resistant cells acquire a spindle-like shape morphology, and both Slug and Snail 
expression was up-regulated. Hence, EMT is associated with chemo- and radio-
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resistance in ovarian cancer. In addition, the acquired chemoresistance was also 
reported in EMTed epithelial breast cancer, while artificially generated 
chemoresistant breast cancer cells also exhibited EMT phenotypes. Hence, EMT 
processes contribute towards cancer recurrent and progression by promoting invasion 
and metastasis. Hence, I believe that intervention of EMT processes has potential 
clinical relevance (Kajiyama, Shibata et al. 2007; Kurrey, Jalgaonkar et al. 2009; 
Ahmed, Abubaker et al. 2010). 
 
Conventional chemotherapeutic agents have acceptable ability to shrink tumor size 
and limit tumor cell growth, but residual tumor cells evolve to gain resistance against 
previously exposed chemotherapeutic drugs. These surviving cells are responsible for 
tumor recurrence and metastasis to distant sites. Consequently, conventional chemo- 
and radio-therapy actually increases the cancer stem cell population by killing off the 
susceptible tumor mass, and thereby increasing the risk of malignancy recurrence. 
Weinberg’s group recently published data which demonstrated that salinomycin can 
effectively and selectively induce breast cancer stem cell death (Gupta, Onder et al. 
2009). Therefore, investigation of selective inhibitor of cancer stem cells can have 
important clinical relevance, and understanding the biological outcome of FOXQ1-
induced EMT and breast cancer stem cell can provide clues to future research. 
 
6.5 Repressed cell proliferation rate by ectopic FOXQ1 expression 
Besides EMT induced by FOXQ1 in colon and breast carcinomas, I also discovered 
another biological function of FOXQ1 which is inhibition of proliferation in both 
colon cancer cells HCT116 and immortalized human mammary epithelial cells 
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(HMLER). These two functions may appear contradictory at first impression, but this 
dual function is similar to TGF-β signalling in terms of regulating proliferation and 
EMT. Proliferation rate is an independent cell process with no ties to EMT process in 
promoting cancer progression. From my observation, EMTed cells showed a much 
slower proliferation rate. This de-differentiation process is proposed to enrich the 
population with cancer stem cells which is widely acknowledged in breast and colon 
cancer. In colorectal cancer, an inverse relationship between cancer progression and 
tumor proliferative activity was reported by Lin and team where primary tumor and 
liver metastasis of colorectal cancer were analyzed. They also found an association 
between more aggressive biological behavior and low proliferation in colorectal 
cancer by analyzing colorectal cancer liver metastases and a series of primary tumors 
differing in metastatic potential. Both metastasizing primaries and liver metastases are 
characterized by reduced proliferative activity compared to non-metastatic colorectal 
cancers (Lin, Chatterjee et al. 2007; Anjomshoaa, Nasri et al. 2009). These findings 
support the slow proliferative rate of HCT116 cells carrying ectopic FOXQ1 
expression vector since ectopic FOXQ1 expression in HCT116 cells induced EMT 
which potentially contributed to cancer progression and metastasis. This impaired cell 
proliferation is only associated with wild type full-length FOXQ1 expression, but not 
the truncated FOXQ1 deletion mutants (D6). Since the rationale of deletion mutant 
design of FOXQ1 is based on the transactivation ability to certain CTGF promoter 
region, there is a certain degree of limitations in the functional study of FOXQ1 in the 
specific CTGF region. The slower proliferation together with induced EMT 
phenotype and acquired chemoresistance ability did not appear in HCT116 cells 
expressing truncated FOXQ1 D6 deletion mutant. This indicated that the decreased 
proliferation rate, and EMT induction by full-length FOXQ1 is not involved in 
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transactivating CTGF promoter, at least in certain examined region. Even though 
FOXQ1 can transcriptionally activate CTGF promoter in vitro, however, the 
biological significance remains to be determined in colon cancer.  
 
6.6 Functional structures of FOXQ1 protein 
Forkhead box family is characterized by the highly conserved DNA binding domain 
(DBD). In this study, I attempted to first identify the functional structure of FOXQ1 
protein based on knowledge of conserved DBD in other forkhead family members. In 
order to do that, CTGF, the potential transcription target of FOXQ1 was used to 
perform this study. A certain genomic region of CTGF (CTGF-P2) was confirmed by 
reporter assay and the functional structure analysis was based on the transcriptional 
activity of truncated FOXQ1 deletion mutant to CTGF-P2 promoter activity. These 
truncated FOXQ1 deletion mutants were designed on the knowledge of the well-
studied forkhead family member FOXO. Molecule of FOXO proteins contains 4 
domains: a highly conserved DNA-binding domain, a nuclear localization signal just 
located downstream of DBD, a nuclear export signal, and a C-terminal transactivation 
domain (Obsilova, Vecer et al. 2005; Gao, Wang et al. 2010). 
 
According to the structures of FOXO proteins, the nuclear localization signal (NLS) is 
right after the DBD region and share several amino acid with DBD. The core protein 
sequence of NLS is RRRRA. The function of FOXO is under the control of 
insulin/insulin-like signalling. The regulation of FOXO depends on the shuttling of 
this factor between nucleus and cytosol. FOXO is in charge of a multitude of 
biological processes including cell-cycle, cell death, DNA repair, metabolism and 
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protection from oxidative stress. The shuttling of FOXO requires protein 
phosphorylation within several domains, and associated with 14-3-3 proteins and the 
nuclear transport machinery (Obsil and Obsilova 2008). FOXO is the most studied 
forkhead family in terms of structures. On the basis of our knowledge of FOXO 
structure, the FOXQ1 protein was truncated from N-terminal or C-terminal region. 
The transactivation and inhibitory domain as well as the nuclear localization signal 
were identified in this study. The transactivation domain locates at the C-terminal 
region of FOXQ1. Similarly, the transactivation domain in FOXO is also in the C-
terminal region but in different sequences. All forkhead proteins showed a high 
degree of amino acid identity in the region of winged helix DNA binding domain. 
 
FOXQ1 could also involve posttranslational modification. Unfortunately, I am not 
able to provide detailed research on this topic. The other limitation of FOXQ1 
structural study is based on the transcriptional activity to activate certain CTGF 
genomic region. However, wild-type FOXQ1 locates to the nucleus rather than 
cytosol to exert its transcriptional activity. This characterization is different from 
FOXO, which only travels into the nucleus when needed. When NLS of FOXQ1 is 
abolished, the ability to enter nucleus to exert transcriptional activity became lost. 





6.7 Significance of this study 
6.7.1 FOXQ1 is an important forkhead factor that regulates EMT 
In this study, I have demonstrated FOXQ1 as a forkhead factor with the ability to 
regulate EMT, functionally similar with FOXC1 and FOXC2. Unlike FOXC1 and 
FOXC2, FOXQ1 regulates EMT in a much broader way, and it induced EMT in both 
breast and colon carcinoma cells. 
 
In human keratinocytes, FOXQ1 has been reported to be decreased in expression in a 
Smad4-dependent manner in response to TGF-β treatment (Levy and Hill 2005). 
Other forkhead factors are also reported to regulate epithelial plasticity and 
dedifferentiation. FOXA1 and FOXA2 for example, are involved in maintaining the 
epithelial phenotype and loss of expression was sufficient to induce the 
dedifferentiation of pancreatic cancer cells (Song, Washington et al.). Next, FOXA2 
influenced epithelial polarity and epithelialization in the endoderm germ layer of 
mouse embryos (Burtscher and Lickert 2009). The first identified DNA-binding 
partner for Smad proteins and thus functionally implicated in mediating TGF-
β/activin responses was the Xenopus Forkhead-factor FAST1 (FOXH1) (Chen, 
Rubock et al. 1996; Attisano, Silvestri et al. 2001). Furthermore, in human 
keratinocytes, FOXO-factors functionally synergized with TGF-β-activated Smad 
factors, which is crucial for the regulation of several immediate early genes in 
response to TGF-β treatment (Gomis, Alarcon et al. 2006). Together, these studies 
demonstrated that the expression of FOX factors is regulated by TGF-β and they play 
important roles for the outcome of TGF-β signalling. However, in the TGF-β receptor 
mutated background such as colon carcinoma, FOXQ1 also retained the ability to 
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induce EMT. This suggested that FOXQ1 may regulate both TGF-β dependent and 
independent pathways. 
 
6.7.2 FOXQ1 may be used as a diagnostic and prognostic biomarker 
for aggressive breast cancer and colon cancer 
Cancer is considered as a chronic disease. Its development requires accumulation of 
genetic mutations including mutations in tumor suppressor genes. Most cancers 
remain silent until there is some clinical manifestations. In fact, benign tumors remain 
silence for years until it becomes malignant. Cancer in the benign stage usually shows 
no symptoms because the benign tumor has limited capability of invading 
surrounding tissue and organ. Clinically, symptoms may not be obvious even in the 
early stages before metastasis of malignant tumors to the various parts of the body. 
Hence, developing technology to detect cancer in early stages can greatly improve the 
treatment outcome and provide patients with a better quality of life. In this study, 
evidence was provided that FOXQ1 is clinically associated with basal-like breast 
cancer, which is associated with poor clinical outcome and an aggressive phenotype. 
This association is supported by our knowledge of FOXQ1 in nature.  The treatment 
for cancer can start with surgical removal of solid tumor mass, followed by systematic 
chemotherapy and/or radiotherapy. However, different cancer types have varying 
responses to chemo- and radio-therapy, and sometimes the outcome is not desirable. 
Cancer cells have the ability to evolve in response to chemo- and radio-therapy. As a 
result, they can acquire resistance to previous therapeutic exposures. The status of 
FOXQ1 in the cells may decide the chemo-responses of these cells. FOXQ1 can 
promote EMT in both colon and breast cancer cells and potentially regulate cell 
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invasion and metastasis. It is therefore logical to decide to monitor FOXQ1 
expression levels in clinical samples which could be used as a biomarker to determine 
disease prognosis and better propose treatment regimen.  
 
6.7.3 FOXQ1 may be used as potential therapeutic target for breast 
and colon cancer 
The role of epithelial to mensenchymal transition (EMT) during tumor progression, 
invasion and metastasis has been recently discussed and applied in anti-cancer drug 
discovery. Growing evidence indicates that EMT in cancer progression occurs in a 
wide range of malignancy and is a potential target for pharmaceutical intervention to 
reduce the aggressive behavior of malignancy and improve patient outcome. Hence, 
targeting genes driving EMT and corresponding downstream signaling pathway 
effectors could be a practical approach to intervene cancer progression.  
 
The gene of FOXQ1 was analyzed by several clinical breast cancer databases on 
Oncomine. FOXQ1 was revealed to be highly associated with basal-like (triple 
negative) breast cancer subtype, high metastasis rate, and higher tumor grades. In 
addition, patients with high level of FOXQ1 have lower survival rate depending on 
presence or absence of distant metastasis (DM). The expression status of FOXQ1 in 
breast cancer is closely correlated with the following findings and potential 
applications. In aggressive basal-like breast cancer MDA-MB-231 cells, lowering 
FOXQ1 expression reduced the invasion ability in vitro and inhibited the 
mesenchymal morphology. At the same time, these FOXQ1 depleted cells exhibit 
more apoptotic responses to several DNA damage agents. It suggested that lowering 
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FOXQ1 expression is able to reduce the aggressive phenotype of MDA-MB-231 
breast cancer. I have examined the capability of FOXQ1 in manipulating epithelial 
plasticity in human mammary epithelial cells (HMLER), EMT process triggered by 
ectopic expressing FOXQ1, and gain of cancer stem cell properties by expressing cell 
surface markers CD44+/CD24-. These phenotypes were coupled with increased 
capability of forming mammospheres in low adherent condition in vitro. 
 
The expression pattern of FOXQ1 in breast cancers is highly associated with basal-
like breast cancers. This type of breast cancer comprised 15% of total breast cancer 
population. It is extremely difficult to target and the outcomes are not desirable. The 
other obstacle of breast cancer treatment is relapse and metastasis to distant sites in 
the brain, lung, and skeleton. Hence, targeting proteins involved in EMT may provide 
a therapeutic strategy for eliminating residual cells to prevent recurrence and improve 
long-term survival in breast cancer patients. Despite advances in detection and 
treatment of metastatic breast cancer, mortality from this disease remains high 
because current therapies are limited by the emergence of therapy-resistant cancer 
cells, which were recently named ‘breast cancer stem cells’. The cancer stem cell 
concept is supported by important clinical finding that for most tumors, there is little 
correlation between response to therapy and long term survival. Certainly, patients 
who do not respond to treatment do not survive, but a large proportion of patients with 
cancer die of their disease despite responding well to chemotherapy. In this paper, I 
provide more evidence to link EMT and breast cancer stem cell. Although direct 
targeting of cancer stem cell is difficult because of difficulty defining what they are, 
targeting proteins that positively regulate EMT is more realistic. Based on this 
rationale, targeting FOXQ1 might therefore be a realistic approach to eliminate 
217 
 
formation of breast cancer stem cells and finally result in better survival outcome for 
patients after chemotherapy.  
 
6.8 Conclusions 
Basal-like breast cancer is an aggressive subtype of breast cancer associated with poor 
clinical outcome. The genetic makeup of this type of breast cancer enables them to 
tolerate and survive after conventional hormonal therapy. In this study, I report that 
forkhead factor FOXQ1 contributed to an aggressive phenotype, cancer cell invasion 
and metastatic ability of this subtype of breast cancer through positively regulating 
EMT. As a consequence of EMT, FOXQ1 triggered breast cancer stem cell phenotype 
in immortalized human mammary epithelial cells, which also provide evidence that 
FOXQ1 contributed to aggressive breast cancer phenotype. On the other hand, in 
colon cancer, FOXQ1 is upregulated in most of colon tumor and FOXQ1 also 
triggered EMT in colon carcinoma cells, enabling these cells to become 
chemoresistance. These EMT phenotype triggered by FOXQ1 in colon cancer may 
have occurred through upregulation of well-known EMT inducers such as Slug and 
CTGF. The above characterization of the roles of FOXQ1 in breast and colon cancer 
shed new light on the complex mechanisms underlying the tumorigenesis of basal-like 
breast cancer and colon cancer. FOXQ1 has been suggested to possibly serve as a 
novel biomarker for determining clinical prognosis and a potential therapeutic target 




6.9 Future prospect 
Following the recognition of EMT in cancer progression, several EMT regulators 
were rapidly identified which included several forkhead transcription factors. In this 
study, I have demonstrated the biological function of FOXQ1 and its importance in 
regulating cancer progression and metastasis through modulation of EMT processes in 
breast and colon cancers. The mechanism by which FOXQ1 regulates EMT will be 
the next priority in future FOXQ1 research. FOXQ1 is believed to play an oncogenic 
role in cancer in view of its clinical expression status. FOXQ1 is worth further 
research especially in the area of transcriptional network in regulating EMT, cancer 












Abell, M. R. (1966). "The nature and classification of ovarian neoplasms." Can Med 
Assoc J 94(21): 1102-1124. 
Adesina, A. M., Y. Nguyen, et al. (2007). "FOXG1 is overexpressed in 
hepatoblastoma." Hum Pathol 38(3): 400-409. 
Ahmed, N., K. Abubaker, et al. (2010). "Epithelial mesenchymal transition and cancer 
stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian 
cancer." Curr Cancer Drug Targets 10(3): 268-278. 
Aigner, K., B. Dampier, et al. (2007). "The transcription factor ZEB1 (deltaEF1) 
promotes tumour cell dedifferentiation by repressing master regulators of 
epithelial polarity." Oncogene 26(49): 6979-6988. 
Ailles, L. E. and I. L. Weissman (2007). "Cancer stem cells in solid tumors." Curr 
Opin Biotechnol 18(5): 460-466. 
Akhurst, R. J. and R. Derynck (2001). "TGF-beta signaling in cancer--a double-edged 
sword." Trends Cell Biol 11(11): S44-51. 
Al-Hajj, M., M. S. Wicha, et al. (2003). "Prospective identification of tumorigenic 
breast cancer cells." Proc Natl Acad Sci U S A 100(7): 3983-3988. 
Albergaria, A., J. Paredes, et al. (2009). "Expression of FOXA1 and GATA-3 in 
breast cancer: the prognostic significance in hormone receptor-negative 
tumours." Breast Cancer Res 11(3): R40. 
Anjomshoaa, A., S. Nasri, et al. (2009). "Slow proliferation as a biological feature of 
colorectal cancer metastasis." Br J Cancer 101(5): 822-828. 
Ansieau, S., J. Bastid, et al. (2008). "Induction of EMT by twist proteins as a 
collateral effect of tumor-promoting inactivation of premature senescence." 
Cancer Cell 14(1): 79-89. 
Anton Aparicio, L. M., R. Garcia Campelo, et al. (2007). "Prostate cancer and 
Hedgehog signalling pathway." Clin Transl Oncol 9(7): 420-428. 
Antony, M. L., R. Nair, et al. (2010). "Changes in expression, and/or mutations in 
TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human 
ovarian tumors." J Cancer Res Clin Oncol 136(3): 351-361. 
Appelbaum, F. R., J. M. Rowe, et al. (2001). "Acute myeloid leukemia." Hematology 
Am Soc Hematol Educ Program: 62-86. 
Arslan, C., O. Dizdar, et al. (2009). "Pharmacotherapy of triple-negative breast 
cancer." Expert Opin Pharmacother 10(13): 2081-2093. 
220 
 
Attisano, L., C. Silvestri, et al. (2001). "The transcriptional role of Smads and FAST 
(FoxH1) in TGFbeta and activin signalling." Mol Cell Endocrinol 180(1-2): 3-
11. 
Avraham, K. B., C. Fletcher, et al. (1995). "Murine chromosomal location of eight 
members of the hepatocyte nuclear factor 3/fork head winged helix family of 
transcription factors." Genomics 25(2): 388-393. 
Badve, S., D. Turbin, et al. (2007). "FOXA1 expression in breast cancer--correlation 
with luminal subtype A and survival." Clin Cancer Res 13(15 Pt 1): 4415-
4421. 
Baker, S. J., A. C. Preisinger, et al. (1990). "p53 gene mutations occur in combination 
with 17p allelic deletions as late events in colorectal tumorigenesis." Cancer 
Res 50(23): 7717-7722. 
Batlle, E., E. Sancho, et al. (2000). "The transcription factor snail is a repressor of E-
cadherin gene expression in epithelial tumour cells." Nat Cell Biol 2(2): 84-89. 
Bellam, N. and B. Pasche (2010). "Tgf-beta signaling alterations and colon cancer." 
Cancer Treat Res 155: 85-103. 
Ben-Porath, I., M. W. Thomson, et al. (2008). "An embryonic stem cell-like gene 
expression signature in poorly differentiated aggressive human tumors." Nat 
Genet 40(5): 499-507. 
Bernardo, G. M., K. L. Lozada, et al. (2010). "FOXA1 is an essential determinant of 
ERalpha expression and mammary ductal morphogenesis." Development 
137(12): 2045-2054. 
Bialek, P., B. Kern, et al. (2004). "A twist code determines the onset of osteoblast 
differentiation." Dev Cell 6(3): 423-435. 
Bieller, A., B. Pasche, et al. (2001). "Isolation and characterization of the human 
forkhead gene FOXQ1." DNA Cell Biol 20(9): 555-561. 
Boehm, J. S. and W. C. Hahn (2004). "Immortalized cells as experimental models to 
study cancer." Cytotechnology 45(1-2): 47-59. 
Bolos, V., H. Peinado, et al. (2003). "The transcription factor Slug represses E-
cadherin expression and induces epithelial to mesenchymal transitions: a 
comparison with Snail and E47 repressors." J Cell Sci 116(Pt 3): 499-511. 
Bonnet, D. and J. E. Dick (1997). "Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell." Nat Med 3(7): 
730-737. 
Bork, P. (1993). "The modular architecture of a new family of growth regulators 
related to connective tissue growth factor." FEBS Lett 327(2): 125-130. 
221 
 
Bos, J. L., E. R. Fearon, et al. (1987). "Prevalence of ras gene mutations in human 
colorectal cancers." Nature 327(6120): 293-297. 
Bradham, D. M., A. Igarashi, et al. (1991). "Connective tissue growth factor: a 
cysteine-rich mitogen secreted by human vascular endothelial cells is related 
to the SRC-induced immediate early gene product CEF-10." J Cell Biol 
114(6): 1285-1294. 
Braig, M., S. Lee, et al. (2005). "Oncogene-induced senescence as an initial barrier in 
lymphoma development." Nature 436(7051): 660-665. 
Brigstock, D. R. (1999). "The connective tissue growth factor/cysteine-rich 
61/nephroblastoma overexpressed (CCN) family." Endocr Rev 20(2): 189-
206. 
Burtscher, I. and H. Lickert (2009). "Foxa2 regulates polarity and epithelialization in 
the endoderm germ layer of the mouse embryo." Development 136(6): 1029-
1038. 
Cano, A., M. A. Perez-Moreno, et al. (2000). "The transcription factor snail controls 
epithelial-mesenchymal transitions by repressing E-cadherin expression." Nat 
Cell Biol 2(2): 76-83. 
Cao, D., S. R. Hustinx, et al. (2004). "Identification of novel highly expressed genes 
in pancreatic ductal adenocarcinomas through a bioinformatics analysis of 
expressed sequence tags." Cancer Biol Ther 3(11): 1081-1089; discussion 
1090-1081. 
Carey, L. A., E. C. Dees, et al. (2007). "The triple negative paradox: primary tumor 
chemosensitivity of breast cancer subtypes." Clin Cancer Res 13(8): 2329-
2334. 
Carr, J. R., H. J. Park, et al. (2010). "FoxM1 mediates resistance to herceptin and 
paclitaxel." Cancer Res 70(12): 5054-5063. 
Ceder, J. A., L. Jansson, et al. (2008). "The characterization of epithelial and stromal 
subsets of candidate stem/progenitor cells in the human adult prostate." Eur 
Urol 53(3): 524-531. 
Chaffer, C. L. and R. A. Weinberg (2011). "A perspective on cancer cell metastasis." 
Science 331(6024): 1559-1564. 
Chan, D. W., V. W. Liu, et al. (2009). "Overexpression of FOXG1 contributes to 
TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in 
ovarian cancer." Br J Cancer 101(8): 1433-1443. 
Chang, C. C., J. Y. Shih, et al. (2004). "Connective tissue growth factor and its role in 




Chen, P. S., M. Y. Wang, et al. (2007). "CTGF enhances the motility of breast cancer 
cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated 
pathway." J Cell Sci 120(Pt 12): 2053-2065. 
Chen, X., M. J. Rubock, et al. (1996). "A transcriptional partner for MAD proteins in 
TGF-beta signalling." Nature 383(6602): 691-696. 
Clark, K. L., E. D. Halay, et al. (1993). "Co-crystal structure of the HNF-3/fork head 
DNA-recognition motif resembles histone H5." Nature 364(6436): 412-420. 
Clarke, M. F. (2005). "A self-renewal assay for cancer stem cells." Cancer Chemother 
Pharmacol 56 Suppl 1: 64-68. 
Clarke, M. F. and M. Fuller (2006). "Stem cells and cancer: two faces of eve." Cell 
124(6): 1111-1115. 
Cleator, S., W. Heller, et al. (2007). "Triple-negative breast cancer: therapeutic 
options." Lancet Oncol 8(3): 235-244. 
Collado, M., J. Gil, et al. (2005). "Tumour biology: senescence in premalignant 
tumours." Nature 436(7051): 642. 
Comijn, J., G. Berx, et al. (2001). "The two-handed E box binding zinc finger protein 
SIP1 downregulates E-cadherin and induces invasion." Mol Cell 7(6): 1267-
1278. 
Crouch, S. P., R. Kozlowski, et al. (1993). "The use of ATP bioluminescence as a 
measure of cell proliferation and cytotoxicity." J Immunol Methods 160(1): 
81-88. 
Dalerba, P., R. W. Cho, et al. (2007). "Cancer stem cells: models and concepts." Annu 
Rev Med 58: 267-284. 
Davies, H., G. R. Bignell, et al. (2002). "Mutations of the BRAF gene in human 
cancer." Nature 417(6892): 949-954. 
Debnath, J., S. K. Muthuswamy, et al. (2003). "Morphogenesis and oncogenesis of 
MCF-10A mammary epithelial acini grown in three-dimensional basement 
membrane cultures." Methods 30(3): 256-268. 
Dent, R., M. Trudeau, et al. (2007). "Triple-negative breast cancer: clinical features 
and patterns of recurrence." Clin Cancer Res 13(15 Pt 1): 4429-4434. 
Derynck, R. and Y. E. Zhang (2003). "Smad-dependent and Smad-independent 
pathways in TGF-beta family signalling." Nature 425(6958): 577-584. 




Dontu, G., W. M. Abdallah, et al. (2003). "In vitro propagation and transcriptional 
profiling of human mammary stem/progenitor cells." Genes Dev 17(10): 
1253-1270. 
Ellenberger, T., D. Fass, et al. (1994). "Crystal structure of transcription factor E47: 
E-box recognition by a basic region helix-loop-helix dimer." Genes Dev 8(8): 
970-980. 
Eramo, A., F. Lotti, et al. (2008). "Identification and expansion of the tumorigenic 
lung cancer stem cell population." Cell Death Differ 15(3): 504-514. 
Fabrizi, E., S. di Martino, et al. (2010). "Therapeutic implications of colon cancer 
stem cells." World J Gastroenterol 16(31): 3871-3877. 
Fang, D. D., Y. J. Kim, et al. (2010). "Expansion of CD133(+) colon cancer cultures 
retaining stem cell properties to enable cancer stem cell target discovery." Br J 
Cancer 102(8): 1265-1275. 
Fearon, E. R. and B. Vogelstein (1990). "A genetic model for colorectal 
tumorigenesis." Cell 61(5): 759-767. 
Fendrich, V., J. Waldmann, et al. (2009). "Unique expression pattern of the EMT 
markers Snail, Twist and E-cadherin in benign and malignant parathyroid 
neoplasia." Eur J Endocrinol 160(4): 695-703. 
Ferlay J, Shin HR, et al. (2010). "GLOBOCAN 2008, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 10." Lyon, France: International Agency 
for Research on Cancer; 2010: Available from: http://globocan.iarc.fr. 
Ferrandina, G., G. Bonanno, et al. (2008). "Expression of CD133-1 and CD133-2 in 
ovarian cancer." Int J Gynecol Cancer 18(3): 506-514. 
Feuerborn, A., P. K. Srivastava, et al. (2010). "The Forkhead factor FoxQ1 influences 
epithelial differentiation." J Cell Physiol 226(3): 710-719. 
Feuerborn, A., P. K. Srivastava, et al. (2011). "The Forkhead factor FoxQ1 influences 
epithelial differentiation." J Cell Physiol 226(3): 710-719. 
Fidler, I. J. (2003). "The pathogenesis of cancer metastasis: the 'seed and soil' 
hypothesis revisited." Nat Rev Cancer 3(6): 453-458. 
Folkman, J. (1975). "Tumor angiogenesis: a possible control point in tumor growth." 
Ann Intern Med 82(1): 96-100. 
Foulkes, W. D., I. E. Smith, et al. (2010). "Triple-negative breast cancer." N Engl J 
Med 363(20): 1938-1948. 
Franco, H. L., J. Casasnovas, et al. (2010). "Redundant or separate entities?--roles of 
Twist1 and Twist2 as molecular switches during gene transcription." Nucleic 
Acids Res 39(4): 1177-1186. 
224 
 
Frank, S. and B. Zoll (1998). "Mouse HNF-3/fork head homolog-1-like gene: 
structure, chromosomal location, and expression in adult and embryonic 
kidney." DNA Cell Biol 17(8): 679-688. 
Galli, R., E. Binda, et al. (2004). "Isolation and characterization of tumorigenic, stem-
like neural precursors from human glioblastoma." Cancer Res 64(19): 7011-
7021. 
Gao, X., Z. Wang, et al. (2010). "Identification of hookworm DAF-16/FOXO 
response elements and direct gene targets." PLoS One 5(8): e12289. 
Gemenetzidis, E., D. Elena-Costea, et al. (2010). "Induction of human epithelial 
stem/progenitor expansion by FOXM1." Cancer Res 70(22): 9515-9526. 
Glinsky, G. V. (2007). "Stem cell origin of death-from-cancer phenotypes of human 
prostate and breast cancers." Stem Cell Rev 3(1): 79-93. 
Goering, W., I. M. Adham, et al. (2008). "Impairment of gastric acid secretion and 
increase of embryonic lethality in Foxq1-deficient mice." Cytogenet Genome 
Res 121(2): 88-95. 
Gold, L. I. (1999). "The role for transforming growth factor-beta (TGF-beta) in 
human cancer." Crit Rev Oncog 10(4): 303-360. 
Gomis, R. R., C. Alarcon, et al. (2006). "A FoxO-Smad synexpression group in 
human keratinocytes." Proc Natl Acad Sci U S A 103(34): 12747-12752. 
Gong, X. Q. and L. Li (2002). "Dermo-1, a multifunctional basic helix-loop-helix 
protein, represses MyoD transactivation via the HLH domain, MEF2 
interaction, and chromatin deacetylation." J Biol Chem 277(14): 12310-12317. 
Goss, K. H. and J. Groden (2000). "Biology of the adenomatous polyposis coli tumor 
suppressor." J Clin Oncol 18(9): 1967-1979. 
Grady, W. and S. Markowitz (2008). "TGF-β signaling pathway and tumor 
suppression." Cold Spring Harbor Laboratory Press; Cold Spring Harbor: 
p889-938. 
Grady, W. M., L. L. Myeroff, et al. (1999). "Mutational inactivation of transforming 
growth factor beta receptor type II in microsatellite stable colon cancers." 
Cancer Res 59(2): 320-324. 
Grady, W. M., A. Rajput, et al. (1998). "Mutation of the type II transforming growth 
factor-beta receptor is coincident with the transformation of human colon 
adenomas to malignant carcinomas." Cancer Res 58(14): 3101-3104. 
Guaita, S., I. Puig, et al. (2002). "Snail induction of epithelial to mesenchymal 
transition in tumor cells is accompanied by MUC1 repression and ZEB1 
expression." J Biol Chem 277(42): 39209-39216. 
225 
 
Gupta, P. B., T. T. Onder, et al. (2009). "Identification of selective inhibitors of 
cancer stem cells by high-throughput screening." Cell 138(4): 645-659. 
Habashy, H. O., D. G. Powe, et al. (2008). "Forkhead-box A1 (FOXA1) expression in 
breast cancer and its prognostic significance." Eur J Cancer 44(11): 1541-
1551. 
Hader, C., A. Marlier, et al. (2009). "Mesenchymal-epithelial transition in epithelial 
response to injury: the role of Foxc2." Oncogene 29(7): 1031-1040. 
Hajra, K. M., D. Y. Chen, et al. (2002). "The SLUG zinc-finger protein represses E-
cadherin in breast cancer." Cancer Res 62(6): 1613-1618. 
Hamamori, Y., V. Sartorelli, et al. (1999). "Regulation of histone acetyltransferases 
p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A." 
Cell 96(3): 405-413. 
Hartwell, K. A., B. Muir, et al. (2006). "The Spemann organizer gene, Goosecoid, 
promotes tumor metastasis." Proc Natl Acad Sci U S A 103(50): 18969-18974. 
Hayashi, H. and T. Kume (2008). "Forkhead transcription factors regulate expression 
of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced 
cell migration." Biochem Biophys Res Commun 367(3): 584-589. 
Heldin, C. H., K. Miyazono, et al. (1997). "TGF-beta signalling from cell membrane 
to nucleus through SMAD proteins." Nature 390(6659): 465-471. 
Hiscox, S., W. G. Jiang, et al. (2006). "Tamoxifen resistance in MCF7 cells promotes 
EMT-like behaviour and involves modulation of beta-catenin 
phosphorylation." Int J Cancer 118(2): 290-301. 
Hoggatt, A. M., A. M. Kriegel, et al. (2000). "Hepatocyte nuclear factor-3 homologue 
1 (HFH-1) represses transcription of smooth muscle-specific genes." J Biol 
Chem 275(40): 31162-31170. 
Honeth, G., P. O. Bendahl, et al. (2008). "The CD44+/CD24- phenotype is enriched in 
basal-like breast tumors." Breast Cancer Res 10(3): R53. 
Hong, H. K., J. K. Noveroske, et al. (2001). "The winged helix/forkhead transcription 
factor Foxq1 regulates differentiation of hair in satin mice." Genesis 29(4): 
163-171. 
Hu, D. G. and P. I. Mackenzie (2010). "Forkhead box protein A1 regulates UDP-
glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer 
cells." Drug Metab Dispos 38(12): 2105-2109. 
Ikenouchi, J., M. Matsuda, et al. (2003). "Regulation of tight junctions during the 
epithelium-mesenchyme transition: direct repression of the gene expression of 
claudins/occludin by Snail." J Cell Sci 116(Pt 10): 1959-1967. 
226 
 
Jemal, A., R. Siegel, et al. (2008). "Cancer statistics, 2008." CA Cancer J Clin 58(2): 
71-96. 
Jiang, X., J. Tan, et al. (2008). "DACT3 is an epigenetic regulator of Wnt/beta-catenin 
signaling in colorectal cancer and is a therapeutic target of histone 
modifications." Cancer Cell 13(6): 529-541. 
Ju, W., B. C. Yoo, et al. (2009). "Identification of genes with differential expression 
in chemoresistant epithelial ovarian cancer using high-density oligonucleotide 
microarrays." Oncol Res 18(2-3): 47-56. 
Kaestner, K. H., W. Knochel, et al. (2000). "Unified nomenclature for the winged 
helix/forkhead transcription factors." Genes Dev 14(2): 142-146. 
Kajiyama, H., K. Shibata, et al. (2007). "Chemoresistance to paclitaxel induces 
epithelial-mesenchymal transition and enhances metastatic potential for 
epithelial ovarian carcinoma cells." Int J Oncol 31(2): 277-283. 
Kalluri, R. (2009). "EMT: when epithelial cells decide to become mesenchymal-like 
cells." J Clin Invest 119(6): 1417-1419. 
Kalluri, R. and E. G. Neilson (2003). "Epithelial-mesenchymal transition and its 
implications for fibrosis." J Clin Invest 112(12): 1776-1784. 
Kalluri, R. and R. A. Weinberg (2009). "The basics of epithelial-mesenchymal 
transition." J Clin Invest 119(6): 1420-1428. 
Kaneda, H., T. Arao, et al. (2010). "FOXQ1 is overexpressed in colorectal cancer and 
enhances tumorigenicity and tumor growth." Cancer Res 70(5): 2053-2063. 
Kang, Y. and J. Massague (2004). "Epithelial-mesenchymal transitions: twist in 
development and metastasis." Cell 118(3): 277-279. 
Kang, Y., P. M. Siegel, et al. (2003). "A multigenic program mediating breast cancer 
metastasis to bone." Cancer Cell 3(6): 537-549. 
Kemper, K., C. Grandela, et al. (2010). "Molecular identification and targeting of 
colorectal cancer stem cells." Oncotarget 1(6): 387-395. 
Khoor, A., M. T. Stahlman, et al. (2004). "Forkhead box A2 transcription factor is 
expressed in all types of neuroendocrine lung tumors." Hum Pathol 35(5): 
560-564. 
Kim, T. H., S. W. Jo, et al. (2009). "Forkhead box O-class 1 and forkhead box G1 as 
prognostic markers for bladder cancer." J Korean Med Sci 24(3): 468-473. 
Kondo, S., S. Kubota, et al. (2002). "Connective tissue growth factor increased by 
hypoxia may initiate angiogenesis in collaboration with matrix 
metalloproteinases." Carcinogenesis 23(5): 769-776. 
227 
 
Koon, H. B., G. C. Ippolito, et al. (2007). "FOXP1: a potential therapeutic target in 
cancer." Expert Opin Ther Targets 11(7): 955-965. 
Kubo, M., K. Kikuchi, et al. (1998). "Expression of fibrogenic cytokines in 
desmoplastic malignant melanoma." Br J Dermatol 139(2): 192-197. 
Kume, T. (2009). "The cooperative roles of Foxc1 and Foxc2 in cardiovascular 
development." Adv Exp Med Biol 665: 63-77. 
Kurrey, N. K., S. P. Jalgaonkar, et al. (2009). "Snail and slug mediate radioresistance 
and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a 
stem-like phenotype in ovarian cancer cells." Stem Cells 27(9): 2059-2068. 
Kurrey, N. K., A. K, et al. (2005). "Snail and Slug are major determinants of ovarian 
cancer invasiveness at the transcription level." Gynecol Oncol 97(1): 155-165. 
Kwok, W. K., M. T. Ling, et al. (2007). "Role of p14ARF in TWIST-mediated 
senescence in prostate epithelial cells." Carcinogenesis 28(12): 2467-2475. 
Lagna, G., A. Hata, et al. (1996). "Partnership between DPC4 and SMAD proteins in 
TGF-beta signalling pathways." Nature 383(6603): 832-836. 
Lai, E., V. R. Prezioso, et al. (1990). "HNF-3A, a hepatocyte-enriched transcription 
factor of novel structure is regulated transcriptionally." Genes Dev 4(8): 1427-
1436. 
Lapidot, T., C. Sirard, et al. (1994). "A cell initiating human acute myeloid leukaemia 
after transplantation into SCID mice." Nature 367(6464): 645-648. 
Larochelle, A., J. Vormoor, et al. (1996). "Identification of primitive human 
hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: 
implications for gene therapy." Nat Med 2(12): 1329-1337. 
Lau, L. F. and S. C. Lam (1999). "The CCN family of angiogenic regulators: the 
integrin connection." Exp Cell Res 248(1): 44-57. 
Lavon, N., O. Yanuka, et al. (2006). "The effect of overexpression of Pdx1 and Foxa2 
on the differentiation of human embryonic stem cells into pancreatic cells." 
Stem Cells 24(8): 1923-1930. 
Lee, Y. M., T. Park, et al. (1997). "Twist-mediated activation of the NK-4 homeobox 
gene in the visceral mesoderm of Drosophila requires two distinct clusters of 
E-box regulatory elements." J Biol Chem 272(28): 17531-17541. 
Levy, L. and C. S. Hill (2005). "Smad4 dependency defines two classes of 
transforming growth factor {beta} (TGF-{beta}) target genes and 
distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its 
antiproliferative and migratory responses." Mol Cell Biol 25(18): 8108-8125. 
Li, C., D. G. Heidt, et al. (2007). "Identification of pancreatic cancer stem cells." 
Cancer Res 67(3): 1030-1037. 
228 
 
Li, L., P. Cserjesi, et al. (1995). "Dermo-1: a novel twist-related bHLH protein 
expressed in the developing dermis." Dev Biol 172(1): 280-292. 
Liedtke, C., C. Mazouni, et al. (2008). "Response to neoadjuvant therapy and long-
term survival in patients with triple-negative breast cancer." J Clin Oncol 
26(8): 1275-1281. 
Lin, B. R., C. C. Chang, et al. (2005). "Connective tissue growth factor inhibits 
metastasis and acts as an independent prognostic marker in colorectal cancer." 
Gastroenterology 128(1): 9-23. 
Lin, H. M., A. Chatterjee, et al. (2007). "Genome wide expression profiling identifies 
genes associated with colorectal liver metastasis." Oncol Rep 17(6): 1541-
1549. 
Linderholm, B. K., H. Hellborg, et al. (2009). "Significantly higher levels of vascular 
endothelial growth factor (VEGF) and shorter survival times for patients with 
primary operable triple-negative breast cancer." Ann Oncol 20(10): 1639-
1646. 
Liu, B. C., J. D. Zhang, et al. (2006). "Role of connective tissue growth factor 
(CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in 
HK-2 cells." Clin Chim Acta 373(1-2): 144-150. 
Liu, F., C. Pouponnot, et al. (1997). "Dual role of the Smad4/DPC4 tumor suppressor 
in TGFbeta-inducible transcriptional complexes." Genes Dev 11(23): 3157-
3167. 
Liu, N., Y. Niu, et al. (2010). "[Diagnostic and prognostic significance of FOXA1 
expression in molecular subtypes of breast invasive ductal carcinomas]." 
Zhonghua Yi Xue Za Zhi 90(20): 1403-1407. 
Lo, P. K., J. S. Lee, et al. (2010). "Epigenetic inactivation of the potential tumor 
suppressor gene FOXF1 in breast cancer." Cancer Res 70(14): 6047-6058. 
Lombaerts, M., T. van Wezel, et al. (2006). "E-cadherin transcriptional 
downregulation by promoter methylation but not mutation is related to 
epithelial-to-mesenchymal transition in breast cancer cell lines." Br J Cancer 
94(5): 661-671. 
Lu, S. L., D. Reh, et al. (2004). "Overexpression of transforming growth factor beta1 
in head and neck epithelia results in inflammation, angiogenesis, and epithelial 
hyperproliferation." Cancer Res 64(13): 4405-4410. 
Lynch, H. T., J. F. Lynch, et al. (2008). "Hereditary colorectal cancer syndromes: 
molecular genetics, genetic counseling, diagnosis and management." Fam 
Cancer 7(1): 27-39. 
Mani, S. A., W. Guo, et al. (2008). "The epithelial-mesenchymal transition generates 
cells with properties of stem cells." Cell 133(4): 704-715. 
229 
 
Mani, S. A., J. Yang, et al. (2007). "Mesenchyme Forkhead 1 (FOXC2) plays a key 
role in metastasis and is associated with aggressive basal-like breast cancers." 
Proc Natl Acad Sci U S A 104(24): 10069-10074. 
Markowitz, S., J. Wang, et al. (1995). "Inactivation of the type II TGF-beta receptor 
in colon cancer cells with microsatellite instability." Science 268(5215): 1336-
1338. 
Martin, F., S. Ladoire, et al. (2010). "Human FOXP3 and cancer." Oncogene 29(29): 
4121-4129. 
Martinez-Ceballos, E., P. Chambon, et al. (2005). "Differences in gene expression 
between wild type and Hoxa1 knockout embryonic stem cells after retinoic 
acid treatment or leukemia inhibitory factor (LIF) removal." J Biol Chem 
280(16): 16484-16498. 
Minn, A. J., Y. Kang, et al. (2005). "Distinct organ-specific metastatic potential of 
individual breast cancer cells and primary tumors." J Clin Invest 115(1): 44-
55. 
Mirosevich, J., N. Gao, et al. (2006). "Expression and role of Foxa proteins in prostate 
cancer." Prostate 66(10): 1013-1028. 
Mirza, M. K., Y. Sun, et al. (2010). "FoxM1 regulates re-annealing of endothelial 
adherens junctions through transcriptional control of beta-catenin expression." 
J Exp Med 207(8): 1675-1685. 
Moore-Smith, L. and B. Pasche (2011). "TGFBR1 Signaling and Breast Cancer." J 
Mammary Gland Biol Neoplasia. 
Morel, A. P., M. Lievre, et al. (2008). "Generation of breast cancer stem cells through 
epithelial-mesenchymal transition." PLoS One 3(8): e2888. 
Muraoka, R. S., N. Dumont, et al. (2002). "Blockade of TGF-beta inhibits mammary 
tumor cell viability, migration, and metastases." J Clin Invest 109(12): 1551-
1559. 
Nakamura, S., I. Hirano, et al. (2010). "The FOXM1 transcriptional factor promotes 
the proliferation of leukemia cells through modulation of cell cycle 
progression in acute myeloid leukemia." Carcinogenesis 31(11): 2012-2021. 
Nakaya, K., M. Murakami, et al. (2008). "Regulatory expression of Brachyury and 
Goosecoid in P19 embryonal carcinoma cells." J Cell Biochem 105(3): 801-
813. 
Nakshatri, H. and S. Badve (2007). "FOXA1 as a therapeutic target for breast cancer." 
Expert Opin Ther Targets 11(4): 507-514. 
Nam, B. H., S. Y. Kim, et al. (2008). "Breast cancer subtypes and survival in patients 
with brain metastases." Breast Cancer Res 10(1): R20. 
230 
 
Neve, R. M., K. Chin, et al. (2006). "A collection of breast cancer cell lines for the 
study of functionally distinct cancer subtypes." Cancer Cell 10(6): 515-527. 
Nielsen, T. O., F. D. Hsu, et al. (2004). "Immunohistochemical and clinical 
characterization of the basal-like subtype of invasive breast carcinoma." Clin 
Cancer Res 10(16): 5367-5374. 
Nieto, M. A. (2002). "The snail superfamily of zinc-finger transcription factors." Nat 
Rev Mol Cell Biol 3(3): 155-166. 
Nilsson, J., K. Helou, et al. (2010). "Nuclear Janus-activated kinase 2/nuclear factor 
1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by 
repressing Forkhead box F1." Cancer Res 70(5): 2020-2029. 
Nowak, K., K. Killmer, et al. (2007). "E2F-1 regulates expression of FOXO1 and 
FOXO3a." Biochim Biophys Acta 1769(4): 244-252. 
Nucera, C., J. Eeckhoute, et al. (2009). "FOXA1 is a potential oncogene in anaplastic 
thyroid carcinoma." Clin Cancer Res 15(11): 3680-3689. 
Obsil, T. and V. Obsilova (2008). "Structure/function relationships underlying 
regulation of FOXO transcription factors." Oncogene 27(16): 2263-2275. 
Obsilova, V., J. Vecer, et al. (2005). "14-3-3 Protein interacts with nuclear 
localization sequence of forkhead transcription factor FoxO4." Biochemistry 
44(34): 11608-11617. 
Oka, H., H. Shiozaki, et al. (1993). "Expression of E-cadherin cell adhesion molecules 
in human breast cancer tissues and its relationship to metastasis." Cancer Res 
53(7): 1696-1701. 
Okada, T., Y. Suehiro, et al. "TWIST1 hypermethylation is observed frequently in 
colorectal tumors and its overexpression is associated with unfavorable 
outcomes in patients with colorectal cancer." Genes Chromosomes Cancer 
49(5): 452-462. 
Onder, T. T., P. B. Gupta, et al. (2008). "Loss of E-cadherin promotes metastasis via 
multiple downstream transcriptional pathways." Cancer Res 68(10): 3645-
3654. 
Pan, D., M. Fujimoto, et al. (2009). "Twist-1 is a PPARdelta-inducible, negative-
feedback regulator of PGC-1alpha in brown fat metabolism." Cell 137(1): 73-
86. 
Parsons, D. W., S. Jones, et al. (2008). "An integrated genomic analysis of human 
glioblastoma multiforme." Science 321(5897): 1807-1812. 
Parsons, D. W., T. L. Wang, et al. (2005). "Colorectal cancer: mutations in a 
signalling pathway." Nature 436(7052): 792. 
231 
 
Parsons, R., L. L. Myeroff, et al. (1995). "Microsatellite instability and mutations of 
the transforming growth factor beta type II receptor gene in colorectal cancer." 
Cancer Res 55(23): 5548-5550. 
Pasche, B., T. J. Knobloch, et al. (2005). "Somatic acquisition and signaling of 
TGFBR1*6A in cancer." JAMA 294(13): 1634-1646. 
Peinado, H., D. Olmeda, et al. (2007). "Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype?" Nat Rev Cancer 
7(6): 415-428. 
Perbal, B. (2004). "CCN proteins: multifunctional signalling regulators." Lancet 
363(9402): 62-64. 
Perl, A. K., P. Wilgenbus, et al. (1998). "A causal role for E-cadherin in the transition 
from adenoma to carcinoma." Nature 392(6672): 190-193. 
Perou, C. M., T. Sorlie, et al. (2000). "Molecular portraits of human breast tumours." 
Nature 406(6797): 747-752. 
Potter, C. S., R. L. Peterson, et al. (2006). "Evidence that the satin hair mutant gene 
Foxq1 is among multiple and functionally diverse regulatory targets for 
Hoxc13 during hair follicle differentiation." J Biol Chem 281(39): 29245-
29255. 
Prince, M. E., R. Sivanandan, et al. (2007). "Identification of a subpopulation of cells 
with cancer stem cell properties in head and neck squamous cell carcinoma." 
Proc Natl Acad Sci U S A 104(3): 973-978. 
Puisieux, A., S. Valsesia-Wittmann, et al. (2006). "A twist for survival and cancer 
progression." Br J Cancer 94(1): 13-17. 
Qi, J., K. Nakayama, et al. (2010). "Siah2-dependent concerted activity of HIF and 
FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine 
prostate tumors." Cancer Cell 18(1): 23-38. 
Rajagopalan, H., A. Bardelli, et al. (2002). "Tumorigenesis: RAF/RAS oncogenes and 
mismatch-repair status." Nature 418(6901): 934. 
Ray, P. S., J. Wang, et al. (2010). "FOXC1 is a potential prognostic biomarker with 
functional significance in basal-like breast cancer." Cancer Res 70(10): 3870-
3876. 
Reya, T., S. J. Morrison, et al. (2001). "Stem cells, cancer, and cancer stem cells." 
Nature 414(6859): 105-111. 
Rho, J. K., Y. J. Choi, et al. (2009). "Epithelial to mesenchymal transition derived 
from repeated exposure to gefitinib determines the sensitivity to EGFR 




Rhodes, D. R., J. Yu, et al. (2004). "ONCOMINE: a cancer microarray database and 
integrated data-mining platform." Neoplasia 6(1): 1-6. 
Ricci-Vitiani, L., E. Fabrizi, et al. (2009). "Colon cancer stem cells." J Mol Med 
87(11): 1097-1104. 
Ricci-Vitiani, L., D. G. Lombardi, et al. (2007). "Identification and expansion of 
human colon-cancer-initiating cells." Nature 445(7123): 111-115. 
Roberts, A. B. and L. M. Wakefield (2003). "The two faces of transforming growth 
factor beta in carcinogenesis." Proc Natl Acad Sci U S A 100(15): 8621-8623. 
Rottenberg, S., J. E. Jaspers, et al. (2008). "High sensitivity of BRCA1-deficient 
mammary tumors to the PARP inhibitor AZD2281 alone and in combination 
with platinum drugs." Proc Natl Acad Sci U S A 105(44): 17079-17084. 
Rouzier, R., C. M. Perou, et al. (2005). "Breast cancer molecular subtypes respond 
differently to preoperative chemotherapy." Clin Cancer Res 11(16): 5678-
5685. 
Saito, R. A., P. Micke, et al. (2010). "Forkhead box F1 regulates tumor-promoting 
properties of cancer-associated fibroblasts in lung cancer." Cancer Res 70(7): 
2644-2654. 
Samowitz, W. S. and M. L. Slattery (1997). "Transforming growth factor-beta 
receptor type 2 mutations and microsatellite instability in sporadic colorectal 
adenomas and carcinomas." Am J Pathol 151(1): 33-35. 
Sanders, M. A. and A. P. Majumdar (2011). "Colon cancer stem cells: implications in 
carcinogenesis." Front Biosci 16: 1651-1662. 
Sarrio, D., S. M. Rodriguez-Pinilla, et al. (2008). "Epithelial-mesenchymal transition 
in breast cancer relates to the basal-like phenotype." Cancer Res 68(4): 989-
997. 
Schipper, J. H., U. H. Frixen, et al. (1991). "E-cadherin expression in squamous cell 
carcinomas of head and neck: inverse correlation with tumor dedifferentiation 
and lymph node metastasis." Cancer Res 51(23 Pt 1): 6328-6337. 
Secker, G. A., A. J. Shortt, et al. (2008). "TGFbeta stimulated re-epithelialisation is 
regulated by CTGF and Ras/MEK/ERK signalling." Exp Cell Res 314(1): 
131-142. 
Seki, K., T. Fujimori, et al. (2003). "Mouse Snail family transcription repressors 
regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan." J 
Biol Chem 278(43): 41862-41870. 
Seo, D. C., J. M. Sung, et al. (2007). "Gene expression profiling of cancer stem cell in 
human lung adenocarcinoma A549 cells." Mol Cancer 6: 75. 
233 
 
Seo, S., H. Fujita, et al. (2006). "The forkhead transcription factors, Foxc1 and Foxc2, 
are required for arterial specification and lymphatic sprouting during vascular 
development." Dev Biol 294(2): 458-470. 
Shakunaga, T., T. Ozaki, et al. (2000). "Expression of connective tissue growth factor 
in cartilaginous tumors." Cancer 89(7): 1466-1473. 
Sheridan, C., H. Kishimoto, et al. (2006). "CD44+/CD24- breast cancer cells exhibit 
enhanced invasive properties: an early step necessary for metastasis." Breast 
Cancer Res 8(5): R59. 
Singh, A. and J. Settleman (2010). "EMT, cancer stem cells and drug resistance: an 
emerging axis of evil in the war on cancer." Oncogene 29(34): 4741-4751. 
Smolak, K. (1971). "[Studies on morphologic structure of the stroma in cancer of the 
breasts]." Patol Pol 22(4): 571-581. 
Song, Y., M. K. Washington, et al. "Loss of FOXA1/2 is essential for the epithelial-
to-mesenchymal transition in pancreatic cancer." Cancer Res 70(5): 2115-
2125. 
Song, Y., M. K. Washington, et al. (2010). "Loss of FOXA1/2 is essential for the 
epithelial-to-mesenchymal transition in pancreatic cancer." Cancer Res 70(5): 
2115-2125. 
Sorlie, T., C. M. Perou, et al. (2001). "Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications." Proc Natl Acad Sci U 
S A 98(19): 10869-10874. 
Spaderna, S., O. Schmalhofer, et al. (2008). "The transcriptional repressor ZEB1 
promotes metastasis and loss of cell polarity in cancer." Cancer Res 68(2): 
537-544. 
Sun, Q., X. Yu, et al. (2009). "Upstream stimulatory factor 2, a novel FoxA1-
interacting protein, is involved in prostate-specific gene expression." Mol 
Endocrinol 23(12): 2038-2047. 
Takahashi, H., H. Ishii, et al. (2011). "Significance of Lgr5(+ve) Cancer Stem Cells in 
the Colon and Rectum." Ann Surg Oncol 18(4): 1166-1174. 
Tang, Y., G. Shu, et al. (2010). "FOXA2 functions as a suppressor of tumor 
metastasis by inhibition of epithelial-to-mesenchymal transition in human lung 
cancers." Cell Res 21(2): 316-326. 
Thiery, J. P. (2002). "Epithelial-mesenchymal transitions in tumour progression." Nat 
Rev Cancer 2(6): 442-454. 
Thiery, J. P. and J. P. Sleeman (2006). "Complex networks orchestrate epithelial-
mesenchymal transitions." Nat Rev Mol Cell Biol 7(2): 131-142. 
234 
 
Thorat, M. A., C. Marchio, et al. (2008). "Forkhead box A1 expression in breast 
cancer is associated with luminal subtype and good prognosis." J Clin Pathol 
61(3): 327-332. 
Turner, N., A. Tutt, et al. (2004). "Hallmarks of 'BRCAness' in sporadic cancers." Nat 
Rev Cancer 4(10): 814-819. 
Umbas, R., W. B. Isaacs, et al. (1994). "Decreased E-cadherin expression is 
associated with poor prognosis in patients with prostate cancer." Cancer Res 
54(14): 3929-3933. 
Underwood, J. C. E. (2004). "General and Systematic Pathology." Churchill 
Livingstone: p223-p262. 
Van Calster, B., I. Vanden Bempt, et al. (2009). "Axillary lymph node status of 
operable breast cancers by combined steroid receptor and HER-2 status: triple 
positive tumours are more likely lymph node positive." Breast Cancer Res 
Treat 113(1): 181-187. 
van der Heul-Nieuwenhuijsen, L., N. Dits, et al. (2009). "The FOXF2 pathway in the 
human prostate stroma." Prostate 69(14): 1538-1547. 
Van Meter, M. E. and E. S. Kim (2010). "Bevacizumab: current updates in treatment." 
Curr Opin Oncol 22(6): 586-591. 
Vandewalle, C., F. Van Roy, et al. (2009). "The role of the ZEB family of 
transcription factors in development and disease." Cell Mol Life Sci 66(5): 
773-787. 
Vazquez, A., E. E. Bond, et al. (2008). "The genetics of the p53 pathway, apoptosis 
and cancer therapy." Nat Rev Drug Discov 7(12): 979-987. 
Veigl, M. L., L. Kasturi, et al. (1998). "Biallelic inactivation of hMLH1 by epigenetic 
gene silencing, a novel mechanism causing human MSI cancers." Proc Natl 
Acad Sci U S A 95(15): 8698-8702. 
Verzi, M. P., A. H. Khan, et al. (2008). "Transcription factor foxq1 controls mucin 
gene expression and granule content in mouse stomach surface mucous cells." 
Gastroenterology 135(2): 591-600. 
Voulgari, A. and A. Pintzas (2009). "Epithelial-mesenchymal transition in cancer 
metastasis: mechanisms, markers and strategies to overcome drug resistance in 
the clinic." Biochim Biophys Acta 1796(2): 75-90. 
Waldmann, J., E. P. Slater, et al. (2009). "Expression of the transcription factor snail 
and its target gene twist are associated with malignancy in 
pheochromocytomas." Ann Surg Oncol 16(7): 1997-2005. 
235 
 
Wang, I. C., Y. Zhang, et al. (2010). "Increased expression of FoxM1 transcription 
factor in respiratory epithelium inhibits lung sacculation and causes Clara cell 
hyperplasia." Dev Biol 347(2): 301-314. 
Wang, J. C. and J. E. Dick (2005). "Cancer stem cells: lessons from leukemia." 
Trends Cell Biol 15(9): 494-501. 
Wang, M. Y., P. S. Chen, et al. (2009). "Connective tissue growth factor confers drug 
resistance in breast cancer through concomitant up-regulation of Bcl-xL and 
cIAP1." Cancer Res 69(8): 3482-3491. 
Wang, Z., A. Ahmad, et al. (2009). "Forkhead box M1 transcription factor: a novel 
target for cancer therapy." Cancer Treat Rev 36(2): 151-156. 
Weidinger, C., K. Krause, et al. (2008). "Forkhead box-O transcription factor: critical 
conductors of cancer's fate." Endocr Relat Cancer 15(4): 917-929. 
Weigel, D., G. Jurgens, et al. (1989). "The homeotic gene fork head encodes a nuclear 
protein and is expressed in the terminal regions of the Drosophila embryo." 
Cell 57(4): 645-658. 
Weissman, I. L. (2000). "Translating stem and progenitor cell biology to the clinic: 
barriers and opportunities." Science 287(5457): 1442-1446. 
Wendling, D. S., C. Luck, et al. (2008). "Characteristic overexpression of the 
forkhead box transcription factor Foxf1 in Patched-associated tumors." Int J 
Mol Med 22(6): 787-792. 
Wenger, C., V. Ellenrieder, et al. (1999). "Expression and differential regulation of 
connective tissue growth factor in pancreatic cancer cells." Oncogene 18(4): 
1073-1080. 
Xie, D., K. Nakachi, et al. (2001). "Elevated levels of connective tissue growth factor, 
WISP-1, and CYR61 in primary breast cancers associated with more advanced 
features." Cancer Res 61(24): 8917-8923. 
Xie, Z., G. Tan, et al. (2010). "Foxm1 transcription factor is required for maintenance 
of pluripotency of P19 embryonal carcinoma cells." Nucleic Acids Res 38(22): 
8027-8038. 
Yamaguchi, N., E. Ito, et al. (2008). "FoxA1 as a lineage-specific oncogene in 
luminal type breast cancer." Biochem Biophys Res Commun 365(4): 711-717. 
Yang, A. D., F. Fan, et al. (2006). "Chronic oxaliplatin resistance induces epithelial-
to-mesenchymal transition in colorectal cancer cell lines." Clin Cancer Res 
12(14 Pt 1): 4147-4153. 
Yang, J., S. A. Mani, et al. (2004). "Twist, a master regulator of morphogenesis, plays 
an essential role in tumor metastasis." Cell 117(7): 927-939. 
236 
 
Yang, J. Y. and M. C. Hung (2009). "A new fork for clinical application: targeting 
forkhead transcription factors in cancer." Clin Cancer Res 15(3): 752-757. 
Yin, Z., X. L. Xu, et al. (1997). "Regulation of the twist target gene tinman by 
modular cis-regulatory elements during early mesoderm development." 
Development 124(24): 4971-4982. 
Yokoyama, K., N. Kamata, et al. (2003). "Increased invasion and matrix 
metalloproteinase-2 expression by Snail-induced mesenchymal transition in 
squamous cell carcinomas." Int J Oncol 22(4): 891-898. 
Yoshida, J., A. Horiuchi, et al. (2009). "Changes in the expression of E-cadherin 
repressors, Snail, Slug, SIP1, and Twist, in the development and progression 
of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and 
progression." Med Mol Morphol 42(2): 82-91. 
Yoshihara, K., A. Tajima, et al. (2009). "Gene expression profiling of advanced-stage 
serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in 
tumor progression and prognosis." Cancer Sci 100(8): 1421-1428. 
Yu, M., G. A. Smolen, et al. (2009). "A developmentally regulated inducer of EMT, 
LBX1, contributes to breast cancer progression." Genes Dev 23(15): 1737-
1742. 
Yu, X., A. Gupta, et al. (2005). "Foxa1 and Foxa2 interact with the androgen receptor 
to regulate prostate and epididymal genes differentially." Ann N Y Acad Sci 
1061: 77-93. 
Zavadil, J. and E. P. Bottinger (2005). "TGF-beta and epithelial-to-mesenchymal 
transitions." Oncogene 24(37): 5764-5774. 
Zeisberg, M. and E. G. Neilson (2009). "Biomarkers for epithelial-mesenchymal 
transitions." J Clin Invest 119(6): 1429-1437. 
Zhang, H., F. Meng, et al. (2011). "Forkhead transcription factor foxq1 promotes 
epithelial-mesenchymal transition and breast cancer metastasis." Cancer Res 
71(4): 1292-1301. 
Zollinger, H. U. (1968). "[Tumors between benign and malignant. Semimalignancy, 






List of Publications 
1. Qiao Yuanyuan, Jiang X, Lee ST, Karuturi RK, Hooi SC, Yu Qiang. FOXQ1 
Regulates Epithelial-Mesenchymal Transition in Human Cancers. Cancer Res. 
2011 Apr 15;71(8):3076-86. Epub 2011 Feb 23. PMID: 21346143 
 
2. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein 
EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating 
Bim expression. Cell Death Differ. 2010 May;17(5):801-10. Epub 2009 Nov 6. 
PMID: 19893569 
 
3. Wu Zhenlong, Shuet Theng Lee, Yuanyuan Qiao, Zhimei Li, Puay Leng Lee, 
Yong Jing Lee, Xia Jiang, Jing Tan, Meiyee Aau, Cheryl Zhi Hui Lim, and 
Qiang Yu. EZH2 regulates cancer cell fate decision in response to DNA 
damage. Cell Death Differ. 2011 May 6. PMID: 21546904 
 
 
